CUMULATIVE SUPPLEMENT 11

JAN'94-NOV'94

APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

14TH EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF MANAGEMENT
DIVISION OF DRUG INFORMATION RESOURCES

Prepared By
Division of Drug Information Resources
Office of Management
Center for Drug Evaluation and Research, FDA

APPROVED DRUG PRODUCTS with THERAPEUTIC EQUIVALENCE EVALUATIONS

14TH EDITION

Cumulative Supplement 11

NOVEMBER 1994

CONTENTS

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

14TH EDITION

CUMULATIVE SUPPLEMENT 11

NOVEMBER 1994

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 14th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Additions new to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >**ADD**> to the left of the line on which new information exists. The >**ADD**> symbol is then dropped in subsequent Cumulative Supplements for that item.

Deletions new to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >**DLT**> (DELETE) to the left of the line containing shaded print. The >**DLT**> symbol is dropped in subsequent Cumulative Supplements for that item. The shaded print remains in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements for this edition. However, the shaded print in the Patent and Exclusivity Data is dropped in subsequent Cumulative Supplements.

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 14th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 15th Edition.

1.2 PRODUCTS REQUIRING REVISED LABELING FOR FULL APPROVAL

Drug products in this category (1) initially received approval only on the basis of safety before effectiveness studies were required, or (2) were conditionally approved under the temporary exemption that allowed these products to be marketed while effectiveness studies were being conducted. Listed below are those drugs which are now required to revise their labeling and provide additional information necessary for full approval on the basis of requirements listed in the Federal Register. As approval is granted by the Agency for a specific product, based on additional information submitted by the applicant, the product will be included in the appropriate Drug Product List.

Products	Federal Register Reference
Nitroglycerin (capsule, controlled release;oral)	SEP 07, 1984 (49 FR 35428)
Nitroglycerin (film, extended release; transdermal*)	JUL 15, 1993 (58 FR 38129)
Nitroglycerin (tablet, controlled release;oral)	SEP 07, 1984 (49 FR 35428)
Nitroglycerin (tablet, controlled release;buccal)	JUL 05, 1985 (50 FR 27688)

*The Federal Register of July 15, 1993 (58 FR 38129) announced that the FDA was revoking the temporary exemption for nitroglycerin in a transdermal delivery system. Marketing of a drug product that is the subject of a conditionally approved ANDA may continue by meeting the requirements listed in the Federal Register. Firms wishing to submit a new ANDA before a drug product is approved (NDA or ANDA) and appears in the List should submit a 505(b)(2) application following the directions contained in the Federal Register. Nitro-Dur has been selected as the reference listed drug. The preamble to the final rule (57 FR 17958) states if there are multiple NDA's, the reference listed drug generally will be the market leader. This is the basis upon which Nitro-Dur was selected. In addition, the preamble states that, in multiple NDA situations, a product not designated as the reference listed drug and not shown to be bioequivalent to the reference listed drug may be shielded from generic competition. This is the case with Summit's Transderm-Nitro. The Office of Generic Drugs (OGD) has been requested to have a second listed drug as provided for in the Final Rule. OGD has granted this request. Therefore, at the time that Schering's and Summit's supplements are fully approved and their products are entered into the List, we will have two reference listed drugs for the nitroglycerin transdermal systems. Firms may, therefore, elect to conduct bioequivalence studies against either of these products. It is conceivable that a non-referenced listed drug may be fully approved and appear in the List; in this case, the Agency's referenced listed drug will not change and a 505(b)(2) application will be appropriate until the reference listed drugs are fully approved. Once they are fully approved, a 505(j) application will be the appropriate mechanism for an ANDA submission.

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to

another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will automatically reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. However, when the applicant name change is one which may not be easily recognized or located in the listing (e.g., White Towne Paulsen [Former Abbreviated Name] is changed to Whiteworth Towne [New Abbreviated Name], the name change will appear in this section and will be identified with an asterisk.

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
ADRIA LABORATORIES DIV ERBAMONT INC (ADRIA)	PHARMACIA INC (PHARMACIA)
BANNER GELATIN PRODUCTS CORP (BANNER GELATIN)	BANNER PHARMACAPS INC (BANNER PHARMACAPS)
*BROCADES PHARMA BV DIV YAMANOUCHI GROUP (BROCADES PHARMA)	*YAMANOUCHI EUROPE BV (YAMANOUCHI)
CLONMEL CHEMICALS CO LTD (CLONMEL)	CLONMEL HEALTH CARE (CLONMEL HLTH CARE)
DUPONT PHARMACEUTICALS (DUPONT)	DUPONT MERCK PHARMACEUTICAL CC (DUPONT MERCK)
*G POHL BOSKAMP GMBH AND CO (BOSKAMP)	*G POHL BOSKAMP GMBH AND CO (POHL BOSKAMP)
GYNEX INC (GYNEX)	BTG PHARMACEUTICALS CORP SUE BIOTECHNOLOGY GENERAL CORP (BTG PHARMS)
KABI PHARMACIA INC (KABI)	PHARMACIA INC (PHARMACIA)

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
*KM LEE LABORATORIES (LEE LABS)	*KM LEE LABORATORIES (KM LEE)
*LABORATOIRES FOURNIER SA (FOURNIER)	*LABORATOIRES FOURNIER SCA (LABS FOURNIER)
*LABORATORIOS ATRAL SARL (ATRAL)	*LABORATORIOS ATRAL SARL (LABS ATRAL)
MALLINCKRODT SPECIALTY CHEMICALS CO (MALLINCKRODT)	MALLINCKRODT CHEMICAL INC (MALLINCKRODT)
*MM MAST AND CO (MAST)	*MM MAST AND CO (MM MAST)
NORTH AMERICAN CHEMICAL CORP (NORTH AM CHEM)	GOLDEN PHARMACEUTICALS INC (GOLDEN PHARMS)
PHARMACEUTICAL BASICS INC (PHARM BASICS)	ROSEMONT PHARMACEUTICAL CORP (ROSEMONT)
*PRIVATE FORMULATIONS INC (PRIVATE FORM)	*PRIVATE FORMULATIONS INC (PVT FORM)
RICHLYN LABORATORIES INC (RICHLYN)	GLOBAL PHARMACEUTICAL CORP (GLOBAL PHARMS)
*SCHWARZ PHARMA DIV KREMERS URBAN CO (SCHWARZ PHARMA)	*SCHWARZ PHARMA KREMERS URBAN CO SUB SCHWARZ PHARMA AG (SPKU)
SQUIBB DIAGNOSTICS (SQUIBB)	BRACCO DIAGNOSTICS INC (BRACCO DXS)
*WHITEWORTH TOWNE PAULSEN INC (WHITE TOWNE PAULSEN)	*WHITEWORTH TOWNE PAULSEN INC (WHITEWORTH TOWNE)

1.4 NEW INDICATIONS FOR PREVIOUSLY APPROVED DRUG PRODUCTS

When an application is submitted to FDA for a new indication for a drug product that duplicates a drug product (same active moiety, same salt, same formulation, or same combination) already approved or marketed in the United States by the same firm, the application is either submitted as a supplement to the original NDA (if the clinical expertise for the review of the new indication resides in the same division that reviewed the original NDA), or as a "Type 6 NDA" and assigned a new NDA number

(if the clinical expertise for the review of the new indication resides in another review division). When an application is submitted to FDA for a new indication for a drug product that duplicates a drug product (same active moiety, same salt, same formulation, or same combination) already approved or marketed in the United States by a different firm, the application is classified as "Type 6" and assigned a new NDA number.For administrative purposes, FDA has been listing all "Type 6 NDA's" in the *Approved Drug Products with Therapeutic Equivalence Evaluations*, (ADP), even when the application was submitted by the original NDA holder. However, FDA has determined that the practice of listing a separate "Type 6 NDA" number in the ADP when the applicant is the original NDA holder may cause confusion to the ADP reader.

Accordingly, to prevent confusion and to eliminate duplicity of data, the approval of an application for a new indication for a previously approved drug product submitted by the original NDA holder will no longer be listed in the ADP. Any exclusivity awarded for that approval will be shown in the Patent and Exclusivity Information Addendum under the original NDA number. However, approval of an application for a new indication submitted by an applicant other than the original NDA holder will be shown in the appropriate drug product list of the ADP. Any exclusivity awarded will be shown under the NDA number of the new applicant.

All approvals of "Type 6" applications submitted by the original NDA holder currently in the ADP are listed in the table below. For reference purposes, the original NDA number is listed next to the corresponding "Type 6 NDA Number". This data ("Type 6 NDA Number") will continue to be listed in the remaining Cumulative Supplements to the 14th Edition of the ADP; but it will not appear in the 15th Edition of the ADP.

TYPE 6 NDA NUMBER	ORIGINAL NDA NUMBER	ACTIVE INGREDIENT (TRADE NAME)	DOSAGE FORM (ROUTE)
17-117	16-020	AMANTADINE HCL (SYMMETREL)	CAPSULE (ORAL)
17-118	16-023	AMANTADINE HCL (SYMMETREL)	SYRUP (ORAL)
50-697	50-662	CLARITHROMYCIN (BIAXIN)	TABLET (ORAL)
19-576	19-084	KETOCONAZOLE (NIZORAL)	CREAM (TOPICAL)
19-648	19-084	KETOCONAZOLE (NIZORAL)	CREAM (TOPICAL)
18-064	18-063	NADOLOL (CORGARD)	TABLET (ORAL)
20-109	19-886	NAFARELIN ACETATE (SYNAREL)	SPRAY, METERED (NASAL)
20-223	19-057	TERAZOSIN HCL (HYTRIN)	TABLET (ORAL)

1.5 USP MONOGRAPH TITLE ADDITIONS OR CHANGES

The U.S. Pharmacopeia (USP) periodically makes additions to or changes in monograph titles. Some of these additions or changes may affect dosage form terms listed in *Approved Drug Products with Therapeutic Equivalence Evaluations* (ADP). Instead of making the change in each affected product, the Cumulative Supplement (CS) will list applicable monograph title and dosage form additions or changes in this section. These will appear as soon as the modified USP monograph title is official. It is possible for these additions or changes to be listed in this section before all applicant holders have made labeling modifications.

The monograph title additions or changes shown below will remain in this section in each succeeding supplement of this edition. Once the next edition of the ADP is published, the products affected by the title additions or changes will be displayed with the new dosage form in the appropriate drug list. As notification to the reader, these monograph title additions or changes will also be listed in a special section of the ADP.

USP MONOGRAPH TITLE ADDITIONS OR CHANGES

FORMER USP MONOGRAPH TITLE (FORMER ADP DOSAGE FORM; ROUTE)	NEW USP MONOGRAPH TITLE (NEW ADP DOSAGE FORM; ROUTE)

THERE WERE NO USP MONOGRAPH TITLE ADDITIONS OR CHANGES DURING THE MONTH OF NOVEMBER 1994.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1993) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 1993	MAR 1994	JUN 1994	SEP 1994
DRUG PRODUCTS LISTED	9140	9153	9079	9092
SINGLE SOURCE	2144 (23.5%)	2151 (23.5%)	2150 (23.7%)	2127 (23.4%)
MULTISOURCE	6996 (76.5%)	7002 (76.5%)	6929 (76.3%)	6965 (76.6%)
THERAPEUTICALLY EQUIVALENT	6292 (68.8%)	6306 (68.9%)	6290 (69.3%)	6329 (69.6%)
NOT THERAPEUTICALLY EQUIVALENT	527 (5.8%)	513 (5.6%)	458 (5.0%)	453 (5.0%)
EXCEPTIONS[1]	177 (1.9%)	183 (2.0%)	181 (2.0%)	183 (2.0%)
NEW MOLECULAR ENTITIES APPROVED	--	6	5	2
NUMBER OF APPLICANTS	526	528	490	539

[1]Amino acid-containing products of varying composition (see Introduction, page xvii of the List).

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

	MEDIGESIC PLUS			
AB	US CHEM	325MG;50MG;40MG	N89115 001	JAN 14, 1986
	@	325MG;50MG;40MG	N89115 001	JAN 14, 1986

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

	COMPAL			
AA	PURDUE FREDERICK	356.4MG;30MG;16MG	N88584 001	MAR 04, 1986
	DHC PLUS			
AA	PURDUE FREDERICK	356.4MG;30MG;16MG	N88584 001	MAR 04, 1986

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL

	CO-GESIC			
AA	CENT PHARMS	500MG;5MG	N89360 001	MAR 02, 1988
	@	500MG;5MG	N89360 001	MAR 02, 1988

ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

		TALACEN			
> ADD >	+	SANOFI WINTHROP	650MG;EQ 25MG BASE	N18458 001	SEP 23, 1982
> ADD >					
> DLT >	+	STERLING WINTHROP	650MG;EQ 25MG BASE	N18458 001	SEP 23, 1982
> DLT >					

ACETIC ACID, GLACIAL; ALUMINUM ACETATE

SOLUTION/DROPS; OTIC

	ACETIC ACID 2% IN AQUEOUS ALUMINUM ACETATE			
AT	BAUSCH AND LOMB	2%;0.79%	N40063 001	FEB 25, 1994
	BOROFAIR			
AT	PHARMAFAIR	2%;0.79%	N88606 001	AUG 21, 1985

ACETIC ACID, GLACIAL; ALUMINUM ACETATE

SOLUTION/DROPS; OTIC

	BOROFAIR			
	@ PHARMAFAIR	2%;0.79%	N88606 001	AUG 21, 1985
	DOMEBORO			
AT	MILES	2%;0.79%	N84476 001	
AT	+	2%;0.79%	N84476 001	

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS; OTIC

	HYDROCORTISONE AND ACETIC ACID			
AT	BAUSCH AND LOMB	2%;1%	N40097 001	OCT 31, 1994

ACETYLCHOLINE CHLORIDE

POWDER FOR RECONSTITUTION; OPHTHALMIC

	MIOCHOL			
	+ CIBA VISION	20MG/VIAL	N16211 001	
	+ IOLAB	20MG/VIAL	N16211 001	
	MIOCHOL-E			
	+ CIBA VISION	20MG/VIAL	N20213 001	SEP 22, 1993
	+ IOLAB	20MG/VIAL	N20213 001	SEP 22, 1993

ACETYLCYSTEINE

SOLUTION; INHALATION, ORAL

	ACETYLCYSTEINE			
AN	ABBOTT	10%	N73664 001	AUG 30, 1994
AN		20%	N74037 001	AUG 30, 1994

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE; ORAL

	SEMPREX-D			
	+ BURROUGHS WELLCOME	8MG;60MG	N19806 001	MAR 25, 1994

ALBUTEROL SULFATE

SYRUP; ORAL
ALBUTEROL SULFATE

AA	MOVA	EQ 2MG BASE/5ML	N74302 001 SEP 30, 1994

TABLET; ORAL
ALBUTEROL SULFATE

AB	WARNER CHILCOTT	EQ 2MG BASE	N72817 001 JAN 09, 1990
AB		EQ 4MG BASE	N72818 001 JAN 09, 1990
@		EQ 2MG BASE	N72817 001 JAN 09, 1990
@		EQ 4MG BASE	N72818 001 JAN 09, 1990

ALPRAZOLAM

TABLET; ORAL
ALPRAZOLAM

AB	MYLAN	0.25MG	N74215 001 JAN 27, 1994
AB		0.5MG	N74215 002 JAN 27, 1994
AB		1MG	N74215 003 JAN 27, 1994
AB		2MG	N74215 004 JAN 27, 1994
AB	NOVOPHARM	0.25MG	N74085 001 FEB 16, 1994
AB		0.5MG	N74085 002 FEB 16, 1994
AB		1MG	N74085 003 FEB 16, 1994
AB	ZENITH LABS	0.25MG	N74294 001 JUL 29, 1994
AB		0.5MG	N74294 002 JUL 29, 1994
AB		1MG	N74294 003 JUL 29, 1994
AB		2MG	N74294 004 JUL 29, 1994

AMANTADINE HYDROCHLORIDE

SYRUP; ORAL
AMANTADINE HCL

AA	HI TECH PHARMA	50MG/5ML	N74170 001 OCT 28, 1994

AMBENONIUM CHLORIDE

TABLET; ORAL
MYTELASE

SANOFI WINTHROP	10MG	N10155 002
STERLING WINTHROP	10MG	N10155 002

AMIKACIN SULFATE

INJECTABLE; INJECTION
AMIKACIN

> ADD >	AP	ABBOTT	EQ 50MG BASE/ML	N63263 001 NOV 30, 1994
> ADD >	AP		EQ 250MG BASE/ML	N63264 001 NOV 30, 1994
> ADD >	AP		EQ 250MG BASE/ML	N63265 001 NOV 30, 1994
> ADD >	AP		EQ 250MG BASE/ML	N63266 001 OCT 31, 1994
			EQ 62.5MG BASE/ML	N63283 001 OCT 31, 1994
> ADD >	AP	BEDFORD	EQ 50MG BASE/ML	N63313 001 APR 11, 1994
> ADD >	AP		EQ 250MG BASE/ML	N63315 001 APR 11, 1994
	AP	ELKINS SINN	EQ 50MG BASE/ML	N63274 001 MAY 18, 1992
	AP +		EQ 50MG BASE/ML	N63274 001 MAY 18, 1992
	AP		EQ 250MG BASE/ML	N63275 001 MAY 18, 1992
	AP +		EQ 250MG BASE/ML	N63275 001 MAY 18, 1992

AMIKIN

@	APOTHECON	EQ 50MG BASE/ML	N50495 001
@		EQ 250MG BASE/ML	N50495 002
AP +	BRISTOL	EQ 50MG BASE/ML	N50495 001
AP		EQ 50MG BASE/ML	N62562 001 SEP 20, 1984
AP +		EQ 250MG BASE/ML	N50495 002

AMIKACIN SULFATE

INJECTABLE; INJECTION

	AMIKIN			
AP	BRISTOL	EQ 250MG BASE/ML	N62562 002	SEP 20, 1984
@		EQ 50MG BASE/ML	N62562 001	SEP 20, 1984
@		EQ 250MG BASE/ML	N62562 002	SEP 20, 1984

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER

	ABBOTT	5%;25GM/100ML	N19565 001	DEC 17, 1986
@		5%;25GM/100ML	N19565 001	DEC 17, 1986

AMINOPHYLLINE

INJECTABLE; INJECTION

	AMINOPHYLLINE			
AP	FUJISAWA	25MG/ML	N87886 001	AUG 30, 1983
@		25MG/ML	N87886 001	AUG 30, 1983
AP	KING PHARMS	25MG/ML	N86606 001	
AP	SMITHKLINE BEECHAM	25MG/ML	N86606 001	

TABLET; ORAL

	AMINOPHYLLINE			
AB	GLOBAL PHARMS	100MG	N84574 001	
AB		200MG	N84576 001	
BD	LANNETT	100MG	N84588 001	
BD		200MG	N84588 002	
@		100MG	N84588 001	
@		200MG	N84588 002	
BD	RICHLYN	100MG	N84574 001	
BD		200MG	N84576 001	

AMINOSALICYLIC ACID

GRANULE, DELAYED RELEASE; ORAL

	PASER			
+	JACOBUS	4GM/PACKET	N74346 001	JUN 30, 1994

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

	AMITRIPTYLINE HCL			
AB	LEMMON	10MG	N86610 001	
AB		25MG	N86859 001	
AB		50MG	N86857 001	
AB		75MG	N86860 001	
AB		100MG	N86854 001	
AB		150MG	N86853 001	
@		10MG	N86610 001	
@		25MG	N86859 001	
@		50MG	N86857 001	
@		75MG	N86860 001	
@		100MG	N86854 001	
@		150MG	N86853 001	

AMOXICILLIN

CAPSULE; ORAL

	AMOXICILLIN			
AB	BIOCHEMIE	250MG	N64076 001	SEP 30, 1994
AB		500MG	N64076 002	SEP 30, 1994
	POLYMOX			
AB	APOTHECON	250MG	N63099 001	MAR 20, 1992
AB		500MG	N63099 002	MAR 20, 1992
AB	BRISTOL MYERS	250MG	N63099 001	MAR 20, 1992
AB		500MG	N63099 002	MAR 20, 1992

POWDER FOR RECONSTITUTION; ORAL

	POLYMOX			
@	APOTHECON	125MG/5ML	N61851 001	
@		125MG/5ML	N62323 001	
@		250MG/5ML	N61851 002	

AMOXICILLIN

POWDER FOR RECONSTITUTION; ORAL

	POLYMOX			
	@ APOTHECON	250MG/5ML	N62323 002	
AB	BRISTOL	125MG/5ML	N61851 001	
AB		125MG/5ML	N62323 001	
AB		250MG/5ML	N61851 002	
AB		250MG/5ML	N62323 002	

AMPHETAMINE SULFATE

TABLET; ORAL

	AMPHETAMINE SULFATE			
	LANNETT	5MG	N83901 001	AUG 31, 1984
		10MG	N83901 002	AUG 31, 1984
	@	5MG	N83901 001	AUG 31, 1984
	@	10MG	N83901 002	AUG 31, 1984

AMPHOTERICIN B

INJECTABLE; INJECTION

	AMPHOTERICIN B			
AP	FUJISAWA	50MG/VIAL	N62728 001	APR 13, 1987
	@	50MG/VIAL	N62728 001	APR 13, 1987

AMPICILLIN/AMPICILLIN TRIHYDRATE

POWDER FOR RECONSTITUTION; ORAL

	POLYCILLIN			
	@ APOTHECON	EQ 125MG BASE/5ML	N62297 001	
	@	EQ 250MG BASE/5ML	N62297 002	
AB	BRISTOL	EQ 125MG BASE/5ML	N62297 001	
AB		EQ 250MG BASE/5ML	N62297 002	

AMRINONE LACTATE

INJECTABLE; INJECTION

	INOCOR			
	SANOFI WINTHROP	EQ 5MG BASE/ML	N18700 001	JUL 31, 1984
	STERLING WINTHROP	EQ 5MG BASE/ML	N18700 001	JUL 31, 1984

ANTAZOLINE PHOSPHATE; NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	VASOCON-A			
+	CIBA VISION	0.5%;0.05%	N18746 001	APR 30, 1990
+	IOLAB	0.5%;0.05%	N18746 001	APR 30, 1990

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

	M.V.C. 9+3			
AP	FUJISAWA	10MG/ML;0.006MG/ML;0.5 UGM/ML; 1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML; 0.4MG/ML;0.36MG/ML;0.3MG/ML; 330 UNITS/ML;1 IU/ML	N18440 002	AUG 08, 1985
	@	10MG/ML;0.006MG/ML;0.5 UGM/ML; 1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML; 0.4MG/ML;0.36MG/ML;0.3MG/ML; 330 UNITS/ML;1 IU/ML	N18440 002	AUG 08, 1985

ASPIRIN; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

	TALWIN COMPOUND			
> ADD >	+ SANOFI WINTHROP	325MG;EQ 12.5MG BASE	N16891 001	
> DLT >	+ STERLING WINTHROP	325MG;EQ 12.5MG BASE	N16891 001	

ATENOLOL

TABLET; ORAL
ATENOLOL

AB	GENPHARM	50MG	N74126 001 MAR 23, 1994
AB		100MG	N74126 002 MAR 23, 1994
AB	INVAMED	25MG	N74265 001 FEB 28, 1994
AB		50MG	N74265 002 FEB 28, 1994
AB		100MG	N74265 003 FEB 28, 1994

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL
LOFENE

AA	LANNETT	0.025MG;2.5MG	N85372 001
	@	0.025MG;2.5MG	N85372 001

AZITHROMYCIN DIHYDRATE

POWDER FOR RECONSTITUTION; ORAL
ZITHROMAX

+	PFIZER	EQ 1GM BASE/PACKET	N50693 001 SEP 28, 1994

BACITRACIN

OINTMENT; OPHTHALMIC
BACITRACIN

AT	PHARMADERM	500 UNITS/GM	N62158 001
	@	500 UNITS/GM	N62158 001
AT	PHARMAFAIR	500 UNITS/GM	N62453 001 MAR 28, 1984
	@	500 UNITS/GM	N62453 001 MAR 28, 1984

BACLOFEN

TABLET; ORAL
BACLOFEN

AB	ROYCE LABS	10MG	N73092 001 JAN 28, 1994

BACLOFEN

TABLET; ORAL
BACLOFEN

AB	ROYCE LABS	20MG	N73093 001 JAN 28, 1994

BENZYL BENZOATE

EMULSION; TOPICAL
BENZYL BENZOATE

+	LANNETT	50%	N84535 001
	@	50%	N84535 001

BETAMETHASONE DIPROPIONATE

CREAM, AUGMENTED; TOPICAL
DIPROLENE

+	SCHERING	EQ 0.05% BASE	N19408 001 JAN 31, 1986
	@	EQ 0.05% BASE	N19408 001 JAN 31, 1986

GEL; TOPICAL
DIPROLENE

+	SCHERING	EQ 0.05% BASE	N19408 002 NOV 22, 1991

LOTION; TOPICAL
BETAMETHASONE DIPROPIONATE

AB	TARO PHARMS	EQ 0.05% BASE	N74272 001 SEP 30, 1994

OINTMENT; TOPICAL
BETAMETHASONE DIPROPIONATE

AB	TARO PHARMS	EQ 0.05% BASE	N74271 001 SEP 15, 1994

BETAMETHASONE VALERATE

LOTION; TOPICAL
BETAMETHASONE VALERATE

AB	PHARMAFAIR	EQ 0.1% BASE	N70484 001 MAY 29, 1987
	@	EQ 0.1% BASE	N70484 001 MAY 29, 1987

BETAMETHASONE VALERATE

OINTMENT; TOPICAL
BETAMETHASONE VALERATE

B*	CLAY PARK	EQ 0.1% BASE	N71478 001 DEC 23, 1987
	@	EQ 0.1% BASE	N71478 001 DEC 23, 1987

BETHANECHOL CHLORIDE

TABLET; ORAL
BETHANECHOL CHLORIDE

AA	LANNETT	5MG	N84702 001
AA		10MG	N84712 001
AA		25MG	N84074 001
	@	5MG	N84702 001
	@	10MG	N84712 001
	@	25MG	N84074 001

BITOLTEROL MESYLATE

AEROSOL, METERED; INHALATION
TORNALATE

	+ SANOFI WINTHROP	0.37MG/INH	N18770 001 DEC 28, 1984
	* STERLING WINTHROP	0.37MG/INH	N18770 001 DEC 28, 1984

SOLUTION; INHALATION
TORNALATE

	SANOFI WINTHROP	0.2%	N19548 001 FEB 19, 1992
	STERLING WINTHROP	0.2%	N19548 001 FEB 19, 1992

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL
DIMETANE-DX

AA	ROBINS AH	2MG/5ML;10MG/5ML;30MG/5ML	N11694 007 MAR 29, 1984

BUDESONIDE

AEROSOL, METERED; NASAL
RHINOCORT

	+ ASTRA	0.05MG/INH	N20233 001 FEB 14, 1994

BUMETANIDE

INJECTABLE; INJECTION
BUMETANIDE

AP	SANOFI WINTHROP	0.25MG/ML	N74332 001 OCT 31, 1994

BUMEX

AP	+ ROCHE	0.25MG/ML	N18226 001 FEB 28, 1983

BUTABARBITAL SODIUM

ELIXIR; ORAL
BUTALAN

	LANNETT	33.3MG/5ML	N85880 001
	@	33.3MG/5ML	N85880 001

TABLET; ORAL
BUTISOL SODIUM

AA	WALLACE	100MG	N00793 005
		100MG	N00793 005

SODIUM BUTABARBITAL

AA	LANNETT	100MG	N85881 001
	@	100MG	N85881 001
AA	ZENITH	30MG	N84040 001
	@ ZENITH LABS	30MG	N84040 001

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY; RECTAL
MIGERGOT

BR	G AND W LABS	100MG;2MG	N86557 001 OCT 04, 1983

WIGRAINE

BR	ORGANON	100MG;2MG	N86557 001 OCT 04, 1983

CALCIFEDIOL

CAPSULE; ORAL
CALDEROL
ORGANON 0.02MG N18312 001
\+ 0.05MG N18312 002

CALCIFEDIOL, ANHYDROUS

CAPSULE; ORAL
CALDEROL
ORGANON 0.02MG N18312 001
\+ 0.05MG N18312 002

CALCIUM; MEGLUMINE; METRIZOIC ACID

INJECTABLE; INJECTION
ISOPAQUE 280
> ADD > @ NYCOMED 0.35MG/ML;140.1MG/ML; 461.8MG/ML N17506 001
> ADD >
> DLT > @ STERLING WINTHROP 0.35MG/ML;140.1MG/ML; 461.8MG/ML N17506 001
> DLT >

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL
> DLT > DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER
> DLT >
> DLT >
AT FRESENIUS 18.4MG/100ML;1.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML N20171 001 AUG 19, 1992
> ADD >
> ADD >
> ADD >
> DLT > DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER
> DLT >
> DLT >
AT FRESENIUS 18.4MG/100ML;2.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML N20171 002 AUG 19, 1992
> ADD >
> ADD >
> ADD >
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER
> DLT >
> DLT >
> DLT >
AT FRESENIUS 18.4MG/100ML;4.25GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML N20171 003 AUG 19, 1992
> DLT >

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL
DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER
AT BAXTER 18.3MG/100ML;1.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML N20183 001 DEC 04, 1992
DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER
AT BAXTER 18.3MG/100ML;2.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML N20183 002 DEC 04, 1992
DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER
AT BAXTER 18.3MG/100ML;3.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML N20183 003 DEC 04, 1992
DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER
AT BAXTER 18.3MG/100ML;4.25GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML N20183 004 DEC 04, 1992
DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER
AT BAXTER 18.3MG/100ML;1.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML N17512 004
INPERSOL W/ DEXTROSE 1.5% IN PLASTIC CONTAINER
> DLT > AT ABBOTT 25.7MG/100ML;1.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML N18379 002
> DLT >
> DLT >
> ADD > AT FRESENIUS 25.7MG/100ML;1.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML N18379 002
> ADD >
> ADD >
INPERSOL W/ DEXTROSE 2.5% IN PLASTIC CONTAINER
> DLT > AT ABBOTT 25.7MG/100ML;2.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML N18379 003
> DLT >
> DLT >
> ADD > AT FRESENIUS 25.7MG/100ML;2.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML N18379 003
> ADD >
> ADD >
INPERSOL W/ DEXTROSE 3.5% IN PLASTIC CONTAINER
> DLT > AT ABBOTT 25.7MG/100ML;3.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML N18379 007 JUN 24, 1988
> DLT >
> DLT >

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

INPERSOL W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

> ADD >	AT	FRESENIUS	25.7MG/100ML;3.5GM/100ML;	
> ADD >			15.2MG/100ML;567MG/100ML;	
> ADD >			392MG/100ML	N18379 007
> ADD				JUN 24, 1988

INPERSOL W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

> DLT >	AT	ABBOTT	25.7MG/100ML;4.25GM/100ML;	
> DLT >			15.2MG/100ML;567MG/100ML;	
> DLT >			392MG/100ML	N18379 001
> ADD >	AT	FRESENIUS	25.7MG/100ML;4.25GM/100ML;	
> ADD >			15.2MG/100ML;567MG/100ML;	
> ADD >			392MG/100ML	N18379 001

INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

	AT	ABBOTT	18.4MG/100ML;1.5GM/100ML;	
			5.08MG/100ML;538MG/100ML;	
			448MG/100ML	N20374 001
				JUN 13, 1994

INPERSOL-LC/LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

	AT	ABBOTT	18.4MG/100ML;2.5GM/100ML;	
			5.08MG/100ML;538MG/100ML;	
			448MG/100ML	N20374 002
				JUN 13, 1994

INPERSOL-LC/LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

	AT	ABBOTT	18.4MG/100ML;3.5GM/100ML;	
			5.08MG/100ML;538MG/100ML;	
			448MG/100ML	N20374 003
				JUN 13, 1994

INPERSOL-LC/LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

	AT	ABBOTT	18.4MG/100ML;4.25GM/100ML;	
			5.08MG/100ML;538MG/100ML;	
			448MG/100ML	N20374 004
				JUN 13, 1994

INPERSOL-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

> DLT >	AT	ABBOTT	25.7MG/100ML;1.5GM/100ML;	
> DLT >			5.08MG/100ML;538MG/100ML;	
> DLT >			448MG/100ML	N18379 004
> DLT >				JUL 07, 1982
> ADD >	AT	FRESENIUS	25.7MG/100ML;1.5GM/100ML;	
> ADD >			5.08MG/100ML;538MG/100ML;	
> ADD >			448MG/100ML	N18379 004
> ADD >				JUL 07, 1982

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

INPERSOL-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

> DLT >	AT	ABBOTT	25.7MG/100ML;2.5GM/100ML;	
> DLT >			5.08MG/100ML;538MG/100ML;	
> DLT >			448MG/100ML	N18379 005
> DLT				JUL 07, 1982
> ADD >	AT	FRESENIUS	25.7MG/100ML;2.5GM/100ML;	
> ADD >			5.08MG/100ML;538MG/100ML;	
> ADD >			448MG/100ML	N18379 005
> ADD >				JUL 07, 1982

INPERSOL-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

> DLT >	AT	ABBOTT	25.7MG/100ML;3.5GM/100ML;	
> DLT >			5.08MG/100ML;538MG/100ML;	
> DLT >			448MG/100ML	N18379 008
> DLT >				JUN 24, 1988
> ADD >	AT	FRESENIUS	25.7MG/100ML;3.5GM/100ML;	
> ADD >			5.08MG/100ML;538MG/100ML;	
> ADD >			448MG/100ML	N18379 008
> ADD >				JUN 24, 1988

INPERSOL-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

> DLT >	AT	ABBOTT	25.7MG/100ML;4.25GM/100ML;	
> DLT >			5.08MG/100ML;538MG/100ML;	
> DLT >			448MG/100ML	N18379 006
> DLT >				JUL 07, 1982
> ADD >	AT	FRESENIUS	25.7MG/100ML;4.25GM/100ML;	
> ADD >			5.08MG/100ML;538MG/100ML;	
> ADD >			448MG/100ML	N18379 006
> ADD >				JUL 07, 1982

CALCIUM CHLORIDE; DEXTROSE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

INPERSOL-ZM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

> DLT >	@ ABBOTT	25.7MG/100ML;1.5GM/100ML;	
> DLT >		538MG/100ML;448MG/100ML	N19395 001
> DLT >			MAR 26, 1986
> ADD >	@ FRESENIUS	25.7MG/100ML;1.5GM/100ML;	
> ADD >		538MG/100ML;448MG/100ML	N19395 001
> ADD >			MAR 26, 1986

INPERSOL-ZM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

> DLT >	@ ABBOTT	25.7MG/100ML;2.5GM/100ML;	
> DLT >		538MG/100ML;448MG/100ML	N19395 002
> DLT >			MAR 26, 1986

CALCIUM CHLORIDE; DEXTROSE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

INPERSOL-ZM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

> ADD >	@	FRESENIUS	25.7MG/100ML;2.5GM/100ML; 538MG/100ML;448MG/100ML	N19395 002 MAR 26, 1986

INPERSOL-ZM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

> DLT >	@	ABBOTT	25.7MG/100ML;4.25GM/100ML; 538MG/100ML;448MG/100ML	N19395 003 MAR 26, 1986
> ADD >	@	FRESENIUS	25.7MG/100ML;4.25GM/100ML; 538MG/100ML;448MG/100ML	N19395 003 MAR 26, 1986

CALCIUM METRIZOATE; MEGLUMINE METRIZOATE; METRIZOATE MAGNESIUM; METRIZOATE SODIUM

INJECTABLE; INJECTION

ISOPAQUE 440

> ADD >	@	NYCOMED	0.78MG/ML;75.9MG/ML;0.15MG/ML; 16.6MG/ML	N16847 001
> DLT >	@	STERLING WINTHROP	0.78MG/ML;75.9MG/ML;0.15MG/ML; 16.6MG/ML	N16847 001

CARBACHOL

INJECTABLE; INJECTION

CARBACHOL

@	PHARMAFAIR	0.01%	N70292 001 MAY 21, 1986

MIOSTAT

+	ALCON	0.01%	N16968 001

SOLUTION; INTRAOCULAR

CARBACHOL

@	PHARMAFAIR	0.01%	N70292 001 MAY 21, 1986

MIOSTAT

+	ALCON	0.01%	N16968 001

CARBAMAZEPINE

SUSPENSION; ORAL

TEGRETOL

+	GEIGY	100MG/5ML	N18927 001 DEC 18, 1987

CARBAMAZEPINE

TABLET; ORAL

TEGRETOL

AB	+	BASEL PHARMS	200MG	N16608 001
AB	+	GEIGY	200MG	N16608 001

TABLET, CHEWABLE; ORAL

TEGRETOL

AB	+	BASEL PHARMS	100MG	N18281 001
AB	+	GEIGY	100MG	N18281 001

CARBIDOPA; LEVODOPA

TABLET; ORAL

CARBIDOPA AND LEVODOPA

AB		SCS	10MG;100MG	N74080 001 MAR 25, 1994
AB			25MG;100MG	N74080 002 MAR 25, 1994
AB			25MG;250MG	N74080 003 MAR 25, 1994

TABLET, EXTENDED RELEASE; ORAL

SINEMET CR

	MERCK SHARP DOHME	25MG;100MG	N19856 002 DEC 24, 1992

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL

CEFADROXIL

AB		APOTHECON	EQ 500MG BASE	N62291 001
AB		ZENITH LABS	EQ 500MG BASE	N62766 001 MAR 03, 1987
	@		EQ 500MG BASE	N62766 001 MAR 03, 1987

ULTRACEF

AB		BRISTOL	EQ 500MG BASE	N62291 001

POWDER FOR RECONSTITUTION; ORAL

CEFADROXIL

AB		APOTHECON	EQ 125MG BASE/5ML	N62334 001

CEFADROXIL/CEFADROXIL HEMIHYDRATE

POWDER FOR RECONSTITUTION; ORAL

CEFADROXIL

AB	APOTHECON	EQ 250MG BASE/5ML	N62334 002
AB		EQ 500MG BASE/5ML	N62334 003
	ULTRACEF		
AB	BRISTOL	EQ 125MG BASE/5ML	N62334 001
AB		EQ 250MG BASE/5ML	N62334 002
AB		EQ 500MG BASE/5ML	N62334 003

TABLET; ORAL

CEFADROXIL

AB	ZENITH LABS	EQ 1GM BASE	N62774 001 APR 08, 1987
	@	EQ 1GM BASE	N62774 001 APR 08, 1987
	ULTRACEF		
AB	APOTHECON	EQ 1GM BASE	N62390 001 JUN 10, 1982
AB	BRISTOL	EQ 1GM BASE	N62390 001 JUN 10, 1982

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUM

AP	FUJISAWA	EQ 500MG BASE/VIAL	N62688 002 NOV 17, 1986
AP		EQ 1GM BASE/VIAL	N62688 003 NOV 17, 1986
AP		EQ 10GM BASE/VIAL	N62688 004 NOV 17, 1986
AP		EQ 20GM BASE/VIAL	N62688 005 AUG 03, 1987
	@	EQ 500MG BASE/VIAL	N62688 002 NOV 17, 1986
	@	EQ 1GM BASE/VIAL	N62688 003 NOV 17, 1986
	@	EQ 10GM BASE/VIAL	N62688 004 NOV 17, 1986
	@	EQ 20GM BASE/VIAL	N62688 005 AUG 03, 1987

CEFTIZOXIME SODIUM

INJECTABLE; INJECTION

CEFIZOX

	FUJISAWA	EQ 1GM BASE/VIAL	N63294 002 MAR 31, 1994
		EQ 2GM BASE/VIAL	N63294 003 MAR 31, 1994

CEFUROXIME AXETIL

POWDER FOR RECONSTITUTION; ORAL

CEFTIN

+	GLAXO	EQ 125MG BASE/5ML	N50672 001 JUN 30, 1994

CEPHALOTHIN SODIUM

INJECTABLE; INJECTION

CEPHALOTHIN SODIUM

> DLT > AP	FUJISAWA	EQ 1GM BASE/VIAL	N62666 002 JUN 10, 1987
> DLT > AP		EQ 2GM BASE/VIAL	N62666 001 JUN 10, 1987
> DLT >	@	EQ 1GM BASE/VIAL	N62666 002 JUN 10, 1987
> DLT >	@	EQ 2GM BASE/VIAL	N62666 001 JUN 10, 1987
	SEFFIN		
> ADD > AP	GLAXO	EQ 1GM BASE/VIAL	N62435 001 NOV 15, 1983
> ADD > AP		EQ 2GM BASE/VIAL	N62435 002 NOV 15, 1983
> ADD >	+	EQ 10GM BASE/VIAL	N62435 003 NOV 15, 1983
> ADD >	@	EQ 1GM BASE/VIAL	N62435 001 NOV 15, 1983
> ADD >	@	EQ 2GM BASE/VIAL	N62435 002 NOV 15, 1983
	@	EQ 10GM BASE/VIAL	N62435 003 NOV 15, 1983

CHENODIOL

TABLET; ORAL
CHENIX
+ SOLVAY 250MG N18513 002 JUL 28, 1983
@ 250MG N18513 002 JUL 28, 1983

CHLORAMPHENICOL

> DLT > CREAM; TOPICAL
> DLT > CHLOROMYCETIN
> DLT > PARKE DAVIS 1% N50183 001
> ADD > @ 1% N50183 001

OINTMENT; OPHTHALMIC
CHLOROFAIR
AT PHARMAFAIR 1% N62439 001 APR 21, 1983
@ 1% N62439 001 APR 21, 1983

SOLUTION/DROPS; OPHTHALMIC
CHLOROFAIR
AT PHARMAFAIR 0.5% N62437 001 APR 14, 1983
@ 0.5% N62437 001 APR 14, 1983

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL
PERIDEX
AT + PROCTER AND GAMBLE 0.12% N19028 001 AUG 13, 1986

PERIOGARD
AT COLGATE PALMOLIVE 0.12% N73695 001 JAN 14, 1994

CHLORMERODRIN, HG-197

INJECTABLE; INJECTION
CHLORMERODRIN HG 197
@ BRACCO DXS 0.6-1.4mCi/ML N17269 001
@ SQUIBB 0.6-1.4mCi/ML N17269 001

CHLORMEZANONE

TABLET; ORAL
TRANCOPAL
SANOFI WINTHROP 100MG N11467 003
200MG N11467 005
STERLING WINTHROP 100MG N11467 003
200MG N11467 005

CHLOROQUINE HYDROCHLORIDE

INJECTABLE; INJECTION
ARALEN HCL
+ SANOFI WINTHROP EQ 40MG BASE/ML N06002 002
+ STERLING WINTHROP EQ 40MG BASE/ML N06002 002

CHLOROQUINE PHOSPHATE

TABLET; ORAL
ARALEN
AA SANOFI WINTHROP EQ 300MG BASE N06002 001
AA STERLING WINTHROP EQ 300MG BASE N06002 001

CHLOROQUINE PHOSPHATE; PRIMAQUINE PHOSPHATE

TABLET; ORAL
ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE
@ SANOFI WINTHROP EQ 300MG BASE; EQ 45MG BASE N14860 002
@ STERLING WINTHROP EQ 300MG BASE; EQ 45MG BASE N14860 002

CHLORPHENIRAMINE MALEATE

TABLET; ORAL
CHLORPHENIRAMINE MALEATE
AA ZENITH 4MG N80779 001
@ ZENITH LABS 4MG N80779 001

CHLORTHALIDONE

TABLET; ORAL
THALITONE
HORUS THERAP 15MG N19574 001 DEC 20, 1988

CHLORTHALIDONE

TABLET; ORAL
THALITONE
+ HORUS THERAP 15MG N19574 001 DEC 20, 1988

CHOLESTYRAMINE

TABLET; ORAL
QUESTRAN
+ BRISTOL MYERS SQUIBB EQ 1GM RESIN N73403 001 APR 28, 1994

CHYMOTRYPSIN

POWDER FOR RECONSTITUTION; OPHTHALMIC
CATARASE
@ CIBA VISION 150 UNITS/VIAL N18121 001
+ 300 UNITS/VIAL N16938 001
@ IOLAB 150 UNITS/VIAL N18121 001
+ 300 UNITS/VIAL N16938 001

CIMETIDINE

TABLET; ORAL
CIMETIDINE

AB	ENDO LABS	200MG	N74281 001 MAY 17, 1994
AB		300MG	N74281 002 MAY 17, 1994
AB		400MG	N74281 003 MAY 17, 1994
AB		800MG	N74329 001 MAY 17, 1994
AB	MYLAN	200MG	N74246 001 MAY 17, 1994
AB		300MG	N74246 002 MAY 17, 1994
AB		400MG	N74246 003 MAY 17, 1994
AB		800MG	N74246 004 MAY 17, 1994
AB	NOVOPHARM	200MG	N74151 001 MAY 17, 1994

CIMETIDINE

TABLET; ORAL
CIMETIDINE

AB	NOVOPHARM	300MG	N74151 002 MAY 17, 1994
AB		400MG	N74151 003 MAY 17, 1994
AB		800MG	N74463 001 MAY 17, 1994

TAGAMET

AB	SMITHKLINE BEECHAM	200MG	N17920 002
AB		300MG	N17920 003
AB		400MG	N17920 004 DEC 14, 1983
AB +		800MG	N17920 005 APR 30, 1986

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
CIMETIDINE HCL

AP	ENDO LABS	EQ 300MG BASE/2ML	N74005 001 AUG 31, 1994

TAGAMET

AP +	SMITHKLINE BEECHAM	EQ 300MG BASE/2ML	N17939 002

SOLUTION; ORAL
CIMETIDINE HCL

AA	BARRE	EQ 300MG BASE/5ML	N74176 001 JUN 01, 1994

TAGAMET

AA	SMITHKLINE BEECHAM	EQ 300MG BASE/5ML	N17924 001

CLEMASTINE FUMARATE

SYRUP; ORAL
CLEMASTINE FUMARATE

AA	LEMMON	EQ 0.5MG BASE/5ML	N73399 001 JUN 30, 1994

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION
CLINDAMYCIN PHOSPHATE

AP	BEDFORD	EQ 150MG BASE/ML	N63163 001 JUN 30, 1994

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION
CLINDAMYCIN PHOSPHATE

AP	DUPONT	EQ 150MG BASE/ML	N62908 001 FEB 01, 1989
	@ DUPONT MERCK	EQ 150MG BASE/ML	N62908 001 FEB 01, 1989
AP	FUJISAWA	EQ 150MG BASE/ML	N62747 001 JUN 03, 1988
	@	EQ 150MG BASE/ML	N62747 001 JUN 03, 1988

SOLUTION; TOPICAL
CLEOCIN

	UPJOHN	EQ 1% BASE	N50537 002 FEB 22, 1994

CLOBETASOL PROPIONATE

CREAM; TOPICAL
CLOBETASOL PROPIONATE

AB	COPLEY PHARM	0.05%	N74087 001 FEB 16, 1994
AB	NMC	0.05%	N74139 001 AUG 03, 1994

TEMOVATE

AB	+ GLAXO	0.05%	N19322 001 DEC 27, 1985
AB	+	0.05%	N20340 001 JUN 17, 1994

TEMOVATE EMOLLIENT

BX	+ GLAXO	0.05%	N20340 001 JUN 17, 1994

GEL; TOPICAL
TEMOVATE

	+ GLAXO	0.05%	N20337 001 APR 29, 1994

OINTMENT; TOPICAL
CLOBETASOL PROPIONATE

AB	COPLEY PHARM	0.05%	N74089 001 FEB 16, 1994
AB	NMC	0.05%	N74128 001 AUG 03, 1994

TEMOVATE

AB	+ GLAXO	0.05%	N19323 001 DEC 27, 1985

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL
ANAFRANIL

	BASEL PHARMS	25MG	N19906 001 DEC 29, 1989
		50MG	N19906 002 DEC 29, 1989
	+	75MG	N19906 003 DEC 29, 1989
	CIBA	25MG	N19906 001 DEC 29, 1989
		50MG	N19906 002 DEC 29, 1989
	+	75MG	N19906 003 DEC 29, 1989

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
PROMETHAZINE VC W/ CODEINE

AA	PENNEX	10MG/5ML;5MG/5ML; 6.25MG/5ML	N88896 001 JAN 04, 1985
	@ PENNEX PHARMS	10MG/5ML;5MG/5ML; 6.25MG/5ML	N88896 001 JAN 04, 1985

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
PROMETHAZINE W/ CODEINE

AA	PENNEX	10MG/5ML;6.25MG/5ML	N88875 001 DEC 17, 1984
	@ PENNEX PHARMS	10MG/5ML;6.25MG/5ML	N88875 001 DEC 17, 1984

COLESTIPOL HYDROCHLORIDE

TABLET; ORAL
COLESTID

	UPJOHN	1GM	N20222 001 JUL 19, 1994

CORTISONE ACETATE

INJECTABLE; INJECTION
CORTISONE ACETATE

BP	STERIS	25MG/ML	N83147 003		
BP		25MG/ML	N85677 001		
BP		50MG/ML	N83147 004		
BP		50MG/ML	N85677 002		
	@	25MG/ML	N83147 003		
	@	25MG/ML	N85677 001		
	@	50MG/ML	N83147 004		
	@	50MG/ML	N85677 002	> ADD >	
BP	UPJOHN	25MG/ML	N08126 002	> ADD >	
	@	25MG/ML	N08126 002		
	CORTONE				
	MERCK SHARP DOHME	25MG/ML	N07110 002		
+		50MG/ML	N07110 003		
BP	MSD	25MG/ML	N07110 002		
BP	+	50MG/ML	N07110 003		

TABLET; ORAL
CORTISONE ACETATE

BP	INWOOD	25MG	N80731 001
	@ INWOOD LABS	25MG	N80731 001

CROMOLYN SODIUM

SOLUTION; INHALATION
CROMOLYN SODIUM

AN	DEY	10MG/ML	N74209 001 APR 26, 1994

INTAL

AN	+ FISONS	10MG/ML	N18596 001 MAY 28, 1982

CYANOCOBALAMIN, CO-57

CAPSULE; ORAL
RUBRATOPE-57

BRACCO DXS	0.5-1 uCi	N16089 002
SQUIBB	0.5-1 uCi	N16089 002

CYANOCOBALAMIN, CO-60

CAPSULE; ORAL
RUBRATOPE-60

@ BRACCO DXS	0.5-1 uCi	N16090 002

CYANOCOBALAMIN, CO-60

CAPSULE; ORAL
RUBRATOPE-60

@ SQUIBB	0.5-1 uCi	N16090 002

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL
CYCLOBENZAPRINE HCL

AB	ROYCE LABS	10MG	N74436 001 NOV 30, 1994

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
CYCLOGYL

AT	* ALCON	0.5%	N84109 001
	+	0.5%	N84109 001
	PENTOLAIR		
AT	BAUSCH AND LOMB	1%	N40075 001 APR 29, 1994
AT	PHARMAFAIR	0.5%	N88643 001 FEB 09, 1987
AT		1%	N88150 001 FEB 25, 1983
	@	0.5%	N88643 001 FEB 09, 1987
	@	1%	N88150 001 FEB 25, 1983

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL
CYPROHEPTADINE HCL

AA	CHELSEA	4MG	N86165 001
	@ CHELSEA LABS	4MG	N86165 001

CYSTEAMINE BITARTRATE

CAPSULE; ORAL
CYSTAGON

MYLAN	EQ 50MG BASE	N20392 001 AUG 15, 1994

CYSTEAMINE BITARTRATE

CAPSULE; ORAL

	CYSTAGON			
+	MYLAN	EQ 150MG BASE	N20392 002	
			AUG 15, 1994	

CYTARABINE

INJECTABLE; INJECTION

	CYTARABINE			
+	BULL D	20MG/ML	N72945 001	
			FEB 28, 1994	
AP	CETUS BEN VENUE	1GM/VIAL	N74245 001	
			AUG 31, 1994	
AP		2GM/VIAL	N74245 002	
			AUG 31, 1994	
	CYTOSAR-U			
AP +	UPJOHN	1GM/VIAL	N16793 003	
			DEC 21, 1987	
AP +		2GM/VIAL	N16793 004	
			DEC 21, 1987	

DACTINOMYCIN

INJECTABLE; INJECTION

	COSMEGEN			
+	MERCK SHARP DOHME	0.5MG/VIAL	N50682 001	
+	MSD	0.5MG/VIAL	N60467 001	

DANAZOL

CAPSULE; ORAL

	DANOCRINE			
	SANOFI WINTHROP	50MG	N17557 003	> DLT >
		100MG	N17557 004	> ADD >
		200MG	N17557 002	
+				
	STERLING WINTHROP	50MG	N17557 003	
		100MG	N17557 004	
+		200MG	N17557 002	

DESMOPRESSIN ACETATE

SPRAY, METERED; NASAL

	DESMOPRESSIN ACETATE			
+	RHONE POULENC RORER	0.15MG/INH	N20355 001	
			MAR 07, 1994	

DESONIDE

OINTMENT; TOPICAL

	DESONIDE			
AB	TARO	0.05%	N74254 001	
			AUG 03, 1994	

DEXAMETHASONE

TABLET; ORAL

	DECADRON			
BP	MERCK SHARP DOHME	0.25MG	N11664 004	
	MSD	0.25MG	N11664 004	

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

	DEXASPORIN			
AT	BAUSCH AND LOMB	0.1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N64063 001	
			JUL 25, 1994	

DEXAMETHASONE SODIUM PHOSPHATE

AEROSOL; NASAL

	DEXACORT			
+	ADAMS LABS	EQ 0.1MG PHOSPHATE/INH	N14242 001	
+	MEDEVA	EQ 0.1MG PHOSPHATE/INH	N14242 001	

AEROSOL, METERED; INHALATION

	DECADRON			
+	MSD	EQ 0.1MG PHOSPHATE/INH	N13413 001	
	DEXACORT			
+	MEDEVA	EQ 0.1MG PHOSPHATE/INH	N13413 001	

OINTMENT; OPHTHALMIC

	DEXAIR			> DLT >
AT	PHARMAFAIR	EQ 0.05% PHOSPHATE	N88071 001	> DLT >
			DEC 28, 1982	> DLT >

DEXAMETHASONE SODIUM PHOSPHATE

OINTMENT; OPHTHALMIC

> DLT >		DEXAIR		
> ADD >		@ PHARMAFAIR	EQ 0.05% PHOSPHATE	N88071 001 DEC 28, 1982
> ADD >				

SOLUTION/DROPS; OPHTHALMIC

DEXAIR			
	PHARMAFAIR	EQ 0.1% PHOSPHATE	N88433 001 DEC 15, 1983
	@	EQ 0.1% PHOSPHATE	N88433 001 DEC 15, 1983

DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE

SOLUTION/DROPS; OPHTHALMIC

NEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE

> DLT >	AT	PHARMAFAIR	EQ 0.1% PHOSPHATE; EQ 3.5MG BASE/ML	N62539 001 JAN 10, 1985
> DLT >				
> DLT >				
> ADD >		@	EQ 0.1% PHOSPHATE; EQ 3.5MG BASE/ML	N62539 001 JAN 10, 1985
> ADD >				
> ADD >				

DEXTROAMPHETAMINE SULFATE

ELIXIR; ORAL

DEXEDRINE			
	SMITHKLINE BEECHAM	5MG/5ML	N83902 001
	@	5MG/5ML	N83902 001

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

AA	LANNETT	5MG	N83903 001
AA		10MG	N83903 003
		15MG	N85652 001
	@	5MG	N83903 001
	@	10MG	N83903 003
	@	15MG	N85652 001

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE W/ DEXTROMETHORPHAN

AA	PENNEX	15MG/5ML;6.25MG/5ML	N88864 001 JAN 04, 1985

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE W/ DEXTROMETHORPHAN

@	PENNEX PHARMS	15MG/5ML;6.25MG/5ML	N88864 001 JAN 04, 1985

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 5% IN PLASTIC CONTAINER

AP	MCGAW	50MG/ML	N16730 002

DEXTROTHYROXINE SODIUM

TABLET; ORAL

CHOLOXIN

	BOOTS	4MG	N12302 004
	*	6MG	N12302 006
	+	4MG	N12302 004
	@	6MG	N12302 006

DIATRIZOATE MEGLUMINE

INJECTABLE; INJECTION

CARDIOGRAFIN

	@ BRACCO DXS	85%	N11620 002
	@ SQUIBB	85%	N11620 002

HYPAQUE

> ADD >	AP	NYCOMED	30%	N16403 002
> ADD >	AP		60%	N16403 001
> DLT >	AP	STERLING WINTHROP	30%	N16403 002
> DLT >	AP		60%	N16403 001

RENO-60

AP	BRACCO DXS	60%	N10040 016

RENO-DIP

AP	BRACCO DXS	30%	N10040 012

RENO-M-60

AP	SQUIBB	60%	N10040 016

RENO-M-DIP

AP	SQUIBB	30%	N10040 012

SOLUTION; URETERAL

RENO-30

AT	BRACCO DXS	30%	N10040 021

RENO-M-30

AT	SQUIBB	30%	N10040 021

DIATRIZOATE MEGLUMINE

SOLUTION; URETHRAL
HYPAQUE-CYSTO

> ADD >	AT	NYCOMED	30%		N16403 003
> DLT >	AT	STERLING WINTHROP	30%		N16403 003

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION
HYPAQUE-76

> ADD >	AP	NYCOMED	66%;10%		N86505 001
> DLT >	AP	STERLING WINTHROP	66%;10%		N86505 001
		HYPAQUE-M,75%			
> ADD >		@ NYCOMED	50%;25%		N10220 003
> DLT >		@ STERLING WINTHROP	50%;25%		N10220 003
		HYPAQUE-M,90%			
> ADD >		@ NYCOMED	60%;30%		N10220 002
> DLT >		@ STERLING WINTHROP	60%;30%		N10220 002
		MD-60			
	AP	MALLINCKRODT	52%;8%		N87074 001
		@	52%;8%		N87074 001

DIATRIZOATE MEGLUMINE; IODIPAMIDE MEGLUMINE

SOLUTION; INTRAUTERINE
SINOGRAFIN

		BRACCO DXS	52.7%;26.8%		N11324 002
		SQUIBB	52.7%;26.8%		N11324 002

DIATRIZOATE SODIUM

INJECTABLE; INJECTION
HYPAQUE

> ADD >	AP	NYCOMED	50%		N09561 001
> ADD >			25%		N09561 003
> DLT >	AP	STERLING WINTHROP	50%		N09561 001
> DLT >			25%		N09561 003

POWDER FOR RECONSTITUTION; ORAL, RECTAL
HYPAQUE

> ADD >		NYCOMED	100%		N11386 001
> DLT >		STERLING WINTHROP	100%		N11386 001

SOLUTION; ORAL, RECTAL
HYPAQUE

> ADD >		NYCOMED	40%		N11386 003

DIATRIZOATE SODIUM

SOLUTION; ORAL, RECTAL
HYPAQUE

> DLT >		STERLING WINTHROP	40%		N11386 003

SOLUTION; URETERAL
HYPAQUE SODIUM 20%

> ADD >		NYCOMED	20%		N09561 002
> DLT >		@ STERLING WINTHROP	20%		N09561 002

DICLOXACILLIN SODIUM

CAPSULE; ORAL
DYNAPEN

	AB	APOTHECON	EQ 500MG BASE		N61454 003

DICUMAROL

TABLET; ORAL
DICUMAROL

		ABBOTT	25MG		N05545 003
		+	25MG		N05545 003

DIENESTROL

CREAM; VAGINAL
ESTRAGUARD

	AT	SOLVAY	0.01%		N84436 001
		@	0.01%		N84436 001

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL
TEPANIL

	AA	3N	25MG		N11673 001
		@	25MG		N11673 001

DIETHYLSTILBESTROL

TABLET; ORAL
DIETHYLSTILBESTROL

	BP	LILLY	1MG		N04041 004
	BP	+	5MG		N04041 005

DIETHYLSTILBESTROL

TABLET; ORAL
DIETHYLSTILBESTROL
LILLY 1MG N04041 004
\+ 5MG N04041 005
STILBESTROL
BP TABLICAPS 1MG N83002 001
BP 5MG N83006 001
@ 1MG N83002 001
@ 5MG N83006 001

TABLET, DELAYED RELEASE; ORAL
STILBESTROL
BE TABLICAPS 0.5MG N83003 001
BE 1MG N83005 001
BE 5MG N83007 001
@ 0.5MG N83003 001
@ 1MG N83005 001
@ 5MG N83007 001
STILBETIN
BE SQUIBB 0.5MG N04056 012
BE 1MG N04056 013
BE 5MG N04056 014
@ 0.5MG N04056 012
@ 1MG N04056 013
@ 5MG N04056 014

DILTIAZEM HYDROCHLORIDE

TABLET; ORAL
DILTIAZEM HCL
AB NOVOPHARM **30MG** **N74084 001** FEB 25, 1994
AB **60MG** **N74084 002** FEB 25, 1994

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL
DIPHENHYDRAMINE HCL
AA LANNETT **25MG** **N80868 001**
AA **50MG** **N80868 002**
@ 25MG N80868 001
@ 50MG N80868 002
AA ROXANE **50MG** **N80635 001**
@ 50MG N80635 001

DIPIVEFRIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
DIPIVEFRIN HCL
AT ALCON **0.1%** **N73636 001** JUN 30, 1994
PROPINE
AT \+ ALLERGAN **0.1%** **N18239 001**

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOBUTAMINE HCL
AP BEDFORD **EQ 12.5MG BASE/ML** **N74277 001** OCT 31, 1994
DOBUTAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER
AP ABBOTT **EQ 400MG BASE/100ML** **N20201 006** JUL 07, 1994
AP \+ BAXTER **EQ 400MG BASE/100ML** **N20255 005** OCT 19, 1993

DOXEPIN HYDROCHLORIDE

CREAM; TOPICAL
ZONALON
\+ GENDERM 5% N20126 001 APR 01, 1994

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
ADRIAMYCIN PFS
AP \+ PHARMACIA **200MG/100ML** **N50629 002** MAY 03, 1988
AP **200MG/100ML** **N63165 002** JAN 30, 1991
\+ 200MG/100ML N50629 002 MAY 03, 1988
200MG/100ML N63165 002 JAN 30, 1991
DOXORUBICIN HCL
AP CETUS BEN VENUE **200MG/100ML** **N64097 001** SEP 13, 1994

ENFLURANE

LIQUID; INHALATION

		ENFLURANE		
AN		INHALON	99.9%	N74396 001 JUL 29, 1994

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

		LIDOCAINE HCL AND EPINEPHRINE		
> ADD >	AP	EASTMAN KODAK	0.01MG/ML;2%	N40057 002 FEB 26, 1993
> ADD >			0.02MG/ML;2%	N40057 001 FEB 26, 1993
> ADD >	AP	STERLING WINTHROP	0.01MG/ML;2%	N40057 002 FEB 26, 1993
> DLT >			0.02MG/ML;2%	N40057 001 FEB 26, 1993

ERGOCALCIFEROL

CAPSULE; ORAL

	DELTALIN		
AA	LILLY	50,000 IU	N80884 001
@		50,000 IU	N80884 001
	DRISDOL		
AA	SANOFI WINTHROP	50,000 IU	N03444 001
AA	STERLING WINTHROP	50,000 IU	N03444 001
	VITAMIN D		
AA	LANNETT	50,000 IU	N80825 001
@		50,000 IU	N80825 001
AA	WEST WARD	50,000 IU	N83102 001
@	WEST WARD PHARM	50,000 IU	N83102 001

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL

	ERYC		
AB	PARKE DAVIS	250MG	N62546 001 JUL 25, 1985
@		250MG	N62546 001 JUL 25, 1985

OINTMENT; OPHTHALMIC

	ERYTHROMYCIN		
AT	BAUSCH AND LOMB	0.5%	N64067 001 JUL 29, 1994

ERYTHROMYCIN

OINTMENT; OPHTHALMIC

		ERYTHROMYCIN		
AT		FOUGERA	0.5%	N62447 001 SEP 26, 1983
AT			5MG/GM	N62447 001 SEP 26, 1983
		ILOTYCIN		
AT	+	DISTA	0.5%	N50368 001
AT	+		5MG/GM	N50368 001

SOLUTION; TOPICAL

	ERYTHROMYCIN		
AT	BARRE	2%	N62957 001 JUL 21, 1988
@		2%	N62957 001 JUL 21, 1988
AT	BAUSCH AND LOMB	2%	N64039 001 JAN 27, 1994
AT	PHARMAFAIR	2%	N62616 001 JUL 25, 1985
@		2%	N62616 001 JUL 25, 1985

TABLET, COATED PARTICLES; ORAL

	PCE		
	ABBOTT	333MG	N50611 001 SEP 09, 1986
+		333MG	N50611 001 SEP 09, 1986

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE; ORAL

		E.E.S.		
> DLT >	AB	+ ABBOTT	EQ 200MG BASE/5ML	N50207 001
> ADD >	AB		EQ 200MG BASE/5ML	N50207 001
		ERYPED		
> DLT >		ABBOTT	EQ 400MG BASE/5ML	N50207 002
> ADD >		+	EQ 200MG BASE/5ML	N50207 003 MAR 30, 1987
> ADD >		+	EQ 400MG BASE/5ML	N50207 002

SUSPENSION; ORAL

	ERYTHROMYCIN ETHYLSUCCINATE		
AB	DISTA	EQ 200MG BASE/5ML	N62177 001
AB		EQ 400MG BASE/5ML	N62177 002

ERYTHROMYCIN ETHYLSUCCINATE

SUSPENSION; ORAL
ERYTHROMYCIN ETHYLSUCCINATE

	@	DISTA	EQ 200MG BASE/5ML	N62177 001
	@		EQ 400MG BASE/5ML	N62177 002
AB		PHARMAFAIR	EQ 200MG BASE/5ML	N62559 001 MAR 15, 1985
AB			EQ 400MG BASE/5ML	N62558 001 MAR 15, 1985
	@		EQ 200MG BASE/5ML	N62559 001 MAR 15, 1985
	@		EQ 400MG BASE/5ML	N62558 001 MAR 15, 1985

TABLET; ORAL
E.E.S. 400

AB	*	ABBOTT	EQ 400MG BASE	N61905 001
AB			EQ 400MG BASE	N61905 002 AUG 12, 1982
AB	+		EQ 400MG BASE	N61905 002 AUG 12, 1982
	@		EQ 400MG BASE	N61905 001

ERYTHROMYCIN STEARATE

TABLET; ORAL
ERYPAR

AB		PARKE DAVIS	EQ 250MG BASE	N62322 001
	@	WARNER CHILCOTT	EQ 250MG BASE	N62322 001

ERYTHROMYCIN STEARATE

AB		PUREPAC	EQ 250MG BASE	N61743 001
	@	PUREPAC PHARM	EQ 250MG BASE	N61743 001

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL
ESTRADERM

BX	+	CIBA	0.05MG/24HR	N19081 002 SEP 10, 1986
BX	+		0.1MG/24HR	N19081 003 SEP 10, 1986

VIVELLE

BX		NOVEN	0.05MG/24HR	N20323 002 OCT 28, 1994
BX			0.1MG/24HR	N20323 004 OCT 28, 1994

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL
VIVELLE

		NOVEN	0.0375MG/24HR	N20323 001 OCT 28, 1994
			0.075MG/24HR	N20323 003 OCT 28, 1994

ESTRADIOL VALERATE; TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION
DELADUMONE

AQ	*	SQUIBB	4MG/ML;90MG/ML	N09545 001
	@		4MG/ML;90MG/ML	N09545 001

TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE

AQ		STERIS	4MG/ML;90MG/ML	N85865 001
	+		4MG/ML;90MG/ML	N85865 001

ESTROGENS, ESTERIFIED

TABLET; ORAL
ESTRATAB

BS		SOLVAY	0.625MG	N83209 001
BS	+		0.625MG	N83209 001
BS			2.5MG	N83857 001
BS	+		2.5MG	N83857 001

MENEST

BS	+	SMITHKLINE BEECHAM	0.625MG	N84948 001
BS			0.625MG	N84948 001
BS	+		2.5MG	N84949 001
BS			2.5MG	N84949 001

ESTRONE

INJECTABLE; INJECTION
ESTRONE

BP		STERIS	2MG/ML	N83397 001
	@		2MG/ML	N83397 001

ETHAMBUTOL HYDROCHLORIDE

TABLET; ORAL
MYAMBUTOL

		LEDERLE	200MG	N16320 002

ETHAMBUTOL HYDROCHLORIDE

TABLET; ORAL
MYAMBUTOL

	LEDERLE	400MG	N16320 003
*		500MG	N16320 004
@		200MG	N16320 002
+		400MG	N16320 003
@		500MG	N16320 004

ETHINAMATE

CAPSULE; ORAL
VALMID

	DISTA	500MG	N09750 001
@		500MG	N09750 001

ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE

TABLET; ORAL-28
NORQUEST FE

+	SYNTEX	0.035MG;75MG;1MG	N18926 001 JUL 18, 1986
@		0.035MG;75MG;1MG	N18926 001 JUL 18, 1986

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21
NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)

	WATSON	0.035MG,0.035MG;0.5MG,1MG	N71041 001 SEP 24, 1991
AB	WATSON LABS	**0.035MG,0.035MG;0.5MG,1MG**	**N71041 001** SEP 24, 1991

ORTHO-NOVUM 7/14-21

AB +	JOHNSON RW	**0.035MG,0.035MG;0.5MG,1MG**	**N19004 001** APR 04, 1984
@		0.035MG,0.035MG;0.5MG,1MG	N19004 001 APR 04, 1984

TABLET; ORAL-28
NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)

	WATSON	0.035MG,0.035MG;0.5MG,1MG	N71042 001 SEP 24, 1991
AB	WATSON LABS	**0.035MG,0.035MG;0.5MG,1MG**	**N71042 001** SEP 24, 1991

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28
ORTHO-NOVUM 7/14-28

AB +	JOHNSON RW	**0.035MG,0.035MG;0.5MG,1MG**	**N19004 002** APR 04, 1984
@		0.035MG,0.035MG;0.5MG,1MG	N19004 002 APR 04, 1984

ETODOLAC

TABLET; ORAL
LODINE

+	WYETH AYERST	400MG	N18922 004 JUL 29, 1993

ETOPOSIDE

INJECTABLE; INJECTION
ETOPOSIDE

AP	GENSIA	**20MG/ML**	**N74284 001** FEB 10, 1994

VEPESID

AP +	BRISTOL	**20MG/ML**	**N18768 001** NOV 10, 1983

FAMCICLOVIR

TABLET; ORAL
FAMVIR

+	SMITHKLINE BEECHAM	500MG	N20363 002 JUN 29, 1994

FAMOTIDINE

INJECTABLE; INJECTION
PEPCID IN PLASTIC CONTAINER

+	MERCK	0.4MG/ML	N20249 001 FEB 18, 1994

FELODIPINE

TABLET, EXTENDED RELEASE; ORAL
PLENDIL
+ ASTRA MERCK 2.5MG N19834 004 SEP 22, 1994
+ 5MG N19834 001 JUL 25, 1991
+ 10MG N19834 002 JUL 25, 1991
MERCK 5MG N19834 001 JUL 25, 1991
10MG N19834 002 JUL 25, 1991

FLUCONAZOLE

TABLET; ORAL
DIFLUCAN
* PFIZER 50MG N19949 001 JAN 29, 1990
* 100MG N19949 002 JAN 29, 1990
50MG N19949 001 JAN 29, 1990
100MG N19949 002 JAN 29, 1990
150MG N20322 001 JUN 30, 1994

FLUDEOXYGLUCOSE, F-18

INJECTABLE; INJECTION
FLUDEOXYGLUCOSE F 18
+ DOWNSTATE CLINCL 6.8-35.7mCi/ML N20306 001 AUG 19, 1994

FLUMAZENIL

INJECTABLE; INJECTION
MAZICON
* ROCHE 0.1MG/ML N20073 001 DEC 20, 1991
ROMAZICON
+ ROCHE 0.1MG/ML N20073 001 DEC 20, 1991

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL
FLUOCINOLONE ACETONIDE
AT TARO PHARMS **0.025%** **N40042 001** OCT 31, 1994
AT **0.1%** **N40035 001** OCT 31, 1994

OINTMENT; TOPICAL
FLUOCINOLONE ACETONIDE
AT TARO PHARMS **0.025%** **N40041 001** SEP 15, 1994

SOLUTION; TOPICAL
FLUOCINOLONE ACETONIDE
AT PHARMAFAIR **0.01%** **N88449 001** FEB 08, 1984
@ 0.01% N88449 001 FEB 08, 1984

FLUOCINONIDE

CREAM; TOPICAL
FLUOCINONIDE
B* CLAY PARK **0.05%** **N71790 001** JUL 13, 1988
@ 0.05% N71790 001 JUL 13, 1988
AB FOUGERA **0.05%** **N73030 001** OCT 17, 1994

FLUORESCEIN SODIUM

INJECTABLE; INJECTION
FUNDUSCEIN-25
+ CIBA VISION 25% N17869 001
* IOLAB 25% N17869 001

FLUOROMETHOLONE

SUSPENSION/DROPS; OPHTHALMIC
FLUOR-OP
AB CIBA VISION **0.1%** **N70185 001** FEB 27, 1986

FLUOROMETHOLONE

SUSPENSION/DROPS; OPHTHALMIC

	FLUOR-OP			
AB	IOLAB	0.1%	N70185 001	FEB 27, 1986

FLUOROURACIL

INJECTABLE; INJECTION

	ADRUCIL			
AP	+ ADRIA	50MG/ML	N17959 001	
AP		50MG/ML	N40023 001	OCT 18, 1991
AP	+ PHARMACIA	50MG/ML	N40023 001	OCT 18, 1991
	@	50MG/ML	N17959 001	

FLURANDRENOLIDE

CREAM; TOPICAL

	CORDRAN SP			
	+ DISTA	0.025%	N12806 003	
	+	0.05%	N12806 002	
	+ LILLY	0.025%	N12806 003	
	+	0.05%	N12806 002	

LOTION; TOPICAL

	CORDRAN			
AT	+ DISTA	0.05%	N13790 001	
AT	+ LILLY	0.05%	N13790 001	

OINTMENT; TOPICAL

	CORDRAN			
	+ DISTA	0.025%	N12806 004	
	+	0.05%	N12806 001	
	+ LILLY	0.025%	N12806 004	
	+	0.05%	N12806 001	

TAPE; TOPICAL

	CORDRAN			
	+ DISTA	0.004MG/SQ CM	N16455 001	
	+ LILLY	0.004MG/SQ CM	N16455 001	

FLURBIPROFEN

TABLET; ORAL

	ANSAID			
AB	UPJOHN	50MG	N18766 002	OCT 31, 1988
AB	+	100MG	N18766 003	OCT 31, 1988
	FLURBIPROFEN			
AB	MYLAN	50MG	N74358 001	JUN 20, 1994
AB		100MG	N74358 002	JUN 20, 1994

FLUTICASONE PROPIONATE

SPRAY, METERED; NASAL

	FLONASE			
	+ GLAXO	0.05MG/INH	N20121 001	OCT 19, 1994

FOLIC ACID

TABLET; ORAL

	FOLIC ACID			
AA	LANNETT	1MG	N80816 001	
	@	1MG	N80816 001	
AA	PUREPAC	1MG	N80784 001	
	@ PUREPAC PHARM	1MG	N80784 001	

> ADD >

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

> ADD >

TABLET; ORAL

> ADD >

	MONOPRIL-HCT			
> ADD >	BRISTOL MYERS SQUIBB	10MG;12.5MG	N20286 002	NOV 30, 1994
> ADD >	+	20MG;12.5MG	N20286 001	NOV 30, 1994
> ADD >				
> ADD >				
> ADD >				

FUROSEMIDE

INJECTABLE; INJECTION

	FUROSEMIDE			
AP	MARSAM	10MG/ML	N74017 001	JUN 30, 1994

FUROSEMIDE

INJECTABLE; INJECTION

		FUROSEMIDE		
AP		**ORGANON**	**10MG/ML**	**N70017 001 DEC 15, 1986**
	@		10MG/ML	N70017 001 DEC 15, 1986
AP		SANOFI WINTHROP	**10MG/ML**	**N74337 001 OCT 31, 1994**
AP		**WARNER CHILCOTT**	**10MG/ML**	**N18420 001 FEB 26, 1982**
	@		10MG/ML	N18420 001 FEB 26, 1982

GADODIAMIDE

INJECTABLE; INJECTION

		OMNISCAN		
>ADD>		NYCOMED	287MG/ML	N20123 001 JAN 08, 1993
>ADD>				
>DLT>		**STERLING WINTHROP**	**287MG/ML**	**N20123 001 JAN 08, 1993**
>DLT>				

GALLIUM CITRATE, GA-67

INJECTABLE; INJECTION

		GALLIUM CITRATE GA 67		
BS		DUPONT	2mCi/ML	N17478 001
BS		**DUPONT MERCK**	**2mCi/ML**	**N17478 001**

GEMFIBROZIL

TABLET; ORAL

		GEMFIBROZIL		
AB		**PUREPAC PHARM**	**600MG**	**N74360 001 AUG 31, 1994**
AB		WATSON LABS	**600MG**	**N74156 001 OCT 24, 1994**

GENTAMICIN SULFATE

CREAM; TOPICAL

		GARAMYCIN		
AT	+	SCHERING	**EQ 0.1% BASE**	**N60462 001**

GENTAMICIN SULFATE

CREAM; TOPICAL

		GARAMYCIN		
AT	+	**SCHERING**	**EQ 1MG BASE/GM**	**N60462 001**
		GENTAFAIR		
AT		**PHARMAFAIR**	**EQ 1MG BASE/GM**	**N62458 001 SEP 01, 1983**
	@		EQ 0.1% BASE	N62458 001 SEP 01, 1983
		GENTAMICIN		
AT		CLAY PARK	**EQ 0.1% BASE**	**N62307 001**
AT			**EQ 1MG BASE/GM**	**N62307 001**
		GENTAMICIN SULFATE		
AT		BAUSCH AND LOMB	**EQ 0.1% BASE**	**N64056 001 APR 29, 1994**
AT		FOUGERA	**EQ 0.1% BASE**	**N62531 001 JUL 05, 1984**
AT			**EQ 1MG BASE/GM**	**N62531 001 JUL 05, 1984**
AT		NMC	**EQ 0.1% BASE**	**N62471 001 SEP 27, 1983**
AT			**EQ 1MG BASE/GM**	**N62471 001 SEP 27, 1983**
AT		THAMES	**EQ 0.1% BASE**	**N62427 001 MAY 26, 1983**
AT			**EQ 1MG BASE/GM**	**N62427 001 MAY 26, 1983**

INJECTABLE; INJECTION

		APOGEN		
AP		**KING PHARMS**	**EQ 10MG BASE/ML**	**N62289 001**
AP			**EQ 40MG BASE/ML**	**N62289 002**
AP		**SMITHKLINE BEECHAM**	**EQ 10MG BASE/ML**	**N62289 001**
AP			**EQ 40MG BASE/ML**	**N62289 002**
		GARAMYCIN		
AP	+	**SCHERING**	**EQ 2MG BASE/ML**	**N50505 001**

INJECTABLE; INTRATHECAL

		GARAMYCIN		
	+	SCHERING	EQ 2MG BASE/ML	N50505 001

OINTMENT; OPHTHALMIC

		GARAMYCIN		
AT	+	SCHERING	**EQ 0.3% BASE**	**N50425 001**
AT	+		**EQ 3MG BASE/GM**	**N50425 001**
		GENTACIDIN		
AT		**IOLAB**	**EQ 0.3% BASE**	**N62501 001 JUL 26, 1984**

GENTAMICIN SULFATE

OINTMENT; OPHTHALMIC

	GENTACIDIN			
AT	IOLAB	EQ 3MG BASE/GM	N62501 001	JUL 26, 1984

OINTMENT; TOPICAL

	GARAMYCIN			
AT	+ SCHERING	EQ 0.1% BASE	N60463 001	
AT	+	EQ 1MG BASE/GM	N60463 001	
	GENTAFAIR			
AT	PHARMAFAIR	EQ 0.1% BASE	N62444 001	MAY 26, 1983
	@	EQ 0.1% BASE	N62444 001	MAY 26, 1983
	GENTAMICIN			
AT	CLAY PARK	EQ 0.1% BASE	N62351 001	FEB 18, 1982
AT		EQ 1MG BASE/GM	N62351 001	FEB 18, 1982
	GENTAMICIN SULFATE			
AT	BAUSCH AND LOMB	EQ 0.1% BASE	N64054 001	APR 29, 1994
AT	FOUGERA	EQ 0.1% BASE	N62533 001	OCT 05, 1984
AT		EQ 1MG BASE/GM	N62533 001	OCT 05, 1984
AT	NMC	EQ 0.1% BASE	N62496 001	MAR 14, 1984
AT		EQ 1MG BASE/GM	N62496 001	MAR 14, 1984
AT	PHARMADERM	EQ 0.1% BASE	N62534 001	OCT 10, 1984
AT		EQ 1MG BASE/GM	N62534 001	OCT 10, 1984
AT	THAMES	EQ 0.1% BASE	N62477 001	DEC 23, 1983
AT		EQ 1MG BASE/GM	N62477 001	DEC 23, 1983

SOLUTION/DROPS; OPHTHALMIC

	GARAMYCIN			
AT	+ SCHERING	EQ 0.3% BASE	N50039 002	
AT	+	EQ 3MG BASE/ML	N50039 002	
	GENOPTIC			
AT	ALLERGAN	EQ 0.3% BASE	N62452 001	OCT 10, 1984

GENTAMICIN SULFATE

SOLUTION/DROPS; OPHTHALMIC

	GENOPTIC			
AT	ALLERGAN	EQ 3MG BASE/ML	N62452 001	OCT 10, 1984
	GENTACIDIN			
AT	IOLAB	EQ 0.3% BASE	N62480 001	MAR 30, 1984
AT		EQ 3MG BASE/ML	N62480 001	MAR 30, 1984
	GENTAFAIR			
	@ PHARMAFAIR	EQ 0.3% BASE	N62440 001	MAY 03, 1983
	GENTAMICIN SULFATE			
AT	AKORN	EQ 0.3% BASE	N62635 001	JAN 08, 1987
AT		EQ 3MG BASE/ML	N62635 001	JAN 08, 1987
AT	BAUSCH AND LOMB	EQ 0.3% BASE	N64048 001	MAY 11, 1994
AT	STERIS	EQ 0.3% BASE	N62523 001	NOV 25, 1985
AT		EQ 3MG BASE/ML	N62523 001	NOV 25, 1985

GLIPIZIDE

TABLET; ORAL

	GLIPIZIDE				
AB	CIRCA	5MG	N74370 001	> ADD >	NOV 22, 1994
AB		10MG	N74370 002	> ADD >	NOV 22, 1994
AB	ENDO LABS	5MG	N74378 001	> ADD >	NOV 28, 1994
AB		10MG	N74378 002	> ADD >	NOV 28, 1994
AB	MYLAN	5MG	N74226 001	> ADD >	MAY 10, 1994
AB		10MG	N74226 002	> ADD >	MAY 10, 1994
	GLUCOTROL				
AB	PFIZER	5MG	N17783 001		MAY 08, 1984
AB	+	10MG	N17783 002		MAY 08, 1984

GLIPIZIDE

TABLET, EXTENDED RELEASE; ORAL
GLUCOTROL XL

+	PFIZER	5MG	N20329 001	APR 26, 1994
+		10MG	N20329 002	APR 26, 1994

GLUTETHIMIDE

TABLET; ORAL
GLUTETHIMIDE

AA	HALSEY	250MG	N89458 001	OCT 10, 1986
		250MG	N89458 001	OCT 10, 1986
AA	LANNETT	250MG	N83475 001	
AA		500MG	N85571 001	
@		250MG	N83475 001	
@		500MG	N85571 001	

GLYCOPYRROLATE

INJECTABLE; INJECTION
GLYCOPYRROLATE

AP	FUJISAWA	0.2MG/ML	N88475 001	JUN 12, 1984
@		0.2MG/ML	N88475 001	JUN 12, 1984

GONADOTROPIN, CHORIONIC

INJECTABLE; INJECTION
A.P.L.

AP	+ WYETH AYERST	20,000 UNITS/VIAL	N17055 003	
+		20,000 UNITS/VIAL	N17055 003	

CHORIONIC GONADOTROPIN

AP	FUJISAWA	5,000 UNITS/VIAL	N17067 001	
AP		20,000 UNITS/VIAL	N17067 003	
@		5,000 UNITS/VIAL	N17067 001	
@		20,000 UNITS/VIAL	N17067 003	
AP	STERIS	20,000 UNITS/VIAL	N17016 004	
+		15,000 UNITS/VIAL	N17016 010	FEB 15, 1985

GONADOTROPIN, CHORIONIC

INJECTABLE; INJECTION
CHORIONIC GONADOTROPIN

@	STERIS	15,000 UNITS/VIAL	N17016 010	FEB 15, 1985
@		20,000 UNITS/VIAL	N17016 004	

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC
NEOMYCIN SULFATE AND POLYMYXIN B SULFATE GRAMICIDIN

AT	PHARMAFAIR	0.025MG/ML;EQ 1.75MG BASE/ML; 10,000 UNITS/ML	N62383 001	AUG 31, 1982
@		0.025MG/ML;EQ 1.75MG BASE/ML; 10,000 UNITS/ML	N62383 001	AUG 31, 1982

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION
KYTRIL

+	SMITHKLINE BEECHAM	EQ 3MG BASE/ML	N20239 001	DEC 29, 1993
+		EQ 1MG BASE/ML	N20239 002	MAR 11, 1994
@		EQ 3MG BASE/ML	N20239 001	DEC 29, 1993

GUANABENZ ACETATE

TABLET; ORAL
GUANABENZ ACETATE

AB	COPLEY PHARM	EQ 4MG BASE	N74267 001	JUN 01, 1994
AB		EQ 8MG BASE	N74267 002	JUN 01, 1994
AB	WATSON LABS	EQ 4MG BASE	N74025 001	FEB 28, 1994
AB		EQ 8MG BASE	N74025 002	FEB 28, 1994

WYTENSIN

AB	WYETH AYERST	EQ 4MG BASE	N18587 001	SEP 07, 1982

GUANABENZ ACETATE

TABLET; ORAL

		WYTENSIN		
AB	+	WYETH AYERST	**EQ 8MG BASE**	N18587 002 SEP 07, 1982

HEPARIN CALCIUM

INJECTABLE; INJECTION

		CALCIPARINE		
	+	CHOAY	25,000 UNITS/ML	N18237 001
	*	DUPONT	25,000 UNITS/ML	N18237 001

HEPARIN SODIUM

INJECTABLE; INJECTION

		HEPARIN SODIUM		
AP		AKORN	1,000 UNITS/ML	N17486 001
AP			5,000 UNITS/ML	N17486 002
AP			10,000 UNITS/ML	N17486 003
AP			20,000 UNITS/ML	N17486 004
AP			40,000 UNITS/ML	N17486 005
	@		1,000 UNITS/ML	N17486 001
	@		5,000 UNITS/ML	N17486 002
	@		10,000 UNITS/ML	N17486 003
	@		20,000 UNITS/ML	N17486 004
	@		40,000 UNITS/ML	N17486 005

HEXACHLOROPHENE

EMULSION; TOPICAL

		PHISOHEX		
	+	SANOFI WINTHROP	3%	N06882 001
	@		3%	N08402 001
>ADD>	*	STERLING WINTHROP	3%	N06882 001
>DLT>	@		3%	N08402 001

SPONGE; TOPICAL

		PHISO-SCRUB		
	@	SANOFI WINTHROP	3%	N17446 001
	@	STERLING WINTHROP	3%	N17446 001

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

		HYDRALAZINE HCL		
AA		AMIDE PHARM	**25MG**	**N88560 001** **OCT 04, 1984**
AA			**50MG**	**N88649 001** **OCT 18, 1984**
	@		25MG	N88560 001 OCT 04, 1984
	@		50MG	N88649 001 OCT 18, 1984

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

		RESERPINE, HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE		
BP		DANBURY PHARMA	**25MG;15MG;0.1MG**	**N87556 001**
	@		25MG;15MG;0.1MG	N87556 001

HYDROCHLOROTHIAZIDE

TABLET; ORAL

		HYDROCHLOROTHIAZIDE		
AB		WEST WARD	**25MG**	**N84899 001**
	@	WEST WARD PHARM	25MG	N84899 001
AB		ZENITH	**50MG**	**N84658 001**
	@	ZENITH LABS	50MG	N84658 001

HYDROCHLOROTHIAZIDE; LABETALOL HYDROCHLORIDE

TABLET; ORAL

		NORMOZIDE		
		SCHERING	**25MG;100MG**	**N19046 001** **APR 06, 1987**
			25MG;200MG	**N19046 002** **APR 06, 1987**
	*		**25MG;300MG**	**N19046 003** **APR 06, 1987**
	@		25MG;100MG	N19046 001 APR 06, 1987
	@		25MG;200MG	N19046 002 APR 06, 1987
	@		25MG;300MG	N19046 003 APR 06, 1987

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL
HYDROCHLOROTHIAZIDE W/ RESERPINE

BP		ROXANE	50MG;0.125MG	N84603 001
	@		50MG;0.125MG	N84603 001

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL
DYAZIDE

AB	+	SMITHKLINE BEECHAM	25MG;50MG	N16042 002
			25MG;37.5MG	N16042 003 MAR 03, 1994
	@		25MG;50MG	N16042 002

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB		GENEVA PHARMS	25MG;50MG	N73191 001 JUL 31, 1991
	+		25MG;50MG	N73191 001 JUL 31, 1991

HYDROCORTISONE

CREAM; TOPICAL
HYDROCORTISONE

AT		LEMMON	1%	N85191 001
	@		1%	N85191 001
AT		PHARMAFAIR	1%	N87838 001 JUL 28, 1982
	@		1%	N87838 001 JUL 28, 1982

ENEMA; RECTAL
CORTENEMA

	+	SOLVAY	100MG/60ML	N16199 001

HYDROCORTISONE

AT		COPLEY PHARM	100MG/60ML	N74171 001 MAY 27, 1994

GEL; TOPICAL
NUTRACORT

AT	+	GALDERMA	1%	N84698 001
	@		1%	N84698 001

PENECORT

AT		ALLERGAN HERBERT	1%	N88215 001 JUN 06, 1984

HYDROCORTISONE

GEL; TOPICAL
PENECORT

	+	ALLERGAN HERBERT	1%	N88215 001 JUN 06, 1984

LOTION; TOPICAL
HYDROCORTISONE

AT		CLAY PARK	1%	N85663 001
	@		1%	N85663 001

OINTMENT; TOPICAL
HYDROCORTISONE

AT		CLAY PARK	1%	N85028 001
	@		1%	N85028 001

TABLET; ORAL
HYDROCORTISONE

BP		DANBURY PHARMA	20MG	N80355 001
	@		20MG	N80355 001
BP		INWOOD	20MG	N80732 001
	@	INWOOD LABS	20MG	N80732 001

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC
NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE

AT		PHARMAFAIR	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62394 001 SEP 29, 1982
	@		1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62394 001 SEP 29, 1982

SUSPENSION; OTIC
OTICAIR

AT		PHARMAFAIR	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62399 001 NOV 18, 1982
	@		1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62399 001 NOV 18, 1982

HYDROCORTISONE ACETATE

CREAM; TOPICAL

	HYDROCORTISONE ACETATE			
AT	PARKE DAVIS	**1%**	**N89914 001**	**JAN 03, 1989**
	@	1%	N89914 001	JAN 03, 1989

INJECTABLE; INJECTION

	HYDROCORTISONE ACETATE			
BP	STERIS	**50MG/ML**	**N85214 001**	
	@	50MG/ML	N85214 001	

HYDROCORTISONE ACETATE; UREA

CREAM; TOPICAL

		CARMOL HC			
AT	+	KENWOOD LABS	**1%;10%**	**N80505 001**	
AT	+	SYNTEX	**1%;10%**	**N80505 001**	

HYDROCORTISONE BUTYRATE

CREAM; TOPICAL

		LOCOID			
	+	BROCADES PHARMA	**0.1%**	**N18514 001**	**MAR 31, 1982**
	+	YAMANOUCHI	0.1%	N18514 001	MAR 31, 1982

OINTMENT; TOPICAL

		LOCOID			
	@	BROCADES PHARMA	**0.1%**	**N18652 001**	**OCT 29, 1982**
	@	YAMANOUCHI	0.1%	N18652 001	OCT 29, 1982

SOLUTION; TOPICAL

		LOCOID			
	+	BROCADES PHARMA	**0.1%**	**N19116 001**	**FEB 25, 1987**
	+	YAMANOUCHI	0.1%	N19116 001	FEB 25, 1987

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

		A-HYDROCORT			
AP		ABBOTT	**EQ 250MG BASE/VIAL**	**N89578 001**	**APR 11, 1989**
AP			**EQ 500MG BASE/VIAL**	**N89579 001**	**APR 11, 1989**
AP			**EQ 1GM BASE/VIAL**	**N89580 001**	**APR 11, 1989**
	@		EQ 250MG BASE/VIAL	N89578 001	APR 11, 1989
	@		EQ 500MG BASE/VIAL	N89579 001	APR 11, 1989
	@		EQ 1GM BASE/VIAL	N89580 001	APR 11, 1989

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

		DILAUDID-HP			
	+	KNOLL PHARM	250MG/VIAL	N19034 002	AUG 04, 1994

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

		HYDROXYCHLOROQUINE SULFATE			
AB		COPLEY PHARM	**200MG**	**N40081 001**	**SEP 30, 1994**
		PLAQUENIL			
AB	+	SANOFI WINTHROP	**200MG**	**N09768 001**	
AB	+	STERLING WINTHROP	**200MG**	**N09768 001**	

HYDROXYPROGESTERONE CAPROATE

INJECTABLE; INJECTION

		DELALUTIN			
AO	+	SQUIBB	**125MG/ML**	**N10347 004**	
AO			**125MG/ML**	**N16911 001**	
AO	+		**250MG/ML**	**N10347 002**	
AO			**250MG/ML**	**N16911 002**	
	@		125MG/ML	N10347 004	
	@		125MG/ML	N16911 001	
	@		250MG/ML	N10347 002	
	@		250MG/ML	N16911 002	

HYDROXYPROGESTERONE CAPROATE

INJECTABLE; INJECTION
HYDROXYPROGESTERONE CAPROATE

AO	AKORN	125MG/ML	N18004 001	
+		125MG/ML	N18004 001	
AO	* STERIS	125MG/ML	N17439 001	
AO		250MG/ML	N17439 002	
@		125MG/ML	N17439 001	
+		250MG/ML	N17439 002	

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION
HYDROXYZINE HCL

AP	SMITH NEPHEW SOLOPAK	25MG/ML	N87591 001	
AP		50MG/ML	N87593 001	> ADD >
AP		50MG/ML	N87595 001	> ADD >
AP	SOLOPAK	25MG/ML	N87591 001	> ADD >
AP		50MG/ML	N87593 001	> ADD >
AP		50MG/ML	N87595 001	> ADD >
	ORGATRAX			> ADD >
AP	ORGANON	25MG/ML	N87014 001	
AP		50MG/ML	N87014 002	
@		25MG/ML	N87014 001	
@		50MG/ML	N87014 002	

SYRUP; ORAL
HYDROXYZINE HCL

AA	HI TECH PHARMA	10MG/5ML	N40010 001 OCT 28, 1994

TABLET; ORAL
HYDROXYZINE HCL

AB	AMIDE PHARM	10MG	N89071 001 JUL 22, 1986
AB		25MG	N89072 001 JUL 22, 1986
AB		50MG	N89073 001 JUL 22, 1986
@		10MG	N89071 001 JUL 22, 1986
@		25MG	N89072 001 JUL 22, 1986
@		50MG	N89073 001 JUL 22, 1986
AB	ROYCE LABS	10MG	N81149 001 MAR 18, 1994

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL
HYDROXYZINE HCL

AB	ROYCE LABS	25MG	N81150 001 MAR 18, 1994
AB		50MG	N81151 001 MAR 18, 1994

IBUPROFEN

TABLET; ORAL
MOTRIN

	MCNEIL CONS PRODS	100MG	N20418 001 NOV 16, 1994

TABLET, CHEWABLE; ORAL
MOTRIN

	MCNEIL CONS PRODS	50MG	N20135 001 NOV 16, 1994
+		100MG	N20135 002 NOV 16, 1994

IMIGLUCERASE

INJECTABLE; INJECTION
CEREZYME

+	GENZYME	200 UNITS/VIAL	N20367 001 MAY 23, 1994

INDIUM IN-111 PENTETREOTIDE KIT

INJECTABLE; INJECTION
OCTREOSCAN

	MALLINCKRODT	3mCi/ML	N20314 001 JUN 02, 1994

INDOMETHACIN

CAPSULE; ORAL
INDOMETHACIN

AB	CHELSEA	25MG	N18690 001 JUL 31, 1984
AB		50MG	N18690 002 JUL 31, 1984

INDOMETHACIN

CAPSULE; ORAL

INDOMETHACIN			
@ CHELSEA LABS	25MG	N18690 001	
		JUL 31, 1984	
@	50MG	N18690 002	
		JUL 31, 1984	

INSULIN BIOSYNTHETIC HUMAN

INJECTABLE; INJECTION

HUMULIN R			
+ LILLY	500 UNITS/ML	N18780 004	
		MAR 31, 1994	

INVERT SUGAR

INJECTABLE; INJECTION

TRAVERT 10% IN PLASTIC CONTAINER			
BAXTER	10GM/100ML	N16717 001	
@	10GM/100ML	N16717 001	

IOBENGUANE SULFATE I 131

INJECTABLE; INJECTION

IOBENGUANE SULFATE I 131			
CIS	2.3mCi/ML	N20084 001	
		MAR 25, 1994	

IODAMIDE MEGLUMINE

INJECTABLE; INJECTION

RENOVUE-65			
+ BRACCO DXS	65%	N17902 001	
+ SQUIBB	65%	N17902 001	> ADD >
			> ADD >
			> DLT >
			> DLT >

IODIPAMIDE MEGLUMINE

INJECTABLE; INJECTION

CHOLOGRAFIN MEGLUMINE			
+ BRACCO DXS	10.3%	N09321 007	> ADD >
			> ADD >
+	52%	N09321 003	> DLT >
+ SQUIBB	10.3%	N09321 007	> DLT >

IODIPAMIDE MEGLUMINE

INJECTABLE; INJECTION

CHOLOGRAFIN MEGLUMINE		
+ SQUIBB	52%	N09321 003

IODIPAMIDE SODIUM

INJECTABLE; INJECTION

CHOLOGRAFIN SODIUM		
@ BRACCO DXS	20%	N09321 001
@ SQUIBB	20%	N09321 001

IODOHIPPURATE SODIUM, I-123

INJECTABLE; INJECTION

NEPHROFLOW		
MEDI PHYSICS	1mCi/ML	N18289 001
		DEC 28, 1984
@	1mCi/ML	N18289 001
		DEC 28, 1984

IODOXAMATE MEGLUMINE

INJECTABLE; INJECTION

CHOLOVUE		
@ BRACCO DXS	9.9%	N18077 001
@	40.3%	N18076 001
@ SQUIBB	9.9%	N18077 001
@	40.3%	N18076 001

IOHEXOL

INJECTABLE; INJECTION

OMNIPAQUE 140		
+ NYCOMED	30.2%	N18956 005
		NOV 30, 1988
+ STERLING WINTHROP	30.2%	N18956 005
		NOV 30, 1988
OMNIPAQUE 210		
+ NYCOMED	45.3%	N18956 006
		JUN 30, 1989
+ STERLING WINTHROP	45.3%	N18956 006
		JUN 30, 1989

IOHEXOL

SOLUTION; INJECTION, ORAL
OMNIPAQUE 350

>ADD>	+ NYCOMED	75.5%	N18956 004	
>ADD>			DEC 26, 1985	
>DLT>	+ STERLING WINTHROP	75.5%	N18956 004	
>DLT>			DEC 26, 1985	

SOLUTION; INJECTION, ORAL, RECTAL
OMNIPAQUE 180

>ADD>	+ NYCOMED	38.8%	N18956 001	
>ADD>			DEC 26, 1985	
>DLT>	+ STERLING WINTHROP	38.8%	N18956 001	
>DLT>			DEC 26, 1985	

OMNIPAQUE 240

>ADD>	+ NYCOMED	51.8%	N18956 002	
>ADD>			DEC 26, 1985	
>DLT>	+ STERLING WINTHROP	51.8%	N18956 002	
>DLT>			DEC 26, 1985	

OMNIPAQUE 300

>ADD>	+ NYCOMED	64.7%	N18956 003	
>ADD>			DEC 26, 1985	
>DLT>	+ STERLING WINTHROP	64.7%	N18956 003	
>DLT>			DEC 26, 1985	

SOLUTION; URETHRAL
OMNIPAQUE 70

>ADD>	+ NYCOMED	15.1%	N18956 007	
>ADD>			JUN 01, 1994	
>DLT>	+ STERLING WINTHROP	15.1%	N18956 007	
>DLT>			JUN 01, 1994	

IOPAMIDOL

INJECTABLE; INTRAVASCULAR
ISOVUE-200

BRACCO DXS	41%	N20327 001	
		OCT 12, 1994	

ISOVUE-250

BRACCO DXS	51%	N20327 002	
		OCT 12, 1994	

ISOVUE-300

BRACCO DXS	61%	N20327 003	
		OCT 12, 1994	

ISOVUE-370

BRACCO DXS	76%	N20327 004	
		OCT 12, 1994	

IOPANOIC ACID

TABLET; ORAL
TELEPAQUE

>ADD>	NYCOMED	500MG	N08032 001	
>DLT>	STERLING WINTHROP	500MG	N08032 001	

IPODATE CALCIUM

GRANULE; ORAL
ORAGRAFIN CALCIUM

BRACCO DXS	3GM/PACKET	N12968 001	
SQUIBB	3GM/PACKET	N12968 001	

IPODATE SODIUM

CAPSULE; ORAL
ORAGRAFIN SODIUM

AA	BRACCO DXS	**500MG**	**N12967 001**
AA	SQUIBB	**500MG**	**N12967 001**

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION
BRONKOSOL

AN	+ SANOFI WINTHROP	**1%**	**N12339 008**	
	@	0.25%	N12339 009	
AN	+ STERLING WINTHROP	**1%**	**N12339 008**	
	@	0.25%	N12339 009	

ISOETHARINE MESYLATE

AEROSOL, METERED; INHALATION
BRONKOMETER

+ SANOFI WINTHROP	0.34MG/INH	N12339 007	
+ STERLING WINTHROP	0.34MG/INH	N12339 007	

ISOFLURANE

LIQUID; INHALATION
ISOFLURANE

AN	INHALON	**99.9%**	**N74416 001**
			SEP 30, 1994

ISONIAZID; PYRAZINAMIDE; RIFAMPIN

		TABLET; ORAL			
		RIFATER			
	+	MARION MERRELL DOW	50MG;300MG;120MG	N50705 001	
				MAY 31, 1994	

ISOPROTERENOL HYDROCHLORIDE

		AEROSOL, METERED; INHALATION			
		ISUPREL			
	+	SANOFI WINTHROP	0.131MG/INH	N11178 001	
	+	STERLING WINTHROP	0.131MG/INH	N11178 001	
		INJECTABLE; INJECTION			
		ISUPREL			
AP	+	SANOFI WINTHROP	0.2MG/ML	N10515 001	
AP	+	STERLING WINTHROP	0.2MG/ML	N10515 001	
		SOLUTION; INHALATION			
		ISUPREL			
	+	SANOFI WINTHROP	0.5%	N06327 002	
	+		1%	N06327 003	
	+	STERLING WINTHROP	0.5%	N06327 002	
	+		1%	N06327 003	
		TABLET; RECTAL, SUBLINGUAL			
		ISUPREL			
	@	SANOFI WINTHROP	10MG	N06328 001	
	@		15MG	N06328 002	
		STERLING WINTHROP	10MG	N06328 001	
	@		15MG	N06328 002	

ISOSORBIDE MONONITRATE

		TABLET; ORAL			
		ISMO			
AB	+	WYETH	20MG	N19091 001	
				DEC 30, 1991	
BX	+		20MG	N19091 001	
				DEC 30, 1991	
		MONOKET			
AB		SCHWARZ	20MG	N20215 001	
				JUN 30, 1993	
BX		SCHWARZ PHARMA	20MG	N20215 001	
				JUN 30, 1993	

ISRADIPINE

		CAPSULE; ORAL			
		DYNACIRC			
		SANDOZ	5MG	N19546 002	
				DEC 20, 1990	
	+		5MG	N19546 002	
				DEC 20, 1990	
		TABLET, EXTENDED RELEASE; ORAL			
		DYNACIRC CR			
	+	SANDOZ	5MG	N20336 001	
				JUN 01, 1994	
	+		10MG	N20336 002	
				JUN 01, 1994	

KANAMYCIN SULFATE

		CAPSULE; ORAL			
		KANTREX			
	+	APOTHECON	EQ 500MG BASE	N61911 001	
	+		EQ 500MG BASE	N62726 001	
				MAR 06, 1987	
	@		EQ 500MG BASE	N60516 001	
	@		EQ 500MG BASE	N61911 001	
	+		EQ 500MG BASE	N62726 001	
				MAR 06, 1987	
AB	+	BRISTOL	EQ 500MG BASE	N60516 001	
		INJECTABLE; INJECTION			
		KANTREX			
AP	+	APOTHECON	EQ 75MG BASE/2ML	N61655 003	
AP			EQ 75MG BASE/2ML	N61901 003	
AP	+		EQ 75MG BASE/2ML	N61901 003	
AP	+		EQ 500MG BASE/2ML	N61655 001	
AP			EQ 500MG BASE/2ML	N61901 001	
AP	+		EQ 500MG BASE/2ML	N61901 001	
AP	+		EQ 1GM BASE/3ML	N61655 002	
AP			EQ 1GM BASE/3ML	N61901 002	
AP	+		EQ 1GM BASE/3ML	N61901 002	
	@		EQ 75MG BASE/2ML	N61655 003	
	@		EQ 75MG BASE/2ML	N62564 001	
				SEP 21, 1984	
	@		EQ 500MG BASE/2ML	N61655 001	
	@		EQ 500MG BASE/2ML	N62564 002	
				SEP 21, 1984	
	@		EQ 1GM BASE/3ML	N61655 002	

KANAMYCIN SULFATE

INJECTABLE; INJECTION

	KANTREX			
	@ APOTHECON	EQ 1GM BASE/3ML	N62564 003	
			SEP 21, 1984	
AP	BRISTOL	EQ 75MG BASE/2ML	N62564 001	
			SEP 21, 1984	
AP		EQ 500MG BASE/2ML	N62564 002	
			SEP 21, 1984	
AP		EQ 1GM BASE/3ML	N62564 003	
			SEP 21, 1984	
	KLEBCIL			
	@ KING PHARMS	EQ 75MG BASE/2ML	N62170 001	
	@	EQ 500MG BASE/2ML	N62170 002	
	@	EQ 1GM BASE/3ML	N62170 003	
	@ SMITHKLINE BEECHAM	EQ 75MG BASE/2ML	N62170 001	
	@	EQ 500MG BASE/2ML	N62170 002	
	@	EQ 1GM BASE/3ML	N62170 003	

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

	LEUCOVORIN CALCIUM			
AP	ELKINS SINN	EQ 100MG BASE/VIAL	N81224 001	
			JUN 03, 1994	
	+ IMMUNEX	EQ 3MG BASE/ML	N08107 001	
	@	EQ 3MG BASE/ML	N08107 001	

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	BETAGAN			
AT	+ ALLERGAN	0.25%	N19814 001	
			JUN 28, 1989	
AT	+	0.5%	N19219 002	
			DEC 19, 1985	
	LEVOBUNOLOL HCL			
AT	BAUSCH AND LOMB	0.25%	N74307 001	
			MAR 04, 1994	
AT		0.5%	N74326 001	
			MAR 04, 1994	

LEVOCABASTINE HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

	LIVOSTIN			
	+ CIBA VISION	EQ 0.05% BASE	N20219 001	
			NOV 10, 1993	
	+ IOLAB	EQ 0.05% BASE	N20219 001	
			NOV 10, 1993	

LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

	ARBSTOCAINE HCL W/ LEVONORDEFRIN			
AP	CARLISLE	0.05MG/ML;2%	N85010 001	
	@ SOLVAY	0.05MG/ML;2%	N85010 001	
	CARBOCAINE W/ NEO-COBEFRIN			
AP	+ COOK WAITE	0.05MG/ML;2%	N12125 002	
AP	+ EASTMAN KODAK	0.05MG/ML;2%	N12125 002	

LEVONORDEFRIN; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

RAVOCAINE AND NOVOCAIN W/ NEO-COBEFRIN			
@ EASTMAN KODAK	0.05MG/ML;2%;0.4%	N08592 007	
@ STERLING WINTHROP	0.05MG/ML;2%;0.4%	N08592 007	

LIDOCAINE HYDROCHLORIDE

SOLUTION; TOPICAL

	MYLOCAINE			
AT	PENNEX	4%	N87881 001	
			NOV 18, 1982	
	@ PENNEX PHARMS	4%	N87881 001	
			NOV 18, 1982	
	PEDIATRIC LTA KIT			
AT	ABBOTT	2%	N88572 001	
			JUL 31, 1984	
	@	2%	N88572 001	
			JUL 31, 1984	

LIOTRIX (T4;T3)

TABLET; ORAL

EUTHROID-0.5			
PARKE DAVIS	0.03MG;0.0075MG	N16680 001	

LIOTRIX (T4;T3)

TABLET; ORAL

	EUTHROID-0.5		
	@ PARKE DAVIS	0.03MG;0.0075MG	N16680 001
	EUTHROID-1		
	PARKE DAVIS	0.06MG;0.015MG	N16680 002
	@	0.06MG;0.015MG	N16680 002
	EUTHROID-2		
	PARKE DAVIS	0.12MG;0.03MG	N16680 003
	@	0.12MG;0.03MG	N16680 003
	EUTHROID-3		
	+ PARKE DAVIS	0.18MG;0.045MG	N16680 004
	@	0.18MG;0.045MG	N16680 004

LISINOPRIL

TABLET; ORAL

	PRINIVIL		
AB	MERCK	2.5MG	N19558 006 JAN 28, 1994
	ZESTRIL		
AB	ZENECA	2.5MG	N19777 005 APR 29, 1993

LITHIUM CARBONATE

TABLET, EXTENDED RELEASE; ORAL

	LITHOBID		
	@ CIBA	300MG	N18027 001
	@ SOLVAY	300MG	N18027 001

LITHIUM CITRATE

SYRUP; ORAL

	CIBALITH-S		
AA	CIBA	EQ 300MG CARBONATE/5ML	N17672 001
AA	SOLVAY	EQ 300MG CARBONATE/5ML	N17672 001

>ADD< LORATADINE; PSEUDOEPHEDRINE SULFATE

>ADD< TABLET, EXTENDED RELEASE; ORAL

>ADD<	CLARITIN-D		
>ADD<	+ SCHERING	5MG;120MG	N19670 001 NOV 14, 1994

LORAZEPAM

INJECTABLE; INJECTION

	ATIVAN		
AP	+ WYETH AYERST	2MG/ML	N18140 001
AP	+	4MG/ML	N18140 002
	LORAZEPAM		
AP	ABBOTT	2MG/ML	N74280 001 MAY 27, 1994
AP		2MG/ML	N74282 001 MAY 27, 1994
AP		4MG/ML	N74280 002 MAY 27, 1994
AP		4MG/ML	N74282 002 MAY 27, 1994
AP	STERIS	2MG/ML	N74276 001 APR 15, 1994
AP		4MG/ML	N74276 002 APR 15, 1994
AP	STERLING WINTHROP	2MG/ML	N74243 001 APR 12, 1994
AP		2MG/ML	N74300 001 APR 12, 1994
AP		4MG/ML	N74243 002 APR 12, 1994

TABLET; ORAL

	LORAZEPAM		
AB	WARNER CHILCOTT	1MG	N71038 001 JAN 12, 1988
AB		2MG	N71039 001 JAN 12, 1988
	@	1MG	N71038 001 JAN 12, 1988
	@	2MG	N71039 001 JAN 12, 1988

MAGNESIUM SULFATE

INJECTABLE; INJECTION

	MAGNESIUM SULFATE IN PLASTIC CONTAINER		
	ABBOTT	4GM/100ML	N20309 001 JUN 24, 1994
		80MG/ML	N20309 002 JUN 24, 1994

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION
DEPO-PROVERA

		UPJOHN	150MG/ML	N20246 001 OCT 29, 1992	
	+		150MG/ML	N20246 001 OCT 29, 1992	

TABLET; ORAL
CYCRIN

> ADD >	AB	ESI	2.5MG	N81239 001 OCT 30, 1992	
> ADD >	AB		5MG	N81240 001 OCT 30, 1992	
> ADD >	AB		10MG	N89386 001 SEP 09, 1987	
> DLT >	AB	WYETH AYERST	2.5MG	N81239 001 OCT 30, 1992	
> DLT >	AB		5MG	N81240 001 OCT 30, 1992	
> DLT >	AB		10MG	N89386 001 SEP 09, 1987	

MENOTROPINS (FSH;LH)

INJECTABLE; INJECTION
HUMEGON

AB	ORGANON	75 IU/VIAL;75 IU/VIAL	N20328 001 SEP 01, 1994	
AB		150 IU/VIAL;150 IU/VIAL	N20328 002 SEP 01, 1994	
		75 IU/VIAL;75 IU/VIAL	N20328 001 SEP 01, 1994	> ADD >
		150 IU/VIAL;150 IU/VIAL	N20328 002 SEP 01, 1994	> ADD >

PERGONAL

AB	+	SERONO	75 IU/AMP;75 IU/AMP	N17646 001	
AB	+		150 IU/AMP;150 IU/AMP	N17646 002 MAY 20, 1985	
	+	SERONO LABS	75 IU/AMP;75 IU/AMP	N17646 001	
	+		150 IU/AMP;150 IU/AMP	N17646 002 MAY 20, 1985	

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION
ARESTOCAINE HCL

AP	CARLISLE	3%	N84777 002 APR 18, 1982	
	@ SOLVAY	3%	N84777 002 APR 18, 1982	

CARBOCAINE

AP	* COOK WAITE	3%	N12125 003	
AP	+ EASTMAN KODAK	3%	N12125 003	

MEPROBAMATE

TABLET; ORAL
MEPRIAM

AA	LEMMON	400MG	N16069 001	
	@	400MG	N16069 001	

METARAMINOL BITARTRATE

INJECTABLE; INJECTION
METARAMINOL BITARTRATE

AP	FUJISAWA	EQ 10MG BASE/ML	N80431 001	
	@	EQ 10MG BASE/ML	N80431 001	

METHADONE HYDROCHLORIDE

CONCENTRATE; ORAL
METHADONE HCL

AA	UDL	10MG/ML	N40088 001 NOV 30, 1994	

METHAZOLAMIDE

TABLET; ORAL
METHAZOLAMIDE

AB	MIKART	25MG	N40062 001 JAN 27, 1994	
AB		50MG	N40062 002 JAN 27, 1994	

METHDILAZINE

TABLET, CHEWABLE; ORAL

	TACARYL		
	WESTWOOD SQUIBB	3.6MG	N11950 009
@		3.6MG	N11950 009

METHDILAZINE HYDROCHLORIDE

SYRUP; ORAL

	TACARYL		
	WESTWOOD SQUIBB	4MG/5ML	N11950 007
@		4MG/5ML	N11950 007

TABLET; ORAL

	TACARYL		
	WESTWOOD SQUIBB	8MG	N11950 006
@		8MG	N11950 006

METHOTREXATE SODIUM

INJECTABLE; INJECTION

	FOLEX PFS		
AP	ADRIA	EQ 25MG BASE/ML	N89180 001 JAN 03, 1986
@	PHARMACIA	EQ 25MG BASE/ML	N89180 001 JAN 03, 1986

TABLET; ORAL

	METHOTREXATE SODIUM		
AB	ROXANE	EQ 2.5MG BASE	N40054 001 AUG 01, 1994

METHSCOPOLAMINE BROMIDE

TABLET; ORAL

	PAMINE		
AA	BRADLEY	2.5MG	N08848 001
AA	KENWOOD LABS	2.5MG	N08848 001

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

	A-METHAPRED		
AP	ABBOTT	EQ 40MG BASE/VIAL	N89573 001 FEB 22, 1991

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

	A-METHAPRED		
AP	ABBOTT	EQ 125MG BASE/VIAL	N89574 001 FEB 22, 1991
AP		EQ 500MG BASE/VIAL	N89575 001 FEB 22, 1991
@		EQ 40MG BASE/VIAL	N89573 001 FEB 22, 1991
@		EQ 125MG BASE/VIAL	N89574 001 FEB 22, 1991
@		EQ 500MG BASE/VIAL	N89575 001 FEB 22, 1991
	METHYLPREDNISOLONE		
AP	ORGANON	EQ 500MG BASE/VIAL	N87535 001 JUN 25, 1982
AP		EQ 1GM BASE/VIAL	N87535 002 JUN 25, 1982
@		EQ 500MG BASE/VIAL	N87535 001 JUN 25, 1982
@		EQ 1GM BASE/VIAL	N87535 002 JUN 25, 1982

METHYLTESTOSTERONE

TABLET; BUCCAL/SUBLINGUAL

	METHYLTESTOSTERONE		
	PRIVATE FORM	5MG	N83836 001
@	PVT FORM	5MG	N83836 001
BP	TABLICAPS	10MG	N85125 001
@		10MG	N85125 001

TABLET; ORAL

	ANDROID 25		
AB	ICN	25MG	N87147 001
AB	+	25MG	N87147 001
	METHYLTESTOSTERONE		
BP	DANBURY PHARMA	10MG	N80933 001
BP		25MG	N80931 001
@		10MG	N80933 001
@		25MG	N80931 001
BP	PUREPAC	10MG	N80475 002
BP		25MG	N80475 003
@	PUREPAC PHARM	10MG	N80475 002
@		25MG	N80475 003
BP	TABLICAPS	10MG	N80313 001
BP		25MG	N85270 001

METHYLTESTOSTERONE

TABLET; ORAL

	METHYLTESTOSTERONE			
	@ TABLICAPS	10MG	N80313 001	
	@	25MG	N85270 001	
BP	WEST WARD	10MG	N84331 001	
BP		25MG	N84331 002	
	@ WEST WARD PHARM	10MG	N84331 001	
	@	25MG	N84331 002	
	ORETON METHYL			
BP	+ SCHERING	25MG	N03158 002	
	@	25MG	N03158 002	

METOCLOPRAMIDE HYDROCHLORIDE

TABLET; ORAL

>_DLT_>		MAXOLON			
>_DLT_>	AB	KING PHARMS	EQ 10MG BASE	N70106 001	
>_DLT_>				MAR 04, 1986	
>_ADD_>		@	EQ 10MG BASE	N70106 001	
>_ADD_>				MAR 04, 1986	

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

		TOPROL XL			
		+ HASSLE AB	EQ 50MG TARTRATE	N19962 001	
				JAN 10, 1992	
		+	EQ 100MG TARTRATE	N19962 002	
				JAN 10, 1992	
		+	EQ 200MG TARTRATE	N19962 003	
				JAN 10, 1992	
		TOPROL-XL			
		+ ASTRA	EQ 50MG TARTRATE	N19962 001	
				JAN 10, 1992	
		+	EQ 100MG TARTRATE	N19962 002	
				JAN 10, 1992	
		+	EQ 200MG TARTRATE	N19962 003	
				JAN 10, 1992	

METOPROLOL TARTRATE

TABLET; ORAL

	METOPROLOL TARTRATE			
AB	APOTHECON	50MG	N74258 001	
			JAN 27, 1994	

METOPROLOL TARTRATE

TABLET; ORAL

	METOPROLOL TARTRATE			
AB	APOTHECON	100MG	N74258 002	
			JAN 27, 1994	
AB	COPLEY PHARM	50MG	N74333 001	
			JAN 27, 1994	
AB		100MG	N74333 002	
			JAN 27, 1994	
AB	GENEVA PHARMS	50MG	N73288 001	
			MAR 25, 1994	
AB		100MG	N73289 001	
			MAR 25, 1994	
AB	NOVOPHARM	50MG	N74143 001	
			SEP 30, 1994	
AB		100MG	N74143 002	
			SEP 30, 1994	
AB	PUREPAC PHARM	50MG	N74380 001	
			JUL 29, 1994	
AB		100MG	N74380 002	
			JUL 29, 1994	
AB	WATSON LABS	50MG	N74217 001	
			MAY 27, 1994	
AB		100MG	N74217 002	
			MAY 27, 1994	

METRIZAMIDE

INJECTABLE; INJECTION

		AMIPAQUE		
>_ADD_>		@ NYCOMED	2.5GM/VIAL	N17982 003
>_ADD_>				SEP 12, 1983
>_ADD_>		+	3.75GM/VIAL	N17982 001
>_ADD_>		+	6.75GM/VIAL	N17982 002
>_ADD_>		@	13.5GM/VIAL	N17982 004
>_ADD_>				SEP 12, 1983
>_DLT_>		@ STERLING WINTHROP	2.5GM/VIAL	N17982 003
>_DLT_>				SEP 12, 1983
>_DLT_>		+	3.75GM/VIAL	N17982 001
>_DLT_>		+	6.75GM/VIAL	N17982 002
>_DLT_>		@	13.5GM/VIAL	N17982 004
>_DLT_>				SEP 12, 1983

MILRINONE LACTATE

INJECTABLE; INJECTION
PRIMACOR
+ SANOFI WINTHROP — EQ 1MG BASE/ML — N19436 001 DEC 31, 1987
+ STERLING WINTHROP — EQ 1MG BASE/ML — N19436 001 DEC 31, 1987

PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER
@ SANOFI WINTHROP — EQ 10MG BASE/100ML — N20343 001 AUG 09, 1994
@ — EQ 15MG BASE/100ML — N20343 002 AUG 09, 1994
+ — EQ 20MG BASE/100ML — N20343 003 AUG 09, 1994
@ STERLING WINTHROP — EQ 10MG BASE/100ML — N20343 001 AUG 09, 1994
@ — EQ 15MG BASE/100ML — N20343 002 AUG 09, 1994
+ — EQ 20MG BASE/100ML — N20343 003 AUG 09, 1994

MINOCYCLINE HYDROCHLORIDE

TABLET; ORAL
MINOCIN
@ LEDERLE — EQ 50MG BASE — N50451 003 AUG 10, 1982
@ — EQ 100MG BASE — N50451 002 AUG 10, 1982

MINOCYCLINE HCL
LEDERLE — EQ 50MG BASE — N50451 003 AUG 10, 1982
EQ 100MG BASE — N50451 002 AUG 10, 1982

MITOMYCIN

INJECTABLE; INJECTION
MUTAMYCIN
AP + BRISTOL — 5MG/VIAL — N50450 001
AP + — 20MG/VIAL — N50450 002
@ — 5MG/VIAL — N50450 001
@ — 20MG/VIAL — N50450 002
AP BRISTOL MYERS — 5MG/VIAL — N62336 001
AP + — 5MG/VIAL — N62336 001
AP — 20MG/VIAL — N62336 002

MITOMYCIN

INJECTABLE; INJECTION
MUTAMYCIN
AP + BRISTOL MYERS — 20MG/VIAL — N62336 002
— 40MG/VIAL — N62336 003 MAR 10, 1988
+ — 40MG/VIAL — N62336 003 MAR 10, 1988

NADOLOL

TABLET; ORAL
CORGARD
AB SQUIBB — 120MG — N18063 003
AB — 120MG — N18064 003
AB + — 160MG — N18063 004
AB — 160MG — N18064 004

NADOLOL
AB COPLEY PHARM — 80MG — N74368 001 AUG 31, 1994
AB — 120MG — N74368 002 AUG 31, 1994
AB — 160MG — N74368 003 AUG 31, 1994

NAFCILLIN SODIUM

INJECTABLE; INJECTION
NAFCIL
AP APOTHECON — EQ 500MG BASE/VIAL — N61984 001
AP — EQ 1GM BASE/VIAL — N61984 002
AP — EQ 2GM BASE/VIAL — N61984 003
AP — EQ 4GM BASE/VIAL — N61984 005
AP BRISTOL — EQ 500MG BASE/VIAL — N61984 001
AP — EQ 1GM BASE/VIAL — N61984 002
AP — EQ 2GM BASE/VIAL — N61984 003
AP — EQ 4GM BASE/VIAL — N61984 005

UNIPEN
AP WYETH AYERST — EQ 10GM BASE/VIAL — N50320 005
@ — EQ 20GM BASE/VIAL — N50320 006

NALIDIXIC ACID

SUSPENSION; ORAL
NEGGRAM
+ SANOFI WINTHROP — 250MG/5ML — N17430 001

NALIDIXIC ACID

SUSPENSION; ORAL

		NEGGRAM		
	*	STERLING WINTHROP	250MG/5ML	N17430 001

TABLET; ORAL

		NEGGRAM		
AB		SANOFI WINTHROP	250MG	N14214 002
AB			500MG	N14214 004
AB	+		1GM	N14214 005
AB		STERLING WINTHROP	250MG	N14214 002
AB			500MG	N14214 004
AB	*		1GM	N14214 005

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

		TALWIN NX		
>ADD>	+	SANOFI WINTHROP	EQ 0.5MG BASE; EQ 50MG BASE	N18733 001 DEC 16, 1982
>DLT>	*	STERLING WINTHROP	EQ 0.5MG BASE; EQ 50MG BASE	N18733 001 DEC 16, 1982

NANDROLONE PHENPROPIONATE

INJECTABLE; INJECTION

		DURABOLIN		
AO	+	ORGANON	50MG/ML	N11891 002
		DURABOLIN-50		
AO	*	ORGANON	50MG/ML	N11891 002

NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

		NAFAZAIR		
AT		BAUSCH AND LOMB	0.1%	N40073 001 MAY 25, 1994
AT		PHARMAFAIR	0.1%	N88101 001 APR 15, 1983
	@		0.1%	N88101 001 APR 15, 1983
		VASOCON		
AT		CIBA VISION	0.1%	N80235 002 MAR 24, 1983

NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

		VASOCON		
AT		TOLAB	0.1%	N80235 002 MAR 24, 1983

NAPROXEN

SUSPENSION; ORAL

		NAPROSYN		
AB	+	SYNTEX	25MG/ML	N18965 001 MAR 23, 1987
		NAPROXEN		
AB		ROXANE	25MG/ML	N74190 001 MAR 30, 1994

TABLET; ORAL

		NAPROSYN		
AB		SYNTEX	500MG	N17581 004 APR 15, 1982
AB	+		500MG	N17581 004 APR 15, 1982
		NAPROXEN		
AB		ROXANE	250MG	N74211 001 FEB 28, 1994
AB			375MG	N74211 002 FEB 28, 1994
AB			500MG	N74211 003 FEB 28, 1994

TABLET, DELAYED RELEASE; ORAL

		EC-NAPROSYN		
	+	SYNTEX	375MG	N20067 002 OCT 14, 1994
	+		500MG	N20067 003 OCT 14, 1994

NAPROXEN SODIUM

TABLET; ORAL

		NAPROXEN SODIUM		
AB		COPLEY PHARM	EQ 250MG BASE	N74289 001 JAN 27, 1994
AB			EQ 500MG BASE	N74289 002 JAN 27, 1994

NAPROXEN SODIUM

TABLET; ORAL

	NAPROXEN SODIUM			
AB	MYLAN	EQ 250MG BASE	N74367 001	AUG 31, 1994
AB		EQ 500MG BASE	N74367 002	AUG 31, 1994

NEOMYCIN SULFATE

TABLET; ORAL

	NEOMYCIN SULFATE			
AA	LANNETT	EQ 350MG BASE	N60607 001	
	@	EQ 350MG BASE	N60607 001	

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

	HABITROL			
BC	BASEL PHARMS	7MG/24HR	N20076 001	NOV 27, 1991
BC	+	7MG/24HR	N20076 001	NOV 27, 1991
BC		14MG/24HR	N20076 002	NOV 27, 1991
BC	+	14MG/24HR	N20076 002	NOV 27, 1991
BC		21MG/24HR	N20076 003	NOV 27, 1991
BC	+	21MG/24HR	N20076 003	NOV 27, 1991

NITROFURANTOIN

TABLET; ORAL

	FURALAN			
AB	LANNETT	50MG	N80017 001	
AB		100MG	N80017 002	
	@	50MG	N80017 001	
	@	100MG	N80017 002	

NITROFURAZONE

OINTMENT; TOPICAL

	NITROFURAZONE			
AT	LANNETT	0.2%	N84393 001	
	@	0.2%	N84393 001	

NITROGLYCERIN

INJECTABLE; INJECTION

	NITROGLYCERIN			
AP	INTL MEDICATION	5MG/ML	N70026 001	SEP 10, 1985
	@	5MG/ML	N70026 001	SEP 10, 1985
	NITROGLYCERIN IN DEXTROSE 5%			
AP	ABBOTT	0.1MG/ML	N74083 001	OCT 26, 1994
	NITRONAL			
	+ BOSKAMP	1MG/ML	N18672 001	AUG 30, 1983
	@ POHL BOSKAMP	1MG/ML	N18672 001	AUG 30, 1983
	NITROSTAT			
AP	PARKE DAVIS	5MG/ML	N70863 001	JAN 08, 1987
		10MG/ML	N70871 001	JAN 08, 1987
		10MG/ML	N70872 001	JAN 08, 1987
	@	5MG/ML	N70863 001	JAN 08, 1987
	@	10MG/ML	N70871 001	JAN 08, 1987
	@	10MG/ML	N70872 001	JAN 08, 1987

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

	LEVOPHED			
	+ SANOFI WINTHROP	EQ 1MG BASE/ML	N07513 001	
	+ STERLING WINTHROP	EQ 1MG BASE/ML	N07513 001	

NOREPINEPHRINE BITARTRATE; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
RAVOCAINE AND NOVOCAIN W/ LEVOPHED
EASTMAN KODAK — EQ 0.033MG BASE/ML;2%; 0.4% — N08592 003
STERLING WINTHROP — EQ 0.033MG BASE/ML;2%; 0.4% — N08592 003

NORETHINDRONE

TABLET; ORAL
NORLUTIN
\+ PARKE DAVIS — 5MG — N10895 002
@ — 5MG — N10895 002

NYSTATIN

SUSPENSION; ORAL
NYSTATIN
AA BAUSCH AND LOMB — 100,000 UNITS/ML — N64042 001 FEB 28, 1994
AA PHARMAFAIR — 100,000 UNITS/ML — N62541 001 JAN 16, 1985
@ — 100,000 UNITS/ML — N62541 001 JAN 16, 1985

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL
MYCOLOG-II
AT + APOTHECON — 100,000 UNITS/GM;0.1% — N60576 002 MAY 01, 1985
AT — 100,000 UNITS/GM;0.1% — N62606 001 MAY 15, 1985
AT * SQUIBB — 100,000 UNITS/GM;0.1% — N60576 002 MAY 01, 1985
AT — 100,000 UNITS/GM;0.1% — N62606 001 MAY 15, 1985
NYSTATIN AND TRIAMCINOLONE ACETONIDE
AT BARRE — 100,000 UNITS/GM;0.1% — N63010 001 DEC 20, 1988
@ — 100,000 UNITS/GM;0.1% — N63010 001 DEC 20, 1988

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL
NYSTATIN AND TRIAMCINOLONE ACETONIDE
B* CLAY PARK — 100,000 UNITS/GM;0.1% — N62186 002 JUN 06, 1985
@ — 100,000 UNITS/GM;0.1% — N62186 002 JUN 06, 1985
AT PHARMAFAIR — 100,000 UNITS/GM;0.1% — N62657 001 JUL 30, 1986
@ — 100,000 UNITS/GM;0.1% — N62657 001 JUL 30, 1986

OINTMENT; TOPICAL
MYCOLOG-II
AT + APOTHECON — 100,000 UNITS/GM;0.1% — N60572 001 JUN 28, 1985
AT * WESTWOOD SQUIBB — 100,000 UNITS/GM;0.1% — N60572 001 JUN 28, 1985
NYSTATIN-TRIAMCINOLONE ACETONIDE
AT PHARMADERM — 100,000 UNITS/GM;0.1% — N62603 001 OCT 09, 1985
@ — 100,000 UNITS/GM;0.1% — N62603 001 OCT 09, 1985

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL
PRILOSEC
\+ ASTRA MERCK — 20MG — N19810 001 SEP 14, 1989
* MERCK — 20MG — N19810 001 SEP 14, 1989

ORPHENADRINE HYDROCHLORIDE

TABLET; ORAL
DISIPAL
3M — 50MG — N10653 001
@ — 50MG — N10653 001

PAROXETINE HYDROCHLORIDE

TABLET; ORAL
PAXIL
SMITHKLINE BEECHAM — EQ 30MG BASE — N20031 003 DEC 29, 1992

PAROXETINE HYDROCHLORIDE

TABLET; ORAL
PAXIL
+ SMITHKLINE BEECHAM — EQ 30MG BASE — N20031 003 — >ADD> >DLT> — DEC 29, 1992

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION
PENICILLIN G POTASSIUM

@ APOTHECON	1,000,000 UNITS/VIAL	N60362 001	
@	5,000,000 UNITS/VIAL	N60362 003	
@	10,000,000 UNITS/VIAL	N60362 004	
@	20,000,000 UNITS/VIAL	N60362 002	
AP SQUIBB	1,000,000 UNITS/VIAL	N60362 001	
AP	5,000,000 UNITS/VIAL	N60362 003	
AP	10,000,000 UNITS/VIAL	N60362 004	
AP	20,000,000 UNITS/VIAL	N60362 002	

PENICILLIN V POTASSIUM

POWDER FOR RECONSTITUTION; ORAL
BETAPEN-VK

@ APOTHECON	EQ 125MG BASE/5ML	N61149 001
@	EQ 250MG BASE/5ML	N61149 002
AA BRISTOL	EQ 125MG BASE/5ML	N61149 001
AA	EQ 250MG BASE/5ML	N61149 002

VEETIDS

AA APOTHECON	EQ 125MG BASE/5ML	N61410 001
AA	EQ 250MG BASE/5ML	N61410 002

TABLET; ORAL — >DLT> >DLT>
UTICILLIN VK

AB UPJOHN	EQ 500MG BASE	N61651 002
@	EQ 500MG BASE	N61651 002

PENTAMIDINE ISETHIONATE — >ADD> >ADD>

INJECTABLE; INJECTION
PENTACARINAT
AP RHONE POULENC RORER — 300MG/VIAL — N73447 001 — APR 28, 1994

PENTAZOCINE LACTATE

INJECTABLE; INJECTION
TALWIN

+ SANOFI WINTHROP	EQ 30MG BASE/ML	N16194 001	
+ STERLING WINTHROP	EQ 30MG BASE/ML	N16194 001	

PENTOBARBITAL SODIUM

CAPSULE; ORAL
PENTOBARBITAL SODIUM

AA LANNETT	50MG	N85937 001	
AA	100MG	N85915 001	
@	50MG	N85937 001	
@	100MG	N85915 001	

PHENDIMETRAZINE TARTRATE

TABLET; ORAL
PHENDIMETRAZINE TARTRATE

AA ZENITH	35MG	N85611 001
@ ZENITH LABS	35MG	N85611 001

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL
PHENTERMINE HCL

AA LANNETT	30MG	N87022 001	FEB 03, 1983
@	30MG	N87022 001	FEB 03, 1983
AA LEMMON	30MG	N88612 001	APR 04, 1984
AA	30MG	N88613 001	APR 09, 1984
AA	30MG	N88614 001	APR 09, 1984
@	30MG	N88612 001	APR 04, 1984
@	30MG	N88613 001	APR 09, 1984
@	30MG	N88614 001	APR 09, 1984

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
PROMETHAZINE VC PLAIN

AA	PENNEX	5MG/5ML;6.25MG/5ML	N88897 001 JAN 04, 1985
	@ PENNEX PHARMS	5MG/5ML;6.25MG/5ML	N88897 001 JAN 04, 1985

PHENYTOIN SODIUM, PROMPT

CAPSULE; ORAL
DIPHENYLAN SODIUM

BX	LANNETT	100MG	N80857 002
		30MG	N80857 001
	@	30MG	N80857 001
	@	100MG	N80857 002

PHYTONADIONE

INJECTABLE; INJECTION
PHYTONADIONE

BP	SMITHKLINE BEECHAM	1MG/0.5ML	N84060 001
BP		10MG/ML	N84060 002
	@	1MG/0.5ML	N84060 001
	@	10MG/ML	N84060 002

PILOCARPINE HYDROCHLORIDE

TABLET; ORAL
SALAGEN

	+ MGI	5MG	N20237 001 MAR 22, 1994

PINDOLOL

TABLET; ORAL
PINDOLOL

AB	MUTUAL PHARM	5MG	N74063 001 JAN 27, 1994
AB		10MG	N74063 002 JAN 27, 1994

PIPERAZINE CITRATE

SYRUP; ORAL
BRYREL

	@ SANOFI WINTHROP	EQ 500MG BASE/5ML	N17796 001
	@ STERLING WINTHROP	EQ 500MG BASE/5ML	N17796 001
	VERMIDOL		
AA	SOLVAY	EQ 500MG BASE/5ML	N80992 001
	@	EQ 500MG BASE/5ML	N80992 001

PIROXICAM

CAPSULE; ORAL
PIROXICAM

AB	NOVOPHARM	10MG	N73637 001 JAN 28, 1994
AB		20MG	N73638 001 JAN 28, 1994

PLICAMYCIN

INJECTABLE; INJECTION
MITHRACIN

	* MILES	2.5MG/VIAL	N50109 001
	+ PFIZER	2.5MG/VIAL	N50109 001

POLYMYXIN B SULFATE

INJECTABLE; INJECTION
AEROSPORIN

AP	* BURROUGHS WELLCOME	500,000 UNITS/VIAL	N62036 001
AP	+	EQ 500,000 U BASE/VIAL	N62036 001
	POLYMIXIN B SULFATE		
AP	PFIZER	500,000 UNITS/VIAL	N60716 001
AP		EQ 500,000 U BASE/VIAL	N60716 001
	POLYMYXIN B SULFATE		
AP	PHARMA TEK	EQ 500,000 U BASE/VIAL	N63000 001 SEP 30, 1994

POTASSIUM CHLORIDE

INJECTABLE; INJECTION
POTASSIUM CHLORIDE

AP	FUJISAWA	2MEQ/ML	N87885 001 FEB 03, 1983

POTASSIUM CHLORIDE

INJECTABLE; INJECTION
POTASSIUM CHLORIDE

	@	FUJISAWA	2MEQ/ML	N87885 001 FEB 03, 1983
> DLT >		SCHERING	20MEQ	N19439 001 JUN 13, 1986
> ADD >	+		20MEQ	N19439 001 JUN 13, 1986

TABLET, EXTENDED RELEASE; ORAL
K-DUR 20

> DLT >		SCHERING	20MEQ	N19439 001 JUN 13, 1986
> ADD >	+		20MEQ	N19439 001 JUN 13, 1986

PREDNISOLONE

TABLET; ORAL
PREDNISOLONE

BX		BUNDY	5MG	N83675 001
	@		5MG	N83675 001
BX		ICN	5MG	N80236 001
	@		5MG	N80236 001
BX		INWOOD	5MG	N80748 001
	@	INWOOD LABS	5MG	N80748 001
BX		TABLICAPS	5MG	N85170 001
	@		5MG	N85170 001

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC
CETAPRED

		ALCON	0.25%;10%	N87771 001 AUG 06, 1993
	+		0.25%;10%	N87771 001 AUG 06, 1993

METIMYD

AT	+	SCHERING	**0.5%;10%**	**N10210 002**

VASOCIDIN

		CIBA VISION	0.5%;10%	N88791 001 OCT 05, 1984
		IOLAB	0.5%;10%	N88791 001 OCT 05, 1984

SUSPENSION/DROPS; OPHTHALMIC
BLEPHAMIDE

		ALLERGAN	0.2%;10%	N12813 002
	+		0.2%;10%	N12813 002

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION/DROPS; OPHTHALMIC
INFLAMASE FORTE

AT	+	CIBA VISION	**EQ 0.9% PHOSPHATE**	**N80751 002**
AT	+	IOLAB	**EQ 0.9% PHOSPHATE**	**N80751 002**

INFLAMASE MILD

AT	+	CIBA VISION	**EQ 0.11% PHOSPHATE**	**N80751 001**
AT	+	IOLAB	**EQ 0.11% PHOSPHATE**	**N80751 001**

PREDAIR FORTE

AT		PHARMAFAIR	**EQ 0.9% PHOSPHATE**	**N88165 001** **MAR 28, 1983**
	@		EQ 0.9% PHOSPHATE	N88165 001 MAR 28, 1983

PREDNISOLONE SODIUM PHOSPHATE

AT		BAUSCH AND LOMB	**EQ 0.11% PHOSPHATE**	**N40065 001** JUL 29, 1994
AT			**EQ 0.9% PHOSPHATE**	**N40070 001** JUL 29, 1994

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC
VASOCIDIN

AT	+	CIBA VISION	**EQ 0.23% PHOSPHATE;10%**	**N18988 001** AUG 26, 1988
AT	+	IOLAB	**EQ 0.23% PHOSPHATE;10%**	**N18988 001** **AUG 26, 1988**

PREDNISONE

TABLET; ORAL
PREDNISONE

	@	1ST TX	5MG	N80371 001
BX		BUNDY	5MG	N83676 001
	@		5MG	N83676 001
BX		DANBURY PHARMA	50MG	N86867 001
	@		50MG	N86867 001
	@	FERRANTE	2.5MG	N80563 001
	@		5MG	N80563 002
BX		FIRST TX	5MG	N80371 001
BX		ICN	5MG	N80237 001
	@		5MG	N80237 001
BX		INWOOD	1MG	N80328 001
BX			2.5MG	N80306 001
	@	INWOOD LABS	1MG	N80328 001
	@		2.5MG	N80306 001

PREDNISONE

TABLET; ORAL
PREDNISONE

BX	MK	2.5MG	N80563 001	
BX		5MG	N80563 002	
BX	NYLOS	5MG	N85115 001	
@		5MG	N85115 001	
BX	REXALL	5MG	N80232 001	
@		5MG	N80232 001	
BX	SPERTI	1MG	N80359 001	
BX		2.5MG	N80359 002	
BX		5MG	N80359 003	
@		1MG	N80359 001	
@		2.5MG	N80359 002	
@		5MG	N80359 003	
BX	WHITE TOWNE PAULSEN	20MG	N84913 002	
@	WHITEWORTH TOWNE	20MG	N84913 002	

PRIMAQUINE PHOSPHATE

TABLET; ORAL
PRIMAQUINE

	SANOFI WINTHROP	EQ 15MG BASE	N08316 001	
	STERLING WINTHROP	EQ 15MG BASE	N08316 001	

PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
PROMETHAZINE PLAIN

AA	PENNEX	6.25MG/5ML	N87953 001	
			NOV 15, 1982	
@	PENNEX PHARMS	6.25MG/5ML	N87953 001	
			NOV 15, 1982	

TABLET; ORAL
PROMETHAZINE HCL

BP	TABLICAPS	12.5MG	N84080 001	
BP		25MG	N84027 001	
@		12.5MG	N84080 001	
@		25MG	N84027 001	
	REMSED			
BP	DUPONT	25MG	N83176 002	
@	DUPONT MERCK	25MG	N83176 002	

PROPANTHELINE BROMIDE

TABLET; ORAL
PRO-BANTHINE

AA	ROBERTS LABS	7.5MG	N08732 003	
AA		15MG	N08732 002	
AA	SCS PHARMS	7.5MG	N08732 003	
AA		15MG	N08732 002	

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
KAINAIR

AT	PHARMAFAIR	0.5%	N88087 001	
			JUN 07, 1983	
@		0.5%	N88087 001	
			JUN 07, 1983	

PROPYLTHIOURACIL

TABLET; ORAL
PROPYLTHIOURACIL

BD	DANBURY PHARMA	50MG	N80932 001	
@		50MG	N80932 001	
BD	LANNETT	50MG	N80016 001	
@		50MG	N80016 001	
BD	TABLICAPS	50MG	N80840 001	
@		50MG	N80840 001	

PROTIRELIN

INJECTABLE; INJECTION
RELEFACT TRH

AP	FERRING LABS	0.5MG/ML	N18087 001	

THYREL TRH

AP	FERRING LABS	0.5MG/ML	N18087 001	

PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
NOVAFED

	DOW PHARMS	120MG	N17603 001	>DLT>
+		120MG	N17603 001	>ADD>

PSEUDOEPHEDRINE HYDROCHLORIDE; TERFENADINE

TABLET, EXTENDED RELEASE; ORAL

	SELDANE-D			
>DLT>	MERRELL DOW	120MG;60MG	N19664 001	
>DLT>			AUG 19, 1991	
>ADD>	+	120MG;60MG	N19664 001	
>ADD>			AUG 19, 1991	

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

TABLET; ORAL

	ALLERFED			
AA	PRIVATE FORM	60MG;2.5MG	N88860 001	
			JAN 31, 1985	
	@ PVT FORM	60MG;2.5MG	N88860 001	
			JAN 31, 1985	
	TRIPHED			
AA	LEMMON	60MG;2.5MG	N88630 001	
			MAY 17, 1984	
	@	60MG;2.5MG	N88630 001	
			MAY 17, 1984	

PYRIDOSTIGMINE BROMIDE

TABLET; ORAL

	PYRIDOSTIGMINE BROMIDE			
	KALI DUPHAR	30MG	N89572 001	
			NOV 27, 1990	
	@ SOLVAY	30MG	N89572 001	
			NOV 27, 1990	

QUINIDINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

	QUINIDEX			
AB	+ ROBINS AH	300MG	N12796 002	
	QUINIDINE SULFATE			
AB	COPLEY PHARM	300MG	N40045 001	
			JUN 30, 1994	

RANITIDINE HYDROCHLORIDE

CAPSULE; ORAL

	ZANTAC 150			
	GLAXO	EQ 150MG BASE	N20095 001	
			MAR 08, 1994	
	ZANTAC 300			
	+ GLAXO	EQ 300MG BASE	N20095 002	
			MAR 08, 1994	

GRANULE, EFFERVESCENT; ORAL

	ZANTAC 150			
	+ GLAXO	EQ 150MG BASE/PACKET	N20251 002	
			MAR 31, 1994	

TABLET, EFFERVESCENT; ORAL

	ZANTAC 150			
	+ GLAXO	EQ 150MG BASE	N20251 001	
			MAR 31, 1994	

RESERPINE

ELIXIR; ORAL

	SERPASIL			
	CIBA	0.2MG/4ML	N09115 005	
	@	0.2MG/4ML	N09115 005	

TABLET; ORAL

	RESERPINE			
BP	EON LABS	0.25MG	N09838 002	
BP	+	0.25MG	N09838 002	
	SERPASIL			
BP	CIBA	0.1MG	N09115 001	
BP	+	0.25MG	N09115 003	
	@	0.1MG	N09115 001	
	@	0.25MG	N09115 003	

ROCURONIUM BROMIDE

INJECTABLE; INJECTION

	ZEMURON			
	+ ORGANON	10MG/ML	N20214 002	
			MAR 17, 1994	
	ZEMURON (P/F)			
	+ ORGANON	10MG/ML	N20214 001	
			MAR 17, 1994	

ROSE BENGAL SODIUM, I-131

INJECTABLE; INJECTION
ROBENGATOPE

@	BRACCO DXS	0.5mCi/VIAL	N16224 001
@		1mCi/VIAL	N16224 002
@		2mCi/VIAL	N16224 003
@	SQUIBB	0.5mCi/VIAL	N16224 001
@		1mCi/VIAL	N16224 002
@		2mCi/VIAL	N16224 003

SALMETEROL XINAFOATE

AEROSOL, METERED; INHALATION
SEREVENT

+	GLAXO	EQ 0.021MG BASE/INH	N20236 001 FEB 04, 1994

SECOBARBITAL SODIUM

CAPSULE; ORAL
SECOBARBITAL SODIUM

AA	LANNETT	50MG	N85909 001
AA		100MG	N85903 001
@		50MG	N85909 001
@		100MG	N85903 001

SECONAL SODIUM

AA	LILLY	50MG	N86101 001 OCT 03, 1983
		50MG	N86101 001 OCT 03, 1983

SELENOMETHIONINE, SE-75

INJECTABLE; INJECTION
SETHOTOPE

@	BRACCO DXS	85-550 uCi/ML	N17047 001
@	SQUIBB	85-550 uCi/ML	N17047 001

SILVER SULFADIAZINE

DRESSING; TOPICAL
SILDIMAC

@	BIOPLASTY	1%	N19608 001 NOV 30, 1989

>DLT>
>DLT>
>ADD>

SILVER SULFADIAZINE

DRESSING; TOPICAL
SILDIMAC

@	ENQUAY	1%	N19608 001 NOV 30, 1989

SODIUM CHLORIDE

INJECTABLE; INJECTION
SODIUM CHLORIDE

	MCGAW	20GM/100ML	N17038 001
@		20GM/100ML	N17038 001

SODIUM CHROMATE, CR-51

INJECTABLE; INJECTION
CHROMITOPE SODIUM

	BRACCO DXS	250 uCi/VIAL	N13993 001
		1mCi/VIAL	N13993 003
		2mCi/VIAL	N13993 002
@			
	SQUIBB	250 uCi/VIAL	N13993 001
		1mCi/VIAL	N13993 003
@		2mCi/VIAL	N13993 002

SODIUM IODIDE, I-123

CAPSULE; ORAL
SODIUM IODIDE I 123

AA	NORTH AM CHEM	100 uCi	N18671 001 MAY 27, 1982
AA		200 uCi	N18671 002 MAY 27, 1982
AA	GOLDEN PHARMS	100 uCi	N18671 001 MAY 27, 1982
AA		200 uCi	N18671 002 MAY 27, 1982

SODIUM IODIDE, I-131

CAPSULE; ORAL
IODOTOPE

	BRACCO DXS	8-100 uCi	N10929 001
		1-50mCi	N10929 003
	SQUIBB	8-100 uCi	N10929 001

SODIUM IODIDE, I-131

CAPSULE; ORAL
IODOTOPE
SQUIBB 1-50mCi N10929 003

SOLUTION; ORAL
IODOTOPE
BRACCO DXS 7-106mCi/BOT N10929 002
SQUIBB 7-106mCi/BOT N10929 002

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION
NITROPRESS
AP ABBOTT 50MG/VIAL N18450 001
@ 50MG/VIAL N18450 001

SODIUM PHOSPHATE, P-32

SOLUTION; INJECTION, ORAL
PHOSPHOTOPE
@ BRACCO DXS 1-8mCi/VIAL N10927 001
@ SQUIBB 1-8mCi/VIAL N10927 001

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL
KAYEXALATE
> ADD > AA SANOFI WINTHROP 453.6GM/BOT N11287 001
> DLT > AA STERLING WINTHROP 453.6GM/BOT N11287 001

SOTALOL HYDROCHLORIDE

TABLET; ORAL
BETAPACE
BERLEX 120MG N19865 005
APR 20, 1994

STANOZOLOL

TABLET; ORAL
WINSTROL
+ SANOFI WINTHROP 2MG N12885 001
MAY 14, 1984

> DLT >
> DLT > STANOZOLOL
> DLT >

TABLET; ORAL
WINSTROL
+ STERLING WINTHROP 2MG N12885 001
MAY 14, 1984

STAVUDINE

CAPSULE; ORAL
ZERIT
@ BRISTOL MYERS SQUIBB 5MG N20412 001
JUN 24, 1994
15MG N20412 002
JUN 24, 1994
20MG N20412 003
JUN 24, 1994
30MG N20412 004
JUN 24, 1994
+ 40MG N20412 005
JUN 24, 1994

STREPTOMYCIN SULFATE

INJECTABLE; INJECTION
STREPTOMYCIN SULFATE
AP PFIZER EQ 1GM BASE/2ML N60111 001
EQ 1GM BASE/2.5ML N60111 001

SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC
SULF-10
AT CIBA VISION 10% N80025 001
AT IOLAB 10% N80025 001
SULFACETAMIDE SODIUM
AT PHARMAFAIR 10% N88947 001
MAY 17, 1985
@ 10% N88947 001
MAY 17, 1985

> DLT > SULFAIR 10
> DLT > AT PHARMAFAIR 10% N87949 001
> DLT > DEC 13, 1982
> ADD > @ 10% N87949 001
> ADD > DEC 13, 1982

SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

	SULFAIR FORTE			
AT	PHARMAFAIR	30%	N88385 001 OCT 13, 1983	
@		30%	N88385 001 OCT 13, 1983	
	SULFAIR-15			
AT	PHARMAFAIR	15%	N88186 001 MAY 25, 1983	
@		15%	N88186 001 MAY 25, 1983	

SULFADIAZINE

TABLET; ORAL

	SULFADIAZINE			
AB	+ EON LABS	500MG	N40091 001 JUL 29, 1994	
AB	EON MANUFACTURE LABS	500MG	N40091 001 JUL 29, 1994	
AB	+ LILLY	500MG	N04122 002	
@		500MG	N04122 002	

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

	SULFAMETHOXAZOLE AND TRIMETHOPRIM			
AP	FUJISAWA	80MG/ML;16MG/ML	N70223 001 DEC 29, 1987	
@		80MG/ML;16MG/ML	N70223 001 DEC 29, 1987	

SUSPENSION; ORAL

	BACTRIM			
AB	+ ROCHE	200MG/5ML;40MG/5ML	N17560 001	
@		200MG/5ML;40MG/5ML	N17560 001	
	BACTRIM PEDIATRIC			
AB	ROCHE	200MG/5ML;40MG/5ML	N17560 002	
AB	+	200MG/5ML;40MG/5ML	N17560 002	
	TRIMETH/SULFA			
AB	BARRE	200MG/5ML;40MG/5ML	N72398 001 MAY 23, 1988	
@		200MG/5ML;40MG/5ML	N72398 001 MAY 23, 1988	

SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL

	SULFAMETHOXAZOLE AND TRIMETHOPRIM			
AB	EON LABS	400MG;80MG	N18598 003 MAY 19, 1982	
@		400MG;80MG	N18598 003 MAY 19, 1982	
	UROPLUS DS			
AB	SHIONOGI	800MG;160MG	N71816 001 SEP 28, 1987	
@		800MG;160MG	N71816 001 SEP 28, 1987	
	UROPLUS SS			
AB	SHIONOGI	400MG;80MG	N71815 001 SEP 28, 1987	
@		400MG;80MG	N71815 001 SEP 28, 1987	

SULFASALAZINE

SUSPENSION; ORAL

	AZULFIDINE			
+	KABI	250MG/5ML	N18605 001	
		250MG/5ML	N86983 001	
@	PHARMACIA	250MG/5ML	N18605 001	
+		250MG/5ML	N86983 001	

SULFISOXAZOLE

TABLET; ORAL

	SULFISOXAZOLE			
AB	LANNETT	500MG	N80085 001	
@		500MG	N80085 001	

TACROLIMUS

CAPSULE; ORAL

	PROGRAF			
+	FUJISAWA	EQ 1MG BASE	N50708 001 APR 08, 1994	
+		EQ 5MG BASE	N50708 002 APR 08, 1994	

INJECTABLE; INJECTION

	PROGRAF			
+	FUJISAWA	EQ 5MG BASE/ML	N50709 001 APR 08, 1994	

TALBUTAL

TABLET; ORAL
LOTUSATE
@ SANOFI WINTHROP 120MG N09410 005
% STERLING WINTHROP 120MG N09410 005

TAMOXIFEN CITRATE

TABLET; ORAL
NOLVADEX
+ ZENECA EQ 20MG BASE N17970 002
MAR 21, 1994
@ EQ 20MG BASE N17970 002
MAR 21, 1994

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE; INJECTION
MACROTEC
BS BRACCO DXS N/A N17833 001
BS SQUIBB N/A N17833 001

> ADD > TECHNETIUM TC-99M BICISATE KIT

> ADD > INJECTABLE; INJECTION
> ADD > NEUROLITE
> ADD > DUPONT MERCK N/A N20256 001
> ADD > NOV 23, 1994

TECHNETIUM TC-99M FERPENTETATE KIT

INJECTABLE; INJECTION
RENOTEC
@ BRACCO DXS N/A N17045 001
@ SQUIBB N/A N17045 001

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION
MDP-SQUIBB
AP BRACCO DXS N/A N18107 001
AP SQUIBB N/A N18107 001

TECHNETIUM TC-99M OXIDRONATE KIT

INJECTABLE; INJECTION
OSTEOSCAN-HDP
MALLINCKRODT N/A N18321 001
TECHNESCAN HDP
MALLINCKRODT N/A N18321 001

TECHNETIUM TC-99M PENTETATE KIT

INJECTABLE; INJECTION
DTPA
AP MERCK N/A N18511 001
DEC 29, 1989
TECHNESCAN DTPA KIT
AP MERCK N/A N18511 001
DEC 29, 1989

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE; INJECTION
CARDIOLITE
DUPONT N/A N19785 001
DEC 21, 1990
DUPONT MERCK N/A N19785 001
DEC 21, 1990

TECHNETIUM TC-99M SULFUR COLLOID KIT

SOLUTION; INJECTION, ORAL
TESULOID
AP SQUIBB N/A N16923 001

SOLUTION; INTRAVENOUS, ORAL
TESULOID
AP BRACCO DXS N/A N16923 001

TETRACYCLINE

SYRUP; ORAL
ACHROMYCIN V
AB + LEDERLE EQ 125MG HCL/5ML N50263 002
SUMYCIN
AB SQUIBB EQ 125MG HCL/5ML N60400 001
TETRACYCLINE
AB BARRE EQ 125MG HCL/5ML N60633 001

TETRACYCLINE

SYRUP; ORAL

	TETRACYCLINE			
AB	MK	EQ 125MG HCL/5ML	N60174 001	
	TETRACYCLINE HCL			
AB	PUREPAC	EQ 125MG HCL/5ML	N60291 001	
	TETRACYN			
AB	PFIPHARMECS	EQ 125MG HCL/5ML	N60095 001	
	TETRAMED			
AB	ZENITH	EQ 125MG HCL/5ML	N61468 001	

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

	TETRACYCLINE HCL			
AB	ICN	500MG	N60471 002	
	@	500MG	N60471 002	

FIBER, EXTENDED RELEASE; PERIODONTAL

	ACTISITE			
	+ ON SITE	12.7MG/FIBER	N50653 001	MAR 25, 1994

SYRUP; ORAL

	ACHROMYCIN V			
AB	+ LEDERLE	125MG/5ML	N50263 002	
	SUMYCIN			
AB	SQUIBB	125MG/5ML	N60400 001	
	TETRACYCLINE HCL			
AB	BARRE	125MG/5ML	N60633 001	
AB	MK LABS	125MG/5ML	N60174 001	
AB	PUREPAC PHARM	125MG/5ML	N60291 001	
	TETRACYN			
AB	PFIPHARMECS	125MG/5ML	N60095 001	
	TETRAMED			
AB	ZENITH LABS	125MG/5ML	N61468 001	

TABLET; ORAL

	PANMYCIN			
AB	UPJOHN	500MG	N61705 002	
	@	250MG	N61705 001	
	@	500MG	N61705 002	
	SUMYCIN			
AB	+ APOTHECON	500MG	N61147 004	
	+	500MG	N61147 004	

TETRAHYDROZOLINE HYDROCHLORIDE

SOLUTION; NASAL

	TYZINE			
	+ KENWOOD LABS	0.05%	N86576 002	
		0.1%	N86576 001	
	+ KEY PHARMS	0.05%	N86576 002	
		0.1%	N86576 001	

SPRAY; NASAL

	TYZINE			
	+ KENWOOD LABS	0.1%	N86576 003	
	+ KEY PHARMS	0.1%	N86576 003	

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

	SLO-BID			
AB	RHONE POULENC RORER	100MG	N87892 001	JAN 31, 1985
AB		125MG	N89540 001	MAY 10, 1989
AB		200MG	N87893 001	JAN 31, 1985
AB	+	300MG	N87894 001	JAN 31, 1985
	THEOPHYLLINE			
AB	INWOOD LABS	100MG	N40052 001	FEB 14, 1994
AB		125MG	N40052 002	FEB 14, 1994
AB		200MG	N40052 003	FEB 14, 1994
AB		300MG	N40052 004	FEB 14, 1994

ELIXIR; ORAL

	LANOPHYLLIN			
AA	LANNETT	80MG/15ML	N84578 001	
	@	80MG/15ML	N84578 001	
	THEOPHYLLINE			
AA	BARRE	80MG/15ML	N89223 001	MAY 27, 1988
	@	80MG/15ML	N89223 001	MAY 27, 1988
	@ CENCI	80MG/15ML	N87679 001	APR 15, 1982

THEOPHYLLINE

ELIXIR; ORAL

		THEOPHYLLINE		
AA		LIFE LABS	80MG/15ML	N87679 001
				APR 15, 1982

INJECTABLE; INJECTION

		THEOPHYLLINE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER		
> DLT >	AP	MCGAW	200MG/100ML	N19212 001
> DLT >				NOV 07, 1984
> ADD >		@	200MG/100ML	N19212 001
> ADD >				NOV 07, 1984
		THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER		
> DLT >	AP	MCGAW	400MG/100ML	N19212 002
> DLT >				NOV 07, 1984
> DLT >	AP		4MG/ML	N19212 003
> DLT >				NOV 07, 1984
> ADD >		@	400MG/100ML	N19212 002
> ADD >				NOV 07, 1984
> ADD >		@	4MG/ML	N19212 003
> ADD >				NOV 07, 1984
		THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER		
	AP	BAXTER	4MG/ML	N18649 007
				JUL 26, 1982
		THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER		
	AP	ABBOTT	4MG/ML	N19211 007
				DEC 14, 1984

SYRUP; ORAL

		ACCURBRON		
		MERRELL DOW	150MG/15ML	N88746 001
				NOV 22, 1985
		@	150MG/15ML	N88746 001
				NOV 22, 1985
		THEOPHYLLINE		
	AA	BARRE	80MG/15ML	N86001 001
		@	80MG/15ML	N86001 001

THYROGLOBULIN

TABLET; ORAL

		PROLOID		
	BP	+ PARKE DAVIS	65MG	N02245 002
			32MG	N02245 005
			100MG	N02245 008
			130MG	N02245 010
			200MG	N02245 007

THYROGLOBULIN

TABLET; ORAL

		PROLOID		
		@ PARKE DAVIS	32MG	N02245 005
		@	65MG	N02245 002
		@	100MG	N02245 008
		@	130MG	N02245 010
		@	200MG	N02245 007
		THYROGLOBULIN		
		+ GLOBAL PHARMS	64.8MG	N80151 001
	BP	RICHLYN	64.8MG	N80151 001

TOBRAMYCIN

SOLUTION/DROPS; OPHTHALMIC

		TOBRAMYCIN		
	AT	STERIS	0.3%	N63176 001
				MAY 25, 1994

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

		TOBRAMYCIN SULFATE		
	AP	APOTHECON	EQ 10MG BASE/ML	N64021 001
				MAY 31, 1994
	AP		EQ 40MG BASE/ML	N64021 002
				MAY 31, 1994
	AP		EQ 40MG BASE/ML	N64026 001
				MAY 31, 1994
	AP	ASTRA	EQ 10MG BASE/ML	N63119 001
				OCT 31, 1994
	AP		EQ 40MG BASE/ML	N63120 001
				OCT 31, 1994
	AP		EQ 40MG BASE/ML	N63121 001
				OCT 31, 1994
	AP		EQ 40MG BASE/ML	N63122 001
				OCT 31, 1994
		TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER		
		+ ABBOTT	EQ 1.6MG BASE/ML	N63081 006
				JUN 02, 1993

TOLMETIN SODIUM

TABLET; ORAL

	TOLMETIN SODIUM			
AB	MYLAN	**EQ 600MG BASE**	**N74473 001**	AUG 30, 1994

TRIAMCINOLONE

TABLET; ORAL

	TRIAMCINOLONE			
BP	NYLAN	2MG	N84406 001	
	@	2MG	N84406 001	

TRIAMCINOLONE ACETONIDE

AEROSOL; TOPICAL

	KENALOG			
	+ APOTHECON	0.147MG/GM	N12104 001	
	+ WESTWOOD SQUIBB	0.147MG/GM	N12104 001	

CREAM; TOPICAL

	KENALOG			
AT	+ APOTHECON	0.025%	N11601 003	
AT	+	0.1%	N11601 006	
AT	+	0.5%	N83943 001	
AT	+ WESTWOOD SQUIBB	0.025%	N11601 003	
AT	+	0.1%	N11601 006	
AT	+	0.5%	N83943 001	
	TRIAMCINOLONE ACETONIDE			
AT	TARO PHARMS	0.025%	N40038 001	OCT 26, 1994

OINTMENT; TOPICAL

	KENALOG			
AT	+ APOTHECON	0.025%	N11600 003	
AT	+	0.1%	N11600 001	
AT	+	0.5%	N83944 001	
AT	+ WESTWOOD SQUIBB	0.025%	N11600 003	
AT	+	0.1%	N11600 001	
AT	+	0.5%	N83944 001	
	TRIAMCINOLONE ACETONIDE			
AT	TARO PHARMS	0.025%	N40040 001	SEP 30, 1994
AT		0.1%	N40037 001	SEP 30, 1994

TRIAZOLAM

TABLET; ORAL

	HALCION			
AB	UPJOHN	**0.125MG**	**N17892 003**	APR 26, 1985
AB		**0.25MG**	**N17892 001**	NOV 15, 1982
	TRIAZOLAM			
AB	ALPHAPHARM	**0.125MG**	**N74031 001**	MAR 25, 1994
AB		**0.25MG**	**N74031 002**	MAR 25, 1994
AB	ROXANE	**0.125MG**	**N74224 001**	JUN 01, 1994
AB		**0.25MG**	**N74224 002**	JUN 01, 1994

TRIHEXYPHENIDYL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

	ARTANE			
*	LEDERLE	5MG	N06773 010	
		5MG	N12947 001	
	@	5MG	N06773 010	
	+	5MG	N12947 001	

TRILOSTANE

CAPSULE; ORAL

	MODRASTANE			
	SANOFI WINTHROP	30MG	N18719 002	DEC 31, 1984
	+	60MG	N18719 001	DEC 31, 1984
	STERLING WINTHROP	30MG	N18719 002	DEC 31, 1984
*		60MG	N18719 001	DEC 31, 1984

TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE;SULFAMETHAZINE)

SUSPENSION; ORAL

	LANTRISUL			
AB	LANNETT	**167MG/5ML;167MG/5ML; 167MG/5ML**	**N80123 002**	

TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE;SULFAMETHAZINE)

SUSPENSION; ORAL

	LANTRISUL			
	@ LANNETT	167MG/5ML;167MG/5ML; 167MG/5ML	N80123 002	

TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC

	MYDRIAFAIR			
AT	PHARMAFAIR	**0.5%**	**N88274 001**	**SEP 16, 1983**
AT		**1%**	**N88230 001**	**SEP 16, 1983**
	@	0.5%	N88274 001	SEP 16, 1983
	@	1%	N88230 001	SEP 16, 1983
	TROPICAMIDE			
AT	BAUSCH AND LOMB	**0.5%**	**N40067 001**	JUL 27, 1994
AT		**1%**	**N40064 001**	JUL 27, 1994

TYROPANOATE SODIUM

CAPSULE; ORAL

	BILOPAQUE			
> ADD >	NYCOMED	750MG	N13731 001	
> DLT >	STERLING WINTHROP	750MG	N13731 001	

VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

	ISOPTIN SR			
AB	+ KNOLL PHARM	**180MG**	**N19152 002**	DEC 15, 1989
	VERAPAMIL HCL			
AB	BAKER NORTON	**180MG**	**N74330 001**	JAN 31, 1994

VINBLASTINE SULFATE

INJECTABLE; INJECTION

	VINBLASTINE SULFATE			
AP	BULL	**10MG/VIAL**	**N89565 001**	**AUG 18, 1987**
AP	FAULDING	**10MG/VIAL**	**N89565 001**	AUG 18, 1987

VINCRISTINE SULFATE

INJECTABLE; INJECTION

	VINCRISTINE SULFATE			
AP	FUJISAWA	**1MG/ML**	**N70411 001**	**SEP 10, 1986**
	@	1MG/ML	N70411 001	SEP 10, 1986
	VINCRISTINE SULFATE PFS			
AP	BULL	**1MG/ML**	**N71484 001**	**APR 19, 1988**
AP	FAULDING	**1MG/ML**	**N71484 001**	APR 19, 1988

ACETAMINOPHEN

SUPPOSITORY; RECTAL
INFANTS' FEVERALL
UPSHER SMITH 80MG N18337 004 AUG 26, 1992

TABLET, EXTENDED RELEASE; ORAL
TYLENOL
+ MCNEIL CONS PRODS 650MG N19872 001 JUN 08, 1994

ASPIRIN

TABLET, EXTENDED RELEASE; ORAL
8-HOUR BAYER
>ADD< + STERLING 650MG N16030 001
>DLT< + STERLING WINTHROP 650MG N16030 001
MEASURIN
>ADD< + STERLING 650MG N16030 002
>DLT< + STERLING WINTHROP 650MG N16030 002

BACITRACIN

OINTMENT; TOPICAL
BACITRACIN
COMBE 500 UNITS/GM N62799 001 MAY 14, 1987
@ 500 UNITS/GM N62799 001 MAY 14, 1987

CHLORPHENIRAMINE MALEATE

TABLET, EXTENDED RELEASE; ORAL
>ADD< EFIDAC 24 CHLORPHENIRAMINE
>ADD< ALZA 16MG N19746 002 NOV 18, 1994
>ADD<

CLOTRIMAZOLE

CREAM, SUPPOSITORY; TOPICAL, VAGINAL
MYCELEX-7 COMBINATION PACK
MILES 1%,100MG N20389 002 JUN 23, 1994

DIPHENHYDRAMINE HYDROCHLORIDE

SYRUP; ORAL
DIPHENHYDRAMINE HCL
BARRE 12.5MG/5ML N70497 001 APR 25, 1989
@ 12.5MG/5ML N70497 001 APR 25, 1989

EPINEPHRINE

AEROSOL, METERED; INHALATION
BRONKAID MIST
>ADD< + STERLING 0.25MG/INH N16803 001
>DLT< + STERLING WINTHROP 0.25MG/INH N16803 001

IBUPROFEN

TABLET; ORAL
IBUPROFEN
MCNEIL CONS PRODS 200MG N73019 001 MAR 30, 1994
PVT FORM 200MG N73691 001 FEB 25, 1994

INSULIN BIOSYNTHETIC HUMAN

INJECTABLE; INJECTION
HUMULIN BR
+ LILLY 100 UNITS/ML N19529 001 APR 28, 1986
@ 100 UNITS/ML N19529 001 APR 28, 1986

INSULIN SUSP ISOPHANE BEEF

INJECTABLE; INJECTION
NPH INSULIN
+ NOVO NORDISK 40 UNITS/ML N17929 001
@ 40 UNITS/ML N17929 001

INSULIN SUSP ISOPHANE BEEF/PORK

INJECTABLE; INJECTION
NPH ILETIN I (BEEF-PORK)

+	LILLY	40 UNITS/ML	N17936 001
@		40 UNITS/ML	N17936 001

NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE

SOLUTION/DROPS; OPHTHALMIC

	NAPHCON-A		
+	ALCON	0.025%;0.3%	N20226 001 JUN 08, 1994
	OPCON-A		
+	BAUSCH AND LOMB	0.027%;0.315%	N20065 001 JUN 08, 1994

NAPROXEN SODIUM

TABLET; ORAL

	ALEVE		
	HAMILTON PHARMS	EQ 200MG BASE	N20204 002 JAN 11, 1994

PERMETHRIN

LOTION; TOPICAL

	NIX		
+	BURROUGHS WELLCOME	1%	N19918 001 MAY 02, 1990
+	WARNER WELLCOME	1%	N19918 001 MAY 02, 1990

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

	EFIDAC/24		
+	CIBA CONS	240MG	N20021 002 DEC 15, 1992
	PSEUDOEPHEDRINE HCL		
	ALZA	240MG	N20021 002 DEC 15, 1992
	SUDAFED 12 HOUR		
+	BURROUGHS WELLCOME	120MG	N73585 001 OCT 31, 1991

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
SUDAFED 12 HOUR

+	WARNER WELLCOME	120MG	N73585 001 OCT 31, 1991

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION USP

INJECTABLE; INJECTION
BLOOD PACK UNIT CPDA-1 IN PLASTIC CONTAINER
BAXTER HLTHCARE — N940404
JUL 28, 1994

INDIUM IN^{111} CHLORIDE STERILE SOLUTION

INJECTABLE; INJECTION
ULTRAPURE
MALLINCKRODT — N/A — N19841
SEP 27, 1994

LIST OF ORPHAN PRODUCT DESIGNATIONS & APPROVALS
[January-November, 1994]

NAME *Generic/Chemical* *TN=Trade Name*	***INDICATION DESIGNATED***	***SPONSOR & ADDRESS*** *DD=Date Designated* *MA=Marketing Approval*
8-METHOXSALEN TN= UVADEX	FOR THE PREVENTION OF ACUTE REJECTION OF CARDIAC ALLOGRAFTS.	THERAKOS, INCORPORATED 201 BRANDYWINE PARKWAY WEST CHESTER PA 19380 DD 05/12/94 MA / /
AMINOSALICYLIC ACID TN= PASER GRANULES	TREATMENT OF TUBERCULOSIS INFECTIONS.	JACOBUS PHARMACEUTICAL COMPANY 37 CLEVELAND LANE PRINCETON NJ 08540 DD 02/19/92 MA 06/30/94
AMINOSIDINE TN= PAROMOMYCIN	TREATMENT OF VISCERAL LEISHMANIASIS (KALA-AZAR).	KANYOK, THOMAS P. PHARM.D. UNIV. OF ILLINOIS AT CHICAGO CHICAGO IL 60612 DD 09/09/94 MA / /
AMIODARONE HCL TN= CORDARONE	FOR THE ACUTE TREATMENT AND PROPHYLAXIS OF LIFE-THREATENING VENTRICULAR TACHYCARDIA OR VENTRICULAR FIBRILLATION.	WYETH-AYERST LABORATORIES P.O. BOX 8299 PHILADELPHIA PA 19101-1245 DD 03/16/94 MA / /
AMMONIUM TETRATHIOMOLYBDATE TN=	TREATMENT OF WILSON'S DISEASE.	BREWER, GEORGE J. M.D. UNIVERSITY OF MICHIGAN MEDICAL SCHOOL ANN ARBOR MI 48109-0618 DD 01/31/94 MA / /
ANTIVENIN, POLYVALENT CROTALID (OVINE) FAB TN= CROTAB	TREATMENT OF ENVENOMATIONS INFLICTED BY NORTH AMERICAN CROTALID SNAKES.	THERAPEUTIC ANTIBODIES INC. 1500 21ST AVENUE SOUTH, SUITE 310 NASHVILLE TN 37212 DD 01/12/94 MA / /
ARGININE BUTYRATE TN=	TREATMENT OF SICKLE CELL DISEASE AND BETA THALASSEMIA.	VERTEX PHARMACEUTICALS INC. 40 ALLSTON STREET CAMBRIDGE MA 02139-4211 DD 05/25/94 MA / /
AUTOLYMPHOCYTE THERAPY TN=	TREATMENT OF RENAL CELL CARCINOMA.	CELLCOR INCORPORATED 200 WELLS AVENUE NEWTON MA 02159 DD 07/12/94 MA / /
BACLOFEN TN= LIORESAL INTRATHECAL	TREATMENT OF SPASTICITY ASSOCIATED WITH CEREBRAL PALSY.	MEDTRONIC, INCORPORATED 800 53RD AVENUE N.E. MINNEAPOLIS MN 55432 DD 09/26/94 MA / /
BETAINE TN=	TREATMENT OF HOMOCYSTINURIA.	ORPHAN MEDICAL 13911 RIDGEDALE DRIVE MINNETONKA MN 55305 DD 05/16/94 MA / /
BOVINE IMMUNOGLOBULIN CONCENTRATE, CRYPTOSPORIDIUM PARVUM TN= SPORIDIN-G	TREATMENT AND SYMPTOMATIC RELIEF OF CRYPTOSPORIDIUM PARVUM INFECTION OF THE GASTROINTESTINAL TRACT IN IMMUNOCOMPROMISED PATIENTS.	GALAGEN, INCORPORATED 4001 LEXINGTON AVENUE NORTH ARDEN HILLS MN 55126-2998 DD 03/01/94 MA / /
BUPRENORPHINE HYDROCHLORIDE TN=	TREATMENT OF OPIATE ADDICTION IN OPIATE USERS.	RECKITT & COLMAN PHARMACEUTICALS, INC. 1901 HUGUENOT ROAD RICHMOND VA 23235 DD 06/15/94 MA / /

CUMULATIVE LIST OF DESIGNATIONS & APPROVALS

NAME Generic/Chemical TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
BUPRENORPHINE IN COMBINATION WITH NALOXONE TN=	TREATMENT OF OPIATE ADDICTION IN OPIATE USERS.	RECKITT & COLMAN PHARMACEUTICALS INC. 1901 HUGUENOT ROAD RICHMOND VA 23235 DD 10/27/94 MA / /
BUSULFAN TN=	FOR USE AS PREPARATIVE THERAPY FOR MALIGNANCIES TREATED WITH BONE MARROW TRANSPLANTATION.	SPARTA PHARMACEUTICALS, INC. P.O. BOX 13288 RESEARCH TRIANGLE PK NC 27709 DD 04/21/94 MA / /
BUSULFAN TN=	AS PREPARATIVE THERAPY IN THE TREATMENT OF MALIGNANCIES WITH BONE MARROW TRANSPLANTATION.	ORPHAN MEDICAL 13911 RIDGEDALE DRIVE MINNETONKA MN 55305 DD 07/28/94 MA / /
CCD 1042 TN=	TREATMENT OF INFANTILE SPASMS.	COCENSYS, INC. 213 TECHNOLOGY DRIVE IRVINE CA 92718 DD 05/25/94 MA / /
CHIMERIC (MURINE VARIABLE, HUMAN CONSTANT) MAB TO CD20 TN=	TREATMENT OF NON-HODGKIN'S B-CELL LYMPHOMA.	IDEC PHARMACEUTICALS CORPORATION 11011 TORREYANA ROAD SAN DIEGO CA 92121 DD 06/13/94 MA / /
CHOLINE CHLORIDE TN=	TREATMENT OF CHOLINE DEFICIENCY,SPECIFICALLY THE CHOLINE DEFICIENCY, HEPATIC STEATOSIS, AND CHOLESTASIS, ASSOCIATED WITH LONG-TERM PARENTERAL NUTRITION.	BUCHMAN, ALAN M.D. 6550 FANNIN, SUITE 1122 HOUSTON TX 77030 DD 02/10/94 MA / /
CLADRIBINE TN= LEUSTATIN	TREATMENT OF THE CHRONIC PROGRESSIVE FORM OF MULTIPLE SCLEROSIS.	R.W. JOHNSON RESEARCH INSTITUTE 700 ROUTE 200 SOUTH, P.O. BOX 670 RARITAN NJ 08869-0670 DD 04/19/94 MA / /
CLONAZEPAM TN= KLONOPIN	TREATMENT OF HYPEREKPLEXIA (STARTLE DISEASE).	HOFFMAN-LA ROCHE, INCORPORATED 340 KINGSLAND STREET NUTLEY NJ 07110-1199 DD 08/04/94 MA / /
COAGULATION FACTOR IX (RECOMBINANT) TN=	TREATMENT OF HEMOPHILIA B.	GENETICS INSTITUTE, INCORPORATED 87 CAMBRIDGE PARK DRIVE CAMBRIDGE MA 02140 DD 10/03/94 MA / /
CY-1899 TN=	TREATMENT OF CHRONIC ACTIVE HEPATITIS B INFECTION IN HLA-A2 POSITIVE PATIENTS.	CYTEL CORPORATION 3525 JOHN HOPKINS COURT SAN DIEGO CA 92121 DD 03/16/94 MA / /
CYSTEAMINE TN= CYSTAGON	TREATMENT OF NEPHROPATHIC CYSTINOSIS.	MYLAN LABORATORIES, INC 781 CHESTNUT RIDGE ROAD, PO BOX 4310 MORGANTOWN WV 26504-4310 DD 01/25/91 MA 08/15/94

CUMULATIVE LIST OF DESIGNATIONS & APPROVALS

NAME Generic/Chemical TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
DAPSONE TN=	PROPHYLAXIS OF TOXOPLASMOSIS IN SEVERELY IMMUNOCOMPROMISED PATIENTS WITH CD4 COUNTS BELOW 100.	JACOBUS PHARMACEUTICAL COMPANY 37 CLEVELAND LANE, PO BOX 5290 PRINCETON NJ 08540 DD 11/07/94 MA / /
DEHYDROEPIANDROSTERONE TN=	TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) AND THE REDUCTION IN THE USE OF STEROIDS IN STEROID-DEPENDENT SLE PATIENTS.	GENELABS TECHNOLOGIES, INC. 505 PENOBSCOT DRIVE REDWOOD CITY CA 94063 DD 07/13/94 MA / /
DESMOPRESSIN ACETATE TN=	TREATMENT OF MILD HEMOPHILIA A AND VON WILLEBRAND'S DISEASE.	RHONE-POULENC RORER PHARM. 500 ARCOLA ROAD COLLEGEVILLE PA 19426 DD 01/22/91 MA 03/07/94
DIMETHYL SULFOXIDE TN=	TREATMENT OF INCREASED INTRACRANIAL PRESSURE IN PATIENTS WITH SEVERE, CLOSED-HEAD INJURY, ALSO KNOWN AS TRAUMATIC BRAIN COMA, FOR WHOM NO OTHER EFFECTIVE TREATMENT IS AVAILABLE.	PHARMA 21 4850 S.W. SCHOLLS FERRY ROAD, SUITE 301 PORTLAND OR 97225-1686 DD 11/22/94 MA / /
ELLIOTT'S B SOLUTION TN=	TREATMENT OF ACUTE LYMPHOCYTIC LEUKEMIAS AND ACUTE LYMPHOBLASTIC LYMPHOMAS.	ORPHAN MEDICAL 13911 RIDGEDALE DRIVE MINNETONKA MN 55305 DD 08/24/94 MA / /
FGN-1 TN=	FOR THE SUPPRESSION AND CONTROL OF COLONIC ADENOMATOUS POLYPS IN THE INHERITED DISEASE ADENOMATOUS POLYPOSIS COLI.	CELL PATHWAYS, INC. 1700 BROADWAY, SUITE 2000 DENVER CO 80290 DD 02/14/94 MA / /
GAMMA-HYDROXYBUTYRATE TN=	TREATMENT OF NARCOLEPSY.	ORPHAN MEDICAL 13911 RIDGEDALE DRIVE MINNETONKA MN 55305 DD 11/07/94 MA / /
GAMMALINOLENIC ACID TN=	TREATMENT OF JUVENILE RHEUMATOID ARTHRITIS.	ZURIER, ROBERT B. M.D. 55 LAKE AVE. UNIV. OF MASS. MED. CTR. WORCESTER MA 01655 DD 07/27/94 MA / /
HEME ARGINATE TN= NORMOSANG	TREATMENT OF MYELODYSPLASTIC SYNDROMES.	LEIRAS, INCORPORATED 1850 CENTENNIAL PARK DRIVE, SUITE 450 RESTON VA 22091 DD 03/01/94 MA / /
I-131 RADIOLABELED B1 MONOCLONAL ANTIBODY TN=	TREATMENT OF NON-HODGKIN'S B-CELL LYMPHOMA.	COULTER CORPORATION 11800 S.W. 147 AVENUE, P.O. BOX 169015 MIAMI FL 33116-9015 DD 05/16/94 MA / /
IMIGLUCERASE TN= CEREZYME	FOR REPLACEMENT THERAPY IN PATIENTS WITH TYPES I, II, AND III GAUCHER'S DISEASE.	GENZYME CORPORATION ONE KENDALL SQUARE CAMBRIDGE MA 02139 DD 11/05/91 MA 05/23/94
IN-111 MURINE MAB(2B8-MX-DTPA) & Y-90 MURINE MAB(2B8-MXDTPA) TN= MELIMMUNE	TREATMENT OF B-CELL NON-HODGKIN'S LYMPHOMA.	IDEC PHARMACEUTICALS CORPORATION 11011 TORREYANA ROAD SAN DIEGO CA 92121 DD 09/06/94 MA / /

CUMULATIVE LIST OF DESIGNATIONS & APPROVALS

NAME Generic/Chemical TN= Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD= Date Designated MA= Marketing Approval
ISOBUTYRAMIDE TN=	TREATMENT OF SICKLE CELL DISEASE AND BETA THALASSEMIA.	VERTEX PHARMACEUTICALS INC. 40 ALLSTON STREET CAMBRIDGE MA 02139-4211 DD 05/25/94 MA / /
L-2-OXOTHIAZOLIDINE-4-CARBOXYLIC ACID TN= PROCYSTEINE	TREATMENT OF ADULT RESPIRATORY DISTRESS SYNDROME.	FREE RADICAL SCIENCES, INC. 245 FIRST STREET CAMBRIDGE MA 02142 DD 06/14/94 MA / /
L-CYSTEINE TN=	FOR THE PREVENTION AND LESSENING OF PHOTOSENSITIVITY IN ERYTHROPOIETIC PROTOPORPHYRIA.	TYSON AND ASSOCIATES 12832 SOUTH CHADRON AVENUE HAWTHORNE CA 90250 DD 05/16/94 MA / /
LIPOSOME ENCAPSULATED RECOMBINANT INTERLEUKIN-2 TN=	TREATMENT OF CANCERS OF THE KIDNEY AND RENAL PELVIS.	ONCOTHERAPEUTICS, INC. 1002 EASTPARK BOULEVARD CRANBURY NJ 08512 DD 06/20/94 MA / /
MELANOMA CELL VACCINE TN=	TREATMENT OF INVASIVE MELANOMA.	MORTON, DONALD L. M.D. JOHN WAYNE CANCER INSTITUTE SANTA MONICA CA 90404 DD 10/13/94 MA / /
MITOGUAZONE TN=	TREATMENT OF DIFFUSE NON-HODGKIN'S LYMPHOMA, INCLUDING AIDS-RELATED DIFFUSE NON-HODGKIN'S LYMPHOMA.	CTRC RESEARCH FOUNDATION 11812 BECKET STREET POTOMAC MD 20854 DD 03/18/94 MA / /
MONOCLONAL AB(MURINE) ANTI-IDIOTYPE MELANOMA ASS'TED ANTIGEN TN= MELIMMUNE	TREATMENT OF INVASIVE CUTANEOUS MELANOMA.	IDEC PHARMACEUTICALS CORPORATION 11011 TORREYANA ROAD SAN DIEGO CA 92121 DD 09/19/94 MA / /
N-TRIFLUOROACETYLADRIAMYCIN-14-VALERATE TN=	TREATMENT OF CARCINOMA IN SITU OF THE URINARY BLADDER.	ANTHRA PHARMACEUTICALS, INC. 19 CARSON ROAD PRINCETON NJ 08540 DD 05/23/94 MA / /
NEUROTROPHIN-1 TN=	TREATMENT OF MOTOR NEURON DISEASE/AMYOTROPHIC LATERAL SCLEROSIS.	ERICSSON, ARTHUR DALE, M.D. 6560 FANNIN, SCURLOCK TOWER, SUITE 720 HOUSTON TX 77303 DD 09/13/94 MA / /
OXANDROLONE TN= HEPANDRIN	TREATMENT OF MODERATE/SEVERE ACUTE ALCOHOLIC HEPATITIS IN THE PRESENCE OF MODERATE PROTEIN CALORIE MALNUTRITION.	BIO-TECHNOLOGY GENERAL CORP. 70 WOOD AVENUE SOUTH ISELIN NJ 08830 DD 03/18/94 MA / /
PEGASPARGASE TN= ONCASPAR	TREATMENT OF ACUTE LYMPHOCYTIC LEUKEMIA (ALL).	ENZON, INC. 40 KINGSBRIDGE ROAD PISCATAWAY NJ 08854-3998 DD 10/20/89 MA 02/01/94
PILOCARPINE TN= SALAGEN	TREATMENT OF XEROSTOMIA INDUCED BY RADIATION THERAPY FOR HEAD AND NECK CANCER.	MGI PHARMA, INC. SUITE 300 E, 9900 BREN ROAD EAST MINNEAPOLIS MN 55343-9667 DD 09/24/90 MA 03/22/94
RECOMBINANT HUMAN GELSOLIN TN=	TREATMENT OF THE RESPIRATORY SYMPTOMS OF CYSTIC FIBROSIS.	BIOGEN, INC. 14 CAMBRIDGE CENTER CAMBRIDGE MA 02124 DD 01/12/94 MA / /

CUMULATIVE LIST OF DESIGNATIONS & APPROVALS

NAME Generic/Chemical TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
RECOMBINANT HUMAN LUTEINIZING HORMONE TN=	FOR USE IN ASSOCIATION WITH RECOMBINANT HUMAN FOLLICLE STIMULATING HORMONE FOR THE TREATMENT OF WOMEN WITH CHRONIC ANOVULATION DUE TO HYPOGONADOTROPIC HYPOGONADISM.	SERONO LABORATORIES, INCORPORATED 100 LONGWATER CIRCLE NORWELL MA 02061 DD 10/07/94 MA / /
RECOMBINANT METHIONYL BRAIN-DERIVED NEUROTROPHIC FACTOR TN=	TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS.	AMGEN, INCORPORATED 1840 DEHAVILLAND DRIVE THOUSAND OAKS CA 91320-1789 DD 11/28/94 MA / /
RECOMBINANT VACCINIA (HUMAN PAPILLOMAVIRUS) TN= TA-HPV	TREATMENT OF CERVICAL CANCER.	CANTAB PHARMACEUTICALS RESEARCH, LTD. 184 CAMBRIDGE SCIENCE PARK CAMBRIDGE CB4 4GN UK DD 08/24/94 MA / /
REDUCED L-GLUTATHIONE TN= CACHEXON	TREATMENT OF AIDS-ASSOCIATED CACHEXIA.	TELLURIDE PHARMACEUTICAL CORPORATION 146 FLANDERS DRIVE HILLSBOROUGH NJ 08876-4656 DD 02/14/94 MA / /
RICIN (BLOCKED) CONJUGATED MURINE MOAB (CD6) TN=	TREATMENT OF CUTANEOUS T-CELL LYMPHOMAS, ACUTE T-CELL LEUKEMIA-LYMPHOMA, AND RELATED MATURE T-CELL MALIGNANCIES.	IMMUNOGEN, INC. 148 SIDNEY STREET CAMBRIDGE MA 02139-4239 DD 09/06/94 MA / /
RIFAMPIN, ISONIAZID, PYRAZINAMIDE TN= RIFATER	SHORT-COURSE TREATMENT OF TUBERCULOSIS.	MARION MERRELL DOW, INC. P.O. BOX 9627 KANSAS CITY MO 64134-0627 DD 09/12/85 MA 05/31/94
SODIUM DICHLOROACETATE TN=	TREATMENT OF LACTIC ACIDOSIS IN PATIENTS WITH SEVERE MALARIA.	STACPOOLE, PETER W., PH.D., M.D. UNIVERSITY OF FLORIDA GAINESVILLE FL 32610-0277 DD 11/10/94 MA / /
SOLUBLE RECOMBINANT HUMAN COMPLEMENT RECEPTOR TYPE 1 TN=	PREVENTION OR REDUCTION OF ADULT RESPIRATORY DISTRESS SYNDROME.	T CELL SCIENCES, INC. 38 SIDNEY STREET CAMBRIDGE MA 02139-4135 DD 11/21/94 MA / /
SOMATROPIN TN= NUTROPIN (EXCLUSIVITY NOT APPLICABLE)	FOR USE IN THE LONG-TERM TREATMENT OF CHILDREN WHO HAVE GROWTH FAILURE DUE TO A LACK OF ADEQUATE ENDOGENOUS GROWTH HORMONE SECRETION.	GENENTECH, INC. 460 POINT SAN BRUNO BOULEVARD SOUTH SAN FRANCISCO CA 94080 DD 03/06/87 MA 03/09/94
SOMATROPIN TN= GENOTROPIN/GENOTONORM	TREATMENT OF ADULTS WITH GROWTH HORMONE DEFICIENCY.	PHARMACIA, INC. P.O. BOX 16529 COLUMBUS OH 43216-6529 DD 09/06/94 MA / /
SULFADIAZINE TN=	FOR USE IN COMBINATION WITH PYRIMETHAMINE FOR THE TREATMENT OF TOXOPLASMA GONDII ENCEPHALITIS IN PATIENTS WITH AND WITHOUT ACQUIRED IMMUNODEFICIENCY SYNDROME.	EON LABS MANUFACTURING, INC. 227-15 NORTH CONDUIT AVENUE LAURELTON NY 11413 DD 03/14/94 MA 07/29/94
TIZANIDINE HCL TN= ZANAFLEX	TREATMENT OF SPASTICITY ASSOCIATED WITH MULTIPLE SCLEROSIS AND SPINAL CORD INJURY.	ATHENA NEUROSCIENCES, INC. 800F GATEWAY BOULEVARD SOUTH SAN FRANCISCO CA 94080 DD 01/31/94 MA / /

CUMULATIVE LIST OF DESIGNATIONS & APPROVALS

NAME Generic/Chemical TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
TOBRAMYCIN FOR INHALATION TN=	TREATMENT OF BRONCHOPULMONARY INFECTIONS OF PSEUDOMONAS AERUGINOSA IN CYSTIC FIBROSIS PATIENTS.	PATHOGENESIS CORPORATION 201 ELLIOTT AVENUE WEST, SUITE 150 SEATTLE WA 98119 DD 10/13/94 MA / /
TREOSULFAN TN= OVASTAT	TREATMENT OF OVARIAN CANCER.	MEDAC GmbH c/o PRINCETON REG. ASSOC. 65 SOUTH MAIN STREET PENNINGTION NJ 08534 DD 05/16/94 MA / /

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY
IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO NOVEMBER 1994 ADDITIONS

BIOPHARMACEUTIC GUIDANCE AVAILABILITY

DRUG NAME (DOSAGE FORM)	DATE	REVISED DATE
ALBUTEROL (METERED DOSE INHALER - *IN VIVO*)	JAN 27, 1994	
DICLOFENAC SODIUM (TABLET)	DEC 24, 1992	OCT 06, 1994
FLURBIPROFEN (TABLET)	DEC 24, 1992	FEB 04, 1994
PHENYTOIN (SUSPENSION AND CHEWABLE TABLET)	MAR 04, 1994	
PHENYTOIN SODIUM (CAPSULE, EXTENDED AND PROMPT)	MAR 04, 1994	
TOLMETIN SODIUM (CAPSULE AND TABLET)	APR 20, 1989	OCT 06, 1994

THE FOLLOWING IS A LIST OF GUIDANCES AVAILABLE FOR *IN VIVO* BIOEQUIVALENCE STUDIES AND *IN VITRO* DISSOLUTION TESTING. COMMENTS AND SUGGESTIONS CONCERNING THESE GUIDANCES ARE ENCOURAGED AND SHOULD BE SENT TO THE DIVISION OF BIOEQUIVALENCE (HFD-650, MPN-2 ROOM 279) 5600 FISHERS LANE, ROCKVILLE, MD 20857.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 14TH EDITION FOR A FULL LISTING OF BIOPHARMACEUTIC GUIDANCE AVAILABILITY DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

ANDA SUITABILITY PETITIONS

PETITIONS APPROVED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
THE FOLLOWING ARE TWO LISTS OF PETITIONS FILED UNDER SECTION 505(j)(2)(C) OF THE ACT WHERE THE AGENCY HAS DETERMINED THAT THE REFERENCED PRODUCT: (1) IS SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS APPROVED) OR (2) IS NOT SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS DENIED). THE DETERMINATION THAT AN ANDA WILL BE APPROVED IS NOT MADE UNTIL THE ANDA ITSELF IS SUBMITTED AND REVIEWED BY THE AGENCY. A COPY OF EACH PETITION IS LISTED BY DOCKET NUMBER ON PUBLIC DISPLAY IN FDA'S DOCKETS MANAGEMENT BRANCH, HFA-305, ROOM 4-62, 5600 FISHERS LANE, ROCKVILLE, MD 20857.					
REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 13TH EDITION FOR A FULL LISTING OF ANDA SUITABILITY PETITIONS DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.					
ACETAMINOPHEN; BUTALBITAL; CAFFEINE; HYDROCODONE BITARTRATE CAPSULE; ORAL	325MG 50MG 40MG 5MG	93 P-0346/ CP1	MIKART	NEW COMBINATION	APPROVED NOV 15, 1994
ACETAMINOPHEN; BUTALBITAL; CAFFEINE; HYDROCODONE BITARTRATE TABLET; ORAL	325MG 50MG 40MG 5MG	93 P-0346/ CP1	MIKART	NEW COMBINATION NEW DOSAGE FORM	APPROVED NOV 15, 1994
ACETAMINOPHEN; BUTALBITAL; CAFFEINE; HYDROCODONE BITARTRATE TABLET; ORAL	500MG 50MG 40MG 5MG	93 P-0298/ CP1	ARNOLD & PORTER	NEW COMBINATION NEW DOSAGE FORM NEW STRENGTH	APPROVED NOV 15, 1994
ACYCLOVIR TABLET; ORAL	200MG	93 P-0339/ CP1	NOVOPHARM	NEW DOSAGE FORM	APPROVED FEB 08, 1994
ACYCLOVIR SODIUM INJECTABLE; INJECTION	25MG/ML (20ML/VIAL) (40ML/VIAL)	93 P-0469/ CP1	FAULDING	NEW DOSAGE FORM	APPROVED JUN 09, 1994
ESTRADIOL TABLET; ORAL	1.5MG	93 P-0344/ CP1	BRISTOL MYERS SQIBB	NEW STRENGTH	APPROVED JUN 08, 1994
LOPERAMIDE HYDROCHLORIDE TABLET, EFFERVESCENT; ORAL	1MG	93 P-0332/ CP1	ELLIS PHARM CONSULTING	NEW DOSAGE FORM	APPROVED FEB 08, 1994
METHYLTESTOSTERONE CAPSULE; ORAL	25MG	93 P-0459/ CP1	ICN	NEW DOSAGE FORM	APPROVED JUN 08, 1994
MORPHINE SULFATE CAPSULE, EXTENDED RELEASE; ORAL	15MG 60MG 100MG	93 P-0446/ CP1	PHARMA CONSULT	NEW DOSAGE FORM	APPROVED JUN 08, 1994
MORPHINE SULFATE CAPSULE, EXTENDED RELEASE; ORAL	90MG	93 P-0446/ CP1	PHARMA CONSULT	NEW DOSAGE FORM NEW STRENGTH	APPROVED JUN 08, 1994
PREDNISONE TABLET, CHEWABLE; ORAL	1MG 2.5MG 20MG 50MG	93 P-0333/ CP1	DURA	NEW DOSAGE FORM	APPROVED JUN 08, 1994
PSEUDOEPHEDRINE HYDROCHLORIDE; TERFENADINE CAPSULE, EXTENDED RELEASE; ORAL	120MG 60MG	93 P-0367/ CP1	EURAND AMERICA	NEW DOSAGE FORM	APPROVED FEB 08, 1994

ANDA SUITABILITY PETITIONS

PETITIONS APPROVED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
		ERRATA			
CIMETIDINE TABLET, EFFERVESCENT; ORAL	200MG 300MG 400MG 800MG	93 P-0048/ CP1*	FLEMINGTON PHARM	NEW DOSAGE FORM	APPROVED SEP 18, 1993

*Not previously published

EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE EXCLUSIVITY COLUMN, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 14TH EDITION FOR A FULL LISTING OF EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). ONLY NEW CODES WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

REFERENCES

NEW DOSING SCHEDULE

D-21	ALTERNATIVE DOSAGE OF 300MG ONCE DAILY AFTER THE EVENING MEAL
D-22	REDUCTION IN INFUSION TIME FROM 24 TO 4 HOURS FOR THE 60MG DOSE
D-23	INCREASE MAXIMUM DOSE AND VARIATIONS IN THE DOSING REGIMEN
D-24	FOR OVARIAN CANCER THE RECOMMENDED REGIMEN IS 135MG/M^2 OR 175MG/M^2 INTRAVENOUSLY OVER THREE HOURS EVERY THREE WEEKS
D-25	ADDITIONAL DOSAGE REGIMEN EQUAL TO HALF OF THE ORIGINAL DOSING REGIMEN

REFERENCES

NEW INDICATION

I-99	PEDIATRIC ANESTHESIA IN CHILDREN 3 YEARS AND OLDER
I-100	TO DECREASE THE INCIDENCE OF CANDIDIASIS IN PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION WHO RECEIVE CYTOTOXIC CHEMOTHERAPY AND/OR RADIATION THERAPY
I-101	TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN-DEPENDENT DIABETES MELLITUS AND RETINOPATHY
I-102	TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER
I-103	PROPHYLAXIS AGAINST PNEUMOCYSTIS CARINII PNEUMONIA IN INDIVIDUALS WHO ARE IMMUNOCOMPROMISED AND CONSIDERED TO BE AT RISK OF DEVELOPING PNEUMOCYSTIS CARINII PNEUMONIA
I-104	TREATMENT OF PULMONARY AND EXTRAPULMONARY ASPERGILLOSIS IN PATIENTS WHO ARE INTOLERANT OF OR WHO ARE REFRACTORY TO AMPHOTERICIN B THERAPY
I-105	TREATMENT OF METASTATIC CARCINOMA OF THE BREAST AFTER FAILURE OF FIRST-LINE OR SUBSEQUENT CHEMOTHERAPY
I-106	TREATMENT OF ACROMEGALY
I-107	VAGINAL CANDIDIASIS
I-108	EXPANDED USE-FOR ICU PATIENTS UNDERGOING LONG-TERM INFUSION DURING MECHANICAL VENTILATION
I-109	TYPHOID FEVER
I-110	PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIOTHERAPY
I-111	TREATMENT OF PAGET'S DISEASE OF BONE
I-112	MANAGEMENT OF MODERATE TO SEVERE PAIN
I-113	TREATMENT OF PROSTATITIS
I-114	USE IN CHILDREN TO VISUALIZE LESIONS WITH ABNORMAL VASCULARITY IN THE BRAIN (INTRACRANIAL LESIONS), SPINE AND ASSOCIATED TISSUE
I-115	USE IN MRI IN ADULTS TO VISUALIZE LESIONS IN THE HEAD AND NECK

REFERENCES

PATENT USE CODE

U-91	ALTERNATIVE THERAPY TO TRIMETHOPRIM-SULFAMETHOXAZOLE FOR TREATMENT OF MODERATE-TO-SEVERE PNEUMOCYSTIS CARINII PNEUMONIA IN IMMUNOCOMPROMISED AND AIDS PATIENTS
U-92	TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN DEPENDENT DIABETES MELLITUS AND RETINOPATHY
U-93	USE AS AN ANTIHISTAMINE/DECONGESTANT
U-94	TREATMENT OF ADULTS WITH ADVANCED HIV INFECTION WHO ARE INTOLERANT OF APPROVED THERAPIES WITH PROVEN CLINICAL BENEFIT OR WHO HAVE EXPERIENCED SIGNIFICANT CLINICAL OR IMMUNOLOGIC DETERIORATION WHILE RECEIVING THESE THERAPIES OR FOR WHOM SUCH THERAPIES ARE CONTRAINDICATED
U-95	SHORT TERM MANAGEMENT OF MODERATE PRURITIS IN ADULTS WITH ATOPIC DERMATITIS AND LICHEN SIMPLEX CHRONICUS

EXCLUSIVITY TERMS

REFERENCES
PATENT USE CODE

U-96	METHOD OF TREATING VARICELLA ZOSTER (SHINGLES) INFECTIONS
U-97	A METHOD OF TREATING A PATIENT IN NEED OF MEMORY ENHANCEMENT
U-98	A METHOD OF INDUCING REGRESSION OF LEUKEMIA CELL GROWTH IN A MAMMAL
U-99	METHOD OF PROVIDING POTASSIUM TO A SUBJECT IN NEED OF POTASSIUM

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	19872 001	ACETAMINOPHEN; TYLENOL				NDF	JUN 08, 1997
	19806 001	ACRIVASTINE; SEMPREX-D	4650807	MAR 17, 2004	U-93		
			4501893	FEB 26, 2002		NC	MAR 25, 1997
						ODE	JUN 30, 2001
	74346 001	AMINOSALICYLIC ACID; PASER					
	18700 001	AMRINONE LACTATE; INOCOR	4072746	JUL 31, 1998	U-7	NCE	JUL 31, 1994
	20304 001	APROTININ BOVINE; TRASYLOL				ODE	DEC 29, 2000
						D-25	OCT 12, 1997
	18831 001	ATRACURIUM BESYLATE; TRACRIUM	4179507	DEC 18, 1996		I-108	JUN 06, 1997
	20233 001	BUDESONIDE; RHINOCORT				NCE	FEB 14, 1999
	18731 001	BUSPIRONE HYDROCHLORIDE; BUSPAR	5015646	MAY 14, 2008	U-13		
	18731 002	BUSPIRONE HYDROCHLORIDE; BUSPAR	5015646	MAY 14, 2008	U-13		
	18343 001	CAPTOPRIL; CAPOTEN	5238924	AUG 24, 2010	U-92	I-101	JAN 28, 1997
	18343 002	CAPTOPRIL; CAPOTEN	5238924	AUG 24, 2010	U-92	I-101	JAN 28, 1997
	18343 003	CAPTOPRIL; CAPOTEN	5238924	AUG 24, 2010	U-92	I-101	JAN 28, 1997
	18343 005	CAPTOPRIL; CAPOTEN	5238924	AUG 24, 2010	U-92	I-101	JAN 28, 1997
>ADD>	18343 006	CAPTOPRIL; CAPOTEN	5238924	AUG 24, 2010	U-92	I-95	SEP 23, 1996
			4105776	AUG 08, 1995		I-101	JAN 28, 1997
	19537 002	CIPROFLOXACIN HYDROCHLORIDE; CIPRO	4670444	OCT 01, 2002	U-36	I-66	JUL 21, 1997
						I-109	JUL 21, 1997
	19537 003	CIPROFLOXACIN HYDROCHLORIDE; CIPRO	4670444	OCT 01, 2002	U-36	I-66	JUL 21, 1997
						I-109	JUL 21, 1997
	19537 004	CIPROFLOXACIN HYDROCHLORIDE; CIPRO	4670444	OCT 01, 2002	U-36	I-66	JUL 21, 1997
						I-109	JUL 21, 1997
	20392 001	CYSTEAMINE BITARTRATE; CYSTAGON				NCE	AUG 15, 1999
						ODE	AUG 15, 2001
	20392 002	CYSTEAMINE BITARTRATE; CYSTAGON				NCE	AUG 15, 1999
						ODE	AUG 15, 2001
	20355 001	DESMOPRESSIN ACETATE; DESMOPRESSIN ACETATE				NP	MAR 07, 1997
						ODE	MAR 07, 2001
>ADD>	20062 001	DILTIAZEM HYDROCHLORIDE; CARDIZEM CD	5364620	NOV 14, 2011	U-3		
			5286497	FEB 14, 2011			
>ADD>	20062 002	DILTIAZEM HYDROCHLORIDE; CARDIZEM CD	5364620	NOV 14, 2011	U-3		
			5286497	FEB 14, 2011			
>ADD>	20062 003	DILTIAZEM HYDROCHLORIDE; CARDIZEM CD	5364620	NOV 14, 2011	U-3		
			5286497	FEB 14, 2011			
>ADD>	20062 004	DILTIAZEM HYDROCHLORIDE; CARDIZEM CD	5364620	NOV 14, 2011	U-3		
			5286497	FEB 14, 2011			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20126 001	DOXEPIN HYDROCHLORIDE; ZONALON	4395420	JUL 26, 2000	U-95	NDF	APR 01, 1997
	20323 001	ESTRADIOL; VIVELLE				NS	OCT 28, 1997
	20323 003	ESTRADIOL; VIVELLE				NS	OCT 28, 1997
	81295 001	ESTRADIOL; ESTRACE				I-76	SEP 08, 1995
	18922 004	ETODOLAC; LODINE	4076831	FEB 28, 1997	U-45	NCE	JAN 31, 1996
	20363 002	FAMCICLOVIR; FAMVIR	5246937	SEP 21, 2010	U-96	NCE	JUN 29, 1999
	20249 001	FAMOTIDINE; PEPCID	4283408	AUG 11, 2000		I-69	DEC 10, 1994
	19834 004	FELODIPINE; PLENDIL	4264611	APR 28, 1998		NCE	JUL 25, 1996
	19304 001	FENOFIBRATE; LIPIDIL	4058552	NOV 15, 1994		NCE	DEC 31, 1998
	19960 001	FLOSEQUINAN; MANOPLAX	4552884	DEC 31, 2006	U-71		
	19960 002	FLOSEQUINAN; MANOPLAX	4552884	DEC 31, 2006	U-71		
	19960 003	FLOSEQUINAN; MANOPLAX	4552884	DEC 31, 2006	U-71		
	19960 004	FLOSEQUINAN; MANOPLAX	4552884	DEC 31, 2006	U-71		
	19949 001	FLUCONAZOLE; DIFLUCAN	4416682	NOV 22, 2000		I-100	DEC 30, 1996
	19949 002	FLUCONAZOLE; DIFLUCAN	4416682	NOV 22, 2000		I-100	DEC 30, 1996
	19949 003	FLUCONAZOLE; DIFLUCAN	4416682	NOV 22, 2000		I-100	DEC 30, 1996
	19950 001	FLUCONAZOLE; DIFLUCAN	4416682	NOV 22, 2000		I-100	DEC 30, 1996
>ADD>	20322 001	FLUCONAZOLE; DIFLUCAN	4416682	NOV 22, 2000		I-100	DEC 30, 1996
>DLT>	~~20322 001~~	~~FLUCONAZOLE; DIFLUCAN~~	~~4552884~~	~~NOV 12, 2002~~		~~I-100~~	~~DEC 30, 1996~~
>ADD>			4404216	OCT 16, 2003		NCE	JAN 29, 1995
>DLT>			~~4302460~~	~~NOV 24, 1998~~		~~NCE~~	~~JAN 29, 1995~~
						NS	JUN 30, 1997
						I-107	JUN 30, 1997
	18936 001	FLUOXETINE HYDROCHLORIDE; PROZAC	4018895	APR 19, 1994	U-12	I-102	FEB 28, 1997
	18936 006	FLUOXETINE HYDROCHLORIDE; PROZAC	4314081	FEB 02, 2001		I-102	FEB 28, 1997
	20101 001	FLUOXETINE HYDROCHLORIDE; PROZAC	4314081	FEB 02, 2001		I-102	FEB 28, 1997
>ADD>	20286 001	FOSINOPRIL SODIUM; MONOPRIL-HCT	5006344	APR 09, 2008			
>ADD>			4384123	MAY 17, 2000			
>ADD>			4337201	JUN 29, 2001		NC	NOV 30, 1997
>ADD>	20286 002	FOSINOPRIL SODIUM; MONOPRIL-HCT	5006344	APR 09, 2008			
>ADD>			4384123	MAY 17, 2000			
>ADD>			4337201	JUN 29, 2001		NC	NOV 30, 1997
	20235 001	GABAPENTIN; NEURONTIN	4894476	JAN 16, 2007			
	20235 002	GABAPENTIN; NEURONTIN	4894476	JAN 16, 2007			
	20235 003	GABAPENTIN; NEURONTIN	4894476	JAN 16, 2007			
	20123 001	GADODIAMIDE; OMNISCAN	4687659	JAN 08, 2007	U-76	NCE	JAN 08, 1998

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	20131 001	GADOTERIDOL; PROHANCE				I-115	NOV 21, 1997
>ADD>						I-114	NOV 21, 1997
	20329 001	GLIPIZIDE; GLUCOTROL XL				NDF	APR 26, 1997
	20329 002	GLIPIZIDE; GLUCOTROL XL				NDF	APR 26, 1997
	19778 003	HYDROCHLOROTHIAZIDE; PRINZIDE 10-12.5	4472380	SEP 18, 2001			
			4374829	DEC 30, 2001	U-3	NS	NOV 18, 1996
	19888 001	HYDROCHLOROTHIAZIDE; ZESTORETIC 20-12.5	4472380	SEP 18, 2001			
			4374829	DEC 30, 2001	U-3		
	19888 002	HYDROCHLOROTHIAZIDE; ZESTORETIC 20-25	4374829	DEC 30, 2001	U-3		
	19888 003	HYDROCHLOROTHIAZIDE; ZESTORETIC 10-12.5	4472380	SEP 18, 2001		NS	NOV 18, 1996
			4374829	DEC 30, 2001	U-3		
	19771 001	IBUPROFEN; ADVIL COLD AND SINUS	4552899	NOV 12, 2002			
>ADD>	20135 001	IBUPROFEN; MOTRIN				NDF	NOV 16, 1997
>ADD>	20135 002	IBUPROFEN; MOTRIN				NDF	NOV 16, 1997
	20367 001	IMIGLUCERASE; CEREZYME				NCE	MAY 23, 1999
						ODE	MAY 23, 2001
	20314 001	INDIUM IN-111 PENTETREOTIDE KIT; OCTREOSCAN				NCE	JUN 02, 1999
	20084 001	IOBENGUANE SULFATE I 131; IOBENGUANE SULFATE I 131	4584187	APR 22, 2003		NCE	MAR 25, 1999
>ADD>	20327 001	IOPAMIDOL; ISOVUE-200	4001323	JAN 04, 1996			
>ADD>	20327 002	IOPAMIDOL; ISOVUE-250	4001323	JAN 04, 1996			
>ADD>	20327 003	IOPAMIDOL; ISOVUE-300	4001323	JAN 04, 1996			
>ADD>	20327 004	IOPAMIDOL; ISOVUE-370	4001323	JAN 04, 1996			
	50705 001	ISONIAZID; RIFATER				ODE	MAY 31, 2001
	20336 001	ISRADIPINE; DYNACIRC CR	5030456	JUL 09, 2008			
			4950486	AUG 21, 2007		NDF	JUN 01, 1997
			4946687	AUG 07, 2007		NCE	DEC 20, 1995
			4816263	MAR 28, 2006	U-3		
			4783337	SEP 16, 2003	U-3		
			4466972	AUG 21, 2003	U-3		
	20336 002	ISRADIPINE; DYNACIRC CR	5030456	JUL 09, 2008			
			4950486	AUG 21, 2007		NDF	JUN 01, 1997
			4946687	AUG 07, 2007		NCE	DEC 20, 1995
			4816263	MAR 28, 2006	U-3		
			4783337	SEP 16, 2003	U-3		
			4466972	AUG 21, 2003	U-3		
	20083 001	ITRACONAZOLE; SPORANOX				I-104	MAR 29, 1997

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	18754 001	KETOPROFEN; ORUDIS				I-112	JAN 06, 1997
	18754 002	KETOPROFEN; ORUDIS				I-112	JAN 06, 1997
	18754 003	KETOPROFEN; ORUDIS				I-112	JAN 06, 1997
	19816 001	KETOPROFEN; ORUVAIL				NDF	SEP 24, 1996
	20219 001	LEVOCABASTINE HYDROCHLORIDE; LIVOSTIN	4369184	JAN 18, 2000		NCE	NOV 10, 1998
	19558 006	LISINOPRIL; PRINIVIL	4374829	DEC 30, 2001		I-92	JUN 09, 1996
	19658 001	LORATADINE; CLARITIN	4282233	AUG 04, 2000	U-77	NCE	APR 12, 1998
>ADD>	19670 001	LORATADINE; CLARITIN-D				NC	NOV 14, 1997
	20264 001	MEGESTROL ACETATE; MEGACE				NDF	SEP 10, 1997
	20343 001	MILRINONE LACTATE; PRIMACOR IN DEXTROSE 5%	4313951	FEB 02, 2001			
	20343 002	MILRINONE LACTATE; PRIMACOR IN DEXTROSE 5%	4313951	FEB 02, 2001			
	20343 003	MILRINONE LACTATE; PRIMACOR IN DEXTROSE 5%	4313951	FEB 02, 2001			
	19297 001	MITOXANTRONE HYDROCHLORIDE; NOVANTRONE	4820738	APR 11, 2006	U-98		
	20065 001	NAPHAZOLINE HYDROCHLORIDE; OPCON-A				NC	JUN 08, 1997
	20226 001	NAPHAZOLINE HYDROCHLORIDE; NAPHCON-A				NC	JUN 08, 1997
>ADD>	20067 002	NAPROXEN; EC-NAPROSYN				NDF	OCT 14, 1997
>ADD>	20067 003	NAPROXEN; EC-NAPROSYN				NDF	OCT 14, 1997
	20204 002	NAPROXEN SODIUM; ALEVE				NS	JAN 11, 1997
	19660 001	NEDOCROMIL SODIUM; TILADE	4474787	OCT 02, 2006		NCE	DEC 30, 1997
>ADD>	20165 001	NICOTINE; NICODERM	5364630	APR 02, 2010			
			5344656	APR 02, 2008			
			5342623	APR 02, 2008			
>ADD>	20165 002	NICOTINE; NICODERM	5364630	APR 02, 2010			
			5344656	APR 02, 2008			
			5342623	APR 02, 2008			
>ADD>	20165 003	NICOTINE; NICODERM	5364630	APR 02, 2010			
			5344656	APR 02, 2008			
			5342623	APR 02, 2008			
>ADD>	19684 001	NIFEDIPINE; PROCARDIA XL	5264446	NOV 23, 2010			
>ADD>	19684 002	NIFEDIPINE; PROCARDIA XL	5264446	NOV 23, 2010			
>ADD>	19684 003	NIFEDIPINE; PROCARDIA XL	5264446	NOV 23, 2010			
>ADD>	19384 002	NORFLOXACIN; NOROXIN				I-113	OCT 24, 1997
	19667 001	OCTREOTIDE ACETATE; SANDOSTATIN	4395403	JUL 26, 2002		I-106	MAY 03, 1997
	19667 002	OCTREOTIDE ACETATE; SANDOSTATIN	4395403	JUL 26, 2002		I-106	MAY 03, 1997
	19667 003	OCTREOTIDE ACETATE; SANDOSTATIN	4395403	JUL 26, 2002		I-106	MAY 03, 1997
	19667 004	OCTREOTIDE ACETATE; SANDOSTATIN	4395403	JUL 26, 2002		I-106	MAY 03, 1997
	19667 005	OCTREOTIDE ACETATE; SANDOSTATIN	4395403	JUL 26, 2002		I-106	MAY 03, 1997

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20103 001	ONDANSETRON HYDROCHLORIDE; ZOFRAN				I-110	SEP 26, 1997
	20103 002	ONDANSETRON HYDROCHLORIDE; ZOFRAN				I-110	SEP 26, 1997
	20262 001	PACLITAXEL; TAXOL				I-105	APR 13, 1997
						D-24	JUN 22, 1997
	20036 001	PAMIDRONATE DISODIUM; AREDIA	4711880	DEC 08, 2004		D-22	APR 15, 1997
						I-111	SEP 21, 1997
	20036 003	PAMIDRONATE DISODIUM; AREDIA	4711880	DEC 08, 2004		D-22	APR 15, 1997
						I-111	SEP 21, 1997
	20036 004	PAMIDRONATE DISODIUM; AREDIA	4711880	DEC 08, 2004		D-22	APR 15, 1997
						I-111	SEP 21, 1997
	20031 001	PAROXETINE HYDROCHLORIDE; PAXIL	4721723	DEC 29, 2006	U-12	NCE	DEC 29, 1997
	20031 002	PAROXETINE HYDROCHLORIDE; PAXIL	4721723	DEC 29, 2006	U-12	NCE	DEC 29, 1997
	20031 003	PAROXETINE HYDROCHLORIDE; PAXIL	4721723	DEC 29, 2006	U-12	NCE	DEC 29, 1997
	20031 004	PAROXETINE HYDROCHLORIDE; PAXIL	4721723	DEC 29, 2006	U-12	NCE	DEC 29, 1997
	20031 005	PAROXETINE HYDROCHLORIDE; PAXIL	4721723	DEC 29, 2006	U-12	NCE	DEC 29, 1997
	20184 001	PERINDOPRIL ERBUMINE; ACEON	4508729	APR 02, 2002		NCE	DEC 30, 1998
	20184 002	PERINDOPRIL ERBUMINE; ACEON	4508729	APR 02, 2002		NCE	DEC 30, 1998
	20184 003	PERINDOPRIL ERBUMINE; ACEON	4508729	APR 02, 2002		NCE	DEC 30, 1998
	20237 001	PILOCARPINE HYDROCHLORIDE; SALAGEN				ODE	MAR 22, 2001
						NDF	MAR 22, 1997
>ADD>	19439 001	POTASSIUM CHLORIDE; K-DUR 20	4863743	SEP 05, 2006	U-99		
>ADD>	19439 002	POTASSIUM CHLORIDE; K-DUR 10	4863743	SEP 05, 2006	U-99		
	19898 002	PRAVASTATIN SODIUM; PRAVACHOL	4346227	JAN 09, 2004		NCE	OCT 31, 1996
	19898 003	PRAVASTATIN SODIUM; PRAVACHOL	4346227	JAN 09, 2004		NCE	OCT 31, 1996
	19898 004	PRAVASTATIN SODIUM; PRAVACHOL	4346227	JAN 09, 2004		NCE	OCT 31, 1996
	20279 001	PREDNICARBATE; DERMATOP				NDF	OCT 29, 1996
	19627 001	PROPOFOL; DIPRIVAN				I-99	OCT 26, 1996
	20021 002	PSEUDOEPHEDRINE HYDROCHLORIDE; EFIDAC/24	4801461	MAY 05, 2004			
			4576604	MAR 18, 2003			
	18703 001	RANITIDINE HYDROCHLORIDE; ZANTAC 150	4128658	DEC 05, 1995		D-21	FEB 28, 1997
	18703 002	RANITIDINE HYDROCHLORIDE; ZANTAC 300	4128658	DEC 05, 1995		D-21	FEB 28, 1997
	19675 001	RANITIDINE HYDROCHLORIDE; ZANTAC	4521431	JUN 04, 2002		D-21	FEB 28, 1997
	20095 001	RANITIDINE HYDROCHLORIDE; ZANTAC 150	5028432	JUL 02, 2008			
			4521431	JUN 04, 2002		I-75	MAY 19, 1995
			4128658	DEC 05, 1995		D-21	FEB 28, 1997

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
20095 002	RANITIDINE HYDROCHLORIDE; ZANTAC 300	5028432	JUL 02, 2008			
		4521431	JUN 04, 2002		I-75	MAY 19, 1995
		4128658	DEC 05, 1995		D-21	FEB 28, 1997
20251 001	RANITIDINE HYDROCHLORIDE; ZANTAC 150	5102665	APR 07, 2009			
		4521431	JUN 04, 2002		I-75	MAY 19, 1995
		4128658	DEC 05, 1995		D-21	FEB 28, 1997
20251 002	RANITIDINE HYDROCHLORIDE; ZANTAC 150	5102665	APR 07, 2009			
		4521431	JUN 04, 2002		I-75	MAY 19, 1995
		4128658	DEC 05, 1995		D-21	FEB 28, 1997
20214 001	ROCURONIUM BROMIDE; ZEMURON (P/F)	4894369	JAN 16, 2007		NCE	MAR 17, 1999
20214 002	ROCURONIUM BROMIDE; ZEMURON	4894369	JAN 16, 2007		NCE	MAR 17, 1999
20236 001	SALMETEROL XINAFOATE; SEREVENT	4992474	FEB 12, 2008		NCE	FEB 04, 1999
19766 001	SIMVASTATIN; ZOCOR	4444784	DEC 24, 2005	U-59	NCE	DEC 23, 1996
19766 002	SIMVASTATIN; ZOCOR	4444784	DEC 24, 2005	U-59	NCE	DEC 23, 1996
19766 003	SIMVASTATIN; ZOCOR	4444784	DEC 24, 2005	U-59	NCE	DEC 23, 1996
19766 004	SIMVASTATIN; ZOCOR	4444784	DEC 24, 2005	U-59	NCE	DEC 23, 1996
19640 001	SOMATROPIN, BIOSYNTHETIC; HUMATROPE				D-23	APR 15, 1997
19640 004	SOMATROPIN, BIOSYNTHETIC; HUMATROPE				D-23	APR 15, 1997
19865 005	SOTALOL HYDROCHLORIDE; BETAPACE				NCE	OCT 30, 1997
					ODE	OCT 30, 1999
20412 001	STAVUDINE; ZERIT	4978655	DEC 18, 2007	U-94	NCE	JUN 24, 1999
20412 002	STAVUDINE; ZERIT	4978655	DEC 18, 2007	U-94	NCE	JUN 24, 1999
20412 003	STAVUDINE; ZERIT	4978655	DEC 18, 2007	U-94	NCE	JUN 24, 1999
20412 004	STAVUDINE; ZERIT	4978655	DEC 18, 2007	U-94	NCE	JUN 24, 1999
20412 005	STAVUDINE; ZERIT	4978655	DEC 18, 2007	U-94	NCE	JUN 24, 1999
40091 001	SULFADIAZINE; SULFADIAZINE				ODE	JUL 29, 2001
17376 001	SULFAMETHOXAZOLE; SEPTRA	4209513	JUN 24, 1997		I-103	JAN 07, 1997
17376 002	SULFAMETHOXAZOLE; SEPTRA DS	4209513	JUN 24, 1997		I-103	JAN 07, 1997
17377 001	SULFAMETHOXAZOLE; BACTRIM				I-103	JAN 07, 1997
17377 002	SULFAMETHOXAZOLE; BACTRIM DS				I-103	JAN 07, 1997
17560 002	SULFAMETHOXAZOLE; BACTRIM PEDIATRIC				I-103	JAN 07, 1997
17598 001	SULFAMETHOXAZOLE; SEPTRA				I-103	JAN 07, 1997
17598 002	SULFAMETHOXAZOLE; SEPTRA GRAPE				I-103	JAN 07, 1997
20080 001	SUMATRIPTAN SUCCINATE; IMITREX	4816470	DEC 29, 2006	U-72		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20070 001	TACRINE HYDROCHLORIDE; COGNEX	4631286	DEC 23, 2003	U-97		
	20070 002	TACRINE HYDROCHLORIDE; COGNEX	4631286	DEC 23, 2003	U-97		
	20070 003	TACRINE HYDROCHLORIDE; COGNEX	4631286	DEC 23, 2003	U-97		
	20070 004	TACRINE HYDROCHLORIDE; COGNEX	4631286	DEC 23, 2003	U-97		
	17970 002	TAMOXIFEN CITRATE; NOLVADEX	4536516	AUG 20, 2002			
>ADD>	20256 001	TECHNETIUM TC-99M BICISATE KIT; NEUROLITE				NCE	NOV 23, 1999
	18163 003	TEMAZEPAM; RESTORIL	5326758	JUL 09, 2008	U-70		
	20192 001	TERBINAFINE HYDROCHLORIDE; LAMISIL	4755534	JUL 05, 2005	U-73	NCE	DEC 30, 1999
	19762 001	TESTOSTERONE; TESTODERM	4867982	FEB 16, 2005			
			4725439	FEB 16, 2005			
			4704282	NOV 03, 2004		NDF	OCT 12, 1996
	19762 002	TESTOSTERONE; TESTODERM	4867982	FEB 16, 2005			
			4725439	FEB 16, 2005			
			4704282	NOV 03, 2004		NDF	OCT 12, 1996
	20330 001	TIMOLOL MALEATE; TIMOPTIC-XE	4861760	AUG 29, 2006			
			4195085	MAR 25, 1997		NP	NOV 04, 1996
	20330 002	TIMOLOL MALEATE; TIMOPTIC-XE	4861760	AUG 29, 2006			
			4195085	MAR 25, 1997		NP	NOV 04, 1996
	20326 001	TRIMETREXATE GLUCURONATE; NEUTREXIN	4694007	SEP 15, 2004	U-91	ODE	DEC 17, 2000
	19908 001	ZOLPIDEM TARTRATE; AMBIEN	4382938	MAY 10, 2005	U-74	NCE	DEC 16, 1997
	19908 002	ZOLPIDEM TARTRATE; AMBIEN	4382938	MAY 10, 2005	U-74	NCE	DEC 16, 1997

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	19841	001	INDIUM 111 CHLORIDE				NCE	DEC 29, 1997

New 15th Edition

APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

15TH EDITION

Superintendent of Documents Subscription Order Form

Order Processing Code
* 7542

Charge your order. It's easy! MasterCard VISA

☐ **Yes,** please send me the following indicated subscriptions:

__ subscriptions of **APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS**, ADP, and the monthly Cumulative Supplements, for $64.00 per year.

The total cost of my order is $_____. Prices include regular domestic postage and handling and are subject to change. International customers please add 25%.

For privacy protection, check the box below:

☐ Do not make my name available to other mailers.

Please choose method of payment:

☐ Check payable to Superintendent of Documents
☐ GPO Deposit Account ☐☐☐☐☐☐☐☐ – ☐☐
☐ VISA or MasterCard
☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐

_____
(Company or personal name)

_____
(Additional address/attention line)

_____
(Street address)

_____
(City, State, ZIP Code)

(_____) _____
(Daytime phone including area code)

_____
(Purchase Order No.)

_____
(Credit card expiration date)

Thank you for your order!

_____
(Authorizing Signature) (10/94)

Mail To: Superintendent of Documents, Government Printing Office, P.O. Box 371954 Pittsburgh, PA 15250-7954
To **FAX** your charge order, call (202) 512-2233.
To charge your subscription call (202) 512-1800.